Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(-)-epigallocatechin 3-O-(E)-p-coumarate
-
(-)-epigallocatechin 3-O-(E)-p-coumaroate
-
(-)-epigallocatechin-3-gallate
-
(-)-epigallocatechin3-O-(Z)-p-coumarate
-
(-)-epigallocatechin3-O-(Z)-p-coumaroate
-
(1S,12aR,12bR)-1,4,9,12a-tetrahydroxy-1,2,11,12,12a,12b-hexahydroperylene-3,10-dione
i.e. altertoxin I
(1S,12S,12aR,12bR)-1,4,9,12,12a-pentahydroxy-1,2,11,12,12a,12b-hexahydroperylene-3,10-dione
i.e. 6-epi-stemphytriol
(2E)-3-[(6R,7S)-7-[(2,4-dihydroxy-6-methylbenzoyl)oxy]-6-hydroxy-7-methyl-8-oxo-6,7,8,8a-tetrahydro-1H-2-benzopyran-3-yl]prop-2-enoic acid
i.e. pinophilin F
(2E)-3-[(7R)-7-[(2,4-dihydroxy-6-methylbenzoyl)oxy]-7-methyl-6,8-dioxo-6,7,8,8a-tetrahydro-1H-2-benzopyran-3-yl]prop-2-enoic acid
i.e. (-)-mitorubrinic acid
(2R)-2-[(2S,3S)-3-acetamido-5-oxooxolan-2-yl]-2-hydroxy-N-[(S)-[(3S)-8-hydroxy-1-oxo-3,4-dihydro-1H-2-benzopyran-3-yl][(propan-2-yl)amino]methyl]acetamide (non-preferred name)
i.e. AI-77-C
(3beta,5alpha,6beta,17alpha,22E)-6-methoxyergost-22-ene-3,5-diol
i.e. 3beta,5alpha-dihydroxy-6beta-methoxy-ergosta-7,22-diene
(3beta,5alpha,6beta,17alpha,22E)-ergost-22-ene-3,5,6-triol
i.e. ergosta-7,22-diene-3beta,5alpha,6beta-triol
(3S,8aR)-3-[[(3S)-7,7-dimethyl-3-(2-methylbut-3-en-2-yl)-2-oxo-1,2,3,7-tetrahydropyrano[2,3-g]indol-3-yl]methyl]-8a-methoxyhexahydropyrrolo[1,2-a]pyrazine-1,4-dione
i.e. notoamide Q
(5aR,7R,9aR)-7',7',8,8-tetramethyl-1',2,3,7',8a,9-hexahydro-1H,2'H,5H,6H,8H,10H-spiro[5a,9a-(epiminomethano)cyclopenta[f]indolizine-7,3'-pyrano[2,3-g]indole]-2',5,10-trione
i.e. (-)-versicolamide B
(5aS,13bS)-1,5a,9,13-tetrahydroxy-3,7-dimethyl-5,5a-dihydro-4H,10H,12H,14H,16H-pyrano[3''',4''',5''':4'',5'']naphtho[2'',1'':4',5']furo[2',3':7,8]naphtho[1,8-cd]pyran-4,10,16-trione (non-preferred name)
i.e. bacillosporin C
(6bR,7aS,12aS,14aS)-6b-hydroxy-3,3-dimethyl-14a-(2-methylbut-3-en-2-yl)-3,6b,7,7a,10,11,12,12a,14a,15-decahydro-8H,13H-pyrano[2,3-g]pyrrolo[1'',2'':4',5']pyrazino[1',2':1,5]pyrrolo[2,3-b]indole-8,13-dione
i.e. notoamide D
(7aS,12aS,13aR)-3,3,14,14-tetramethyl-3,7,11,12,13,13a,14,15-octahydro-8H,10H-7a,12a-(epiminomethano)indolizino[6,7-h]pyrano[3,2-a]carbazole-8,16-dione
i.e. 6-epi-stephacidin A
(7aS,12aS,13aS)-3,3,14,14-tetramethyl-3,7,11,12,13,13a,14,15-octahydro-8H,10H-7a,12a-(epiminomethano)indolizino[6,7-h]pyrano[3,2-a]carbazole-8,16-dione
i.e. stephacidin A
(7R)-3-[(1E)-3-hydroxyprop-1-en-1-yl]-7-methyl-6,8-dioxo-6,7,8,8a-tetrahydro-1H-2-benzopyran-7-yl 2,4-dihydroxy-6-methylbenzoate
i.e. (-)-mitorubrinol
(7S,8S,8aS)-7-hydroxy-3-[(1E)-3-hydroxyprop-1-en-1-yl]-7-methyl-6-oxo-6,7,8,8a-tetrahydro-1H-2-benzopyran-8-yl 2,4-dihydroxy-6-methylbenzoate
i.e. pinophilin B
(7S,8S,8aS)-8-hydroxy-3-[(1E)-3-hydroxyprop-1-en-1-yl]-7-methyl-6-oxo-6,7,8,8a-tetrahydro-1H-2-benzopyran-7-yl 2,4-dihydroxy-6-methylbenzoate
i.e. pinophilin D
1,3-[6-(3-Amino-1-propyl)-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline]-[5',6'-dihydro-6'-(3'-amino-1'-propyl)-5',11'-dioxo-11'H-indeno[1,2-c]-isoquinoline]propane bis(trifluoroacetate)
-
11-hydroxy-3-[(1R)-1-hydroxy-3-methylbutyl]-4-methoxy-9-methyl-5H,7H-dibenzo[b,g][1,5]dioxocin-5-one
i.e. vermixocin A
12H-5,11a-diazadibenzo[b,h]fluoren-11-one
i.e. rosettacin
14-(1-imidazolylmethyl)-2H-5,11a-diazadibenzo[b,h]fluoren-11-one
-
14-(1-morpholinomethyl)-2H-5,11a-diazadibenzo[b,h]fluoren-11-one
-
14-(10'-aminodecyl-1'-aminomethyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trihydrochloride
-
14-(11'-aminoundecyl-1'-aminomethyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trihydrochloride
-
14-(12'-aminododecyl-1'-aminomethyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trihydrochloride
-
14-(2'-aminoethyl-1'-aminomethyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trihydrochloride
-
14-(3'-aminopropyl-1'-aminomethyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trihydrochloride
-
14-(3-aminopropyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one dihydrochloride
-
14-(3-N-ethanolaminopropyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trifluoroacetate
-
14-(4'-aminobutyl-1'-aminomethyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trihydrochloride
-
14-(5'-aminopentyl-1'-aminomethyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trihydrochloride
-
14-(6'-aminohexyl-1'-aminomethyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trihydrochloride
-
14-(7'-aminoheptyl-1'-aminomethyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trihydrochloride
-
14-(8'-aminooctyl-1'-aminomethyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trihydrochloride
-
14-(9'-aminononyl-1'-aminomethyl)-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trihydrochloride
-
14-(N,N-dimethylaminomethyl)-2H-5,11a-diazadibenzo[b,h]fluoren-11-one
-
14-(N-ethanolaminomethyl)-2H-5,11a-diazadibenzo[b,h]fluoren-11one
-
14-aminomethyl-12H-5,11a-diazadibenzo[b,h]fluoren-11-one dihydrochloride
-
14-chloromethyl-12H-5,11a-diazadibenzo[b,h]fluoren-11-one
-
14-[(1-imidazolyl)propylaminomethyl]-12H-5,11a-diazadibenzo[b,h]fluoren-11-one
-
14-[1-(N-methylpiperazinylmethyl)]-2H-5,11a-diazadibenzo[b,h]fluoren-11-one
-
14-[3(1-morpholinopropyl)]-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trifluoroacetate
-
14-[3-(1-imidazolylpropyl)]-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trifluoroacetate
-
14-[3-(N,N-dimethylaminopropyl)]-12H-5,11a-diazadibenzo[b,h]fluoren-11-one trifluoroacetate
-
14-[N-(S)-3-hydroxypyrrolidinomethyl]-12H-5,11a diazadibenzo[b,h]fluoren-11-one
-
2(2.6-dihydrobenzoyl)-3-hydroxy-5-hydroxymethylbenzoic acid methyl ester
-
2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
i.e. NSC314622
2,3-dimethoxy-8,9-methylenedioxy-10-(1H-imidazol-yl)methyl-11H-indeno[1,2-c]isoquinoline
-
2,3-dimethoxy-8,9-methylenedioxy-10-(4-methylpiperazin-1-yl)-methyl-11H-indeno[1,2-c]isoquinoline
-
2,3-dimethoxy-8,9-methylenedioxy-10-(4-morpholino)methyl-11H-indeno[1,2-c]isoquinoline
-
2,3-dimethoxy-8,9-methylenedioxy-10-(dimethylamino)methyl-11H-indeno[1,2-c]isoquinoline
influence of protonation state on Top1 inhibition
2,3-dimethoxy-8,9-methylenedioxy-10-(N,N',N'-trimethylethylenediamino)methyl-11H-indeno[1,2-c]isoquinoline
-
2,3-dimethoxy-8,9-methylenedioxy-10-(pyrrolidin-1-yl)methyl-11H-indeno[1,2-c]isoquinoline
influence of protonation state on Top1 inhibition
2,3-dimethoxy-8,9-methylenedioxy-10-methyl-11H-indeno[1,2-c]-isoquinoline
-
2-O-(3,4-dihydroxybenzoyl)-2,4,6-trihydroxyphenylacetic acid
-
4-[3-[ethyl(methyl)amino]propyl]furo[3,2-c]phenanthridine-5,10,11(4H)-trione
-
6-(3-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
class of non-camptothecin topoisomerase I inhibitors, exert cytotoxicity by trapping the covalent complex formed between DNA and Top1during relaxation of DNA supercoils
6-{3-[(2-hydroxyethyl)amino]propyl}-2,3-dimethoxy-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
i.e. MJ-III-65
bis-1,2-[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-(ethylamino)-ethylamino]ethane tetra(trifluoroacetate)
-
bis-1,2-[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-ethylamino]ethane bis(trifluoroacetate)
weak activity
bis-1,2-[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino]ethane bis(trifluoroacetate)
similar activity as 1 microM camptothecin
bis-1,3-[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-ethylamino]propane bis(trifluoroacetate)
similar activity as 1 microM camptothecin
bis-1,3-[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino]propane bis(trifluoroacetate)
similar activity as 1 microM camptothecin
bis-1,3-[(5,6-dihydro-5,11-diketo-2,3-dimethoxy-11H-indeno-[1,2-c]isoquinoline)-6-ethylamino]propane bis(trifluoroacetate)
-
bis-1,3-[(5,6-dihydro-5,11-diketo-2,3-dimethoxy-11H-indeno-[1,2-c]isoquinoline)-6-propylamino]propane bis(trifluoroacetate)
-
bis-1,3-[(5,6-dihydro-5,11-diketo-3-nitro-11H-indeno[1,2-c]isoquinoline)-6-ethylamino]propane bis(trifluoroacetate)
-
bis-1,4-[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-(6-propyl-tert-BOCamino)]butane
weak activity
bis-1,4-[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino]butane bis(trifluoroacetate)
similar activity as 6-(3-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
bis[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-(ethylamino)-ethyl]amine tris(trifluoroacetate)
similar activity as 6-(3-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
bis[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-ethyl]amine
weak activity
bis[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propyl]amine
weak activity
bis[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propyl]methylamine
weak activity
bis[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)]-(6-ethyl,6'-propyl)ammonium Trifluoroacetate
weak activity
bis[(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)]-(6-propyl,6'-butyl)amine hydrochloride
weak activity
curcumin sulfate
i.e. diferuloylmethane sulfate
dihydroquercetin
i.e. (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydro-4H-1-benzopyran-4-one
hydroxylcamptothecin
topoisomerase I inhibitor
methyl (2R)-2-([3-[(3,3-dimethyloxiran-2-yl)methyl]-4-hydroxyphenyl]methyl)-4-hydroxy-3-(4-hydroxyphenyl)-5-oxo-2,5-dihydrofuran-2-carboxylate
i.e. butyrolactone I
methyl (2R)-4-hydroxy-2-[[4-hydroxy-3-(3-methylbutyl)phenyl]methyl]-3-(4-hydroxyphenyl)-5-oxo-2,5-dihydrofuran-2-carboxylate
i.e. butyrolactone III
N,N-dimethyl(6-methyl-10,11-dioxo-10,11-dihydrophenanthro[1,2-b]furan-1-yl)methanaminium (2E)-3-carboxyprop-2-enoate
-
-
pyridoxal 5'-diphospho-5'-adenosine
-
pyridoxal 5'-phosphate
competitive inhibitor of Candida guilliermondii topoisomerase I
tanshinone-1
less than 10% inhibition at 0.005 mM
Urea
inhibitory effect to W203A/W205A/W206A mutant
Zn(isaepy)Cl2
complete inhibition at 0.3 mM
[Cu(isaepy)H2O]ClO4
complete inhibition at 0.15 mM
[Cu(isapnsal)]ClO4
poor inhibition
[Zn(isapnsal)]ClO4
poor inhibition
(+)-cheilanthifoline
-
very weak inhibition
(-)-cavidine
-
very weak inhibition
(-)-cryptotanshinone
-
diterpenoid from Salvia castanea f. tomentos
(-)-pallidine
-
comparable to camptothecin
(-)-scoulerine
-
inhibition comparable to camptothecin
(-)-tetrahydropalmatine
-
very weak inhibition
(1,1',1'',1'''-[(1,4-dihydroporphyrin-5,10,15,20-tetrayl-k4N21,N22,N23,N24)tetrakis(benzene-4,1-diylmethanediyl)]tetrakis[1-methylpiperidiniumato(2-)])nickel(4+) tetraiodide
-
-
(1,1',1'',1'''-[(1,4-dihydroporphyrin-5,10,15,20-tetrayl-k4N21,N22,N23,N24)tetrakis(benzene-4,1-diylmethanediyl)]tetrakis[1-methylpiperidiniumato(2-)])zinc(4+) tetraiodide
-
-
(2,2',2'',2''',2'''',2''''',2'''''',2'''''''-[(5,28-dihydro-29H,31H-tetrabenzoporphine-2,3,9,10,16,17,23,24-octayl-k4N29,N30,N31,N32)octasulfanediyl]octakis(N,N-diethyl-N-methylethanaminiumato)(2-))zinc(8+) octaiodide
-
-
(2S,3R)-5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-8-phenyl-2,3,8,9-tetrahydro-10H-[1,4]dioxino[2,3-f]chromen-10-one
-
-
(2S,3R,4S,6R)-4-amino-2-methyl-6-((3-(2-phenyl-1-tosyl-1H-indol-3-yl)prop-2-yn-1-yl)oxy)tetrahydro-2H-pyran-3-ol
-
92.8% inhibition at 0.1 mM
(2S,3R,4S,6R)-4-amino-2-methyl-6-((3-(2-phenylbenzofuran-3-yl)prop-2-yn-1-yl)oxy)tetrahydro-2H-pyran-3-ol
-
25.5% inhibition at 0.1 mM
(2S,3R,4S,6R)-4-amino-2-methyl-6-((3-(2-phenylbenzo[b]thiophen-3-yl)prop-2-yn-1-yl)oxy)tetrahydro-2H-pyran-3-ol
-
32.2% inhibition at 0.1 mM
(2S,3R,4S,6R)-4-amino-2-methyl-6-(3-(2-phenyl-1H-indol-3-yl)prop-2-ynyloxy)tetrahydro-2H-pyran-3-ol
(2S,3S,6R)-2-methyl-6-(3-(2-phenyl-1-tosyl-1H-indol-3-yl)prop-2-ynyloxy)tetrahydro-2H-pyran-3-amine
-
43.2% inhibition at 0.1 mM
(2S,3S,6R)-2-methyl-6-(3-(2-phenyl-1H-indol-3-yl)prop-2-ynyloxy)tetrahydro-2H-pyran-3-amine
-
4.0% inhibition at 0.1 mM
(2S,3S,6R)-2-methyl-6-(3-(2-phenylbenzo[b]thiophen-3-yl)prop-2-ynyloxy)tetrahydro-2H-pyran-3-amine
-
7.9% inhibition at 0.1 mM
(5Z,7E,9E,14Z,17Z)-icosa-5,7,9,14,17-pentaenoic acid
-
-
(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]-isoquinolin-3-yl)carbamic acid
-
-
(6aR,11aS)-11-[(4-methylphenyl)sulfonyl]-6,6a,11,11a-tetrahydro-5H-benzo[a]carbazole
-
binds selectively to PfTopoI
(7aR,12aS)-5-methylidene-12-[(4-methylphenyl)sulfonyl]-7,7a,12,12a-tetrahydrobenzo[6,7]chromeno[4,3-b]indol-13(5H)-one
-
-
(7aS,12aS)-10-methoxy-5-methylidene-5,7,7a,12a-tetrahydro-13H-[1]benzofuro[3,2-c]benzo[g]chromen-13-one
-
-
(7aS,12aS)-11-methoxy-5-methylidene-13-oxo-5,7a,12a,13-tetrahydro-7H-[1]benzofuro[3,2-c]benzo[g]chromene-9-carbaldehyde
-
-
(7aS,12aS)-5-methylidene-5,7,7a,12a-tetrahydro-13H-[1]benzofuro[3,2-c]benzo[g]chromen-13-one
-
-
(9-([2-(1H-Indol-3-yl)ethyl]amino)-3-acridinyl)(4-methyl-1-piperazinyl)methanone
-
-
(9-([2-(1H-indol-3-yl)ethyl]amino)acridin-3-yl)(4-methylpiperazin-1-yl)methanone
-
-
(9-([2-(1H-indol-3-yl)ethyl]amino)acridin-4-yl)(4-methylpiperazin-1-yl)methanone
-
-
(9-[(1-benzylpiperidin-4-yl)amino]acridin-3-yl)(4-methylpiperazin-1-yl)methanone
-
-
(S)-6-(6-nitrobenzothiazol-2-yl)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine
-
-
(S)-6-(benzothiazol-2-yl)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-de][1,4]-benzoxazine
-
-
1,1',1'',1'''-[1,4-dihydroporphyrin-5,10,15,20-tetrayltetrakis(benzene-4,1-diylmethanediyl)]tetrakis(1-methylpiperidinium) tetraiodide
-
-
1,1',1'',1'''-[1,4-dihydroporphyrin-5,10,15,20-tetrayltetrakis(benzene-4,1-diylmethanediyl)]tetrakis[3-(ethoxycarbonyl)-1-methylpiperidinium] tetraiodide
-
-
1,1',1'',1'''-[1,4-dihydroporphyrin-5,10,15,20-tetrayltetrakis(benzene-4,1-diylmethanediyl)]tetrakis[3-(hydroxymethyl)-1-methylpiperidinium] tetraiodide
-
-
1,5-dideoxy-1-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)-D-xylo-hexitol
-
-
1-(alpha-L-idopyranosyl)-N-(2-methylbenzoyl)-5-(methylsulfanyl)-1H-1,2,4-triazol-3-amine
-
-
1-(hydroxymethyl)-3-(2-hydroxypropan-2-yl)-2-(5-methoxy-9H-beta-carbolin-1-yl)-cyclopentanol
-
-
1-deoxy-1-(3-nitro-5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)-D-glucitol
-
-
1-deoxy-1-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)-D-allitol
-
-
1-deoxy-1-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)-D-arabinitol
-
-
1-deoxy-1-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)-D-galactitol
-
-
1-deoxy-1-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)-D-glucitol
-
-
1-deoxy-1-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)-D-mannitol
-
-
1-deoxy-1-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)-D-ribitol
-
-
1-ethoxycarbonyl-naphthoquinone-[2,3-d]indolizidine-6,11-dione
-
0.1 mg/ml, 4.1% inhibition of relaxation
1-ethyl-3-(5-aminobenzimidazol-2-yl)-6-fluoro-7-(4-methyl-1-piperazinyl)-4(1H)-quinolone
-
-
1-ethyl-3-(6-aminobenzoimidazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-1,8-naph- thyridin-4(1H)-one
-
-
1-ethyl-3-(6-aminobenzoimidazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-1,8-naphthyridin-4(1H)-one
-
-
1-ethyl-3-(6-aminobenzoimidazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-4(1H)-quinolone
-
-
1-ethyl-3-(6-chlorobenzimidazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-1,8-naphthyridine-4(1H)-one
-
-
1-ethyl-3-(6-chlorobenzimidazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-4(1H)-quinolone
-
-
1-ethyl-3-(6-nitrobenzimidazol-2-yl)-6-fluoro-7-(4-methyl-1-piperazinyl)-4(1H)-quinolone
-
-
1-ethyl-3-(6-nitrobenzimidazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-1,8-naphthyridine-4(1H)-one
-
-
1-ethyl-3-(6-nitrobenzimidazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-4(1H)-quinolone
-
-
1-ethyl-3-(6-nitrobenzothiazol-2-yl)-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4(1H)-quinolone
-
-
1-ethyl-3-(6-nitrobenzothiazol-2-yl)-6-fluoro-7-(4-methylpiperazin-1-yl)-4(1H)-quinolone
-
-
1-ethyl-3-(6-nitrobenzothiazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-1,8-naphthyridine-4(1H)-one
-
-
1-ethyl-3-(6-nitrobenzothiazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-4(1H)-quinolone
-
-
1-ethyl-3-(6-nitrobenzoxazol-2-yl)-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4(1H)-quinolone
1-ethyl-3-(6-nitrobenzoxazol-2-yl)-6-fluoro-7-(4-methylpiperazin-1-yl)-4(1H)-quinolone
-
-
1-ethyl-3-(6-nitrobenzoxazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-1,8-naphthyridine-4(1H)-one
-
-
1-ethyl-3-(6-nitrobenzoxazol-2-yl)-6-fluoro-7-chloro-4(1H)-quinolone
-
-
1-ethyl-3-(benzimidazol-2-yl)-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4(1H)-quinolone
-
9% and 11% inhibition at 0.1 mM and 0.02 mM, respectively
1-ethyl-3-(benzothiazol-2-yl)-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4(1H)-quinolone
-
-
1-ethyl-3-(benzothiazol-2-yl)-6-fluoro-7-(4-methylpiperazin-1-yl)-4(1H)-quinolone
-
-
1-ethyl-3-(benzothiazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-1,8-naphthyridine-4(1H)-one
-
-
1-ethyl-3-(benzothiazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-4(1H)-quinolone
-
-
1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-3-(6-nitro-1,3-benzoxazol-2-yl)quinolin-4(1H)-one
-
interacts with DNA-Top I complex and induces cancer cell apoptosis to produce antitumor effects
1-ethylKuQuinone
-
synthesis of the pentacyclic-diquinoid synthetic compound, overview. It efficiently inhibits the cleavage step of the enzyme reaction fitting well into the catalytic site. When incubated with the binary topoisomerase-DNA cleaved complex, the compound helps the enzyme to remove itself from the cleaved DNA and close the DNA gap, increasing the religation rate. Et-KuQ inhibits the relaxation activity of Top1. The compound also induces the religation of the stalled enzyme-camptothecin-DNA ternary complex. Docking and molecular modeling, overview
1-hydroxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one
-
-
1-hydroxy-3-[2-hydroxy-3-[(2-hydroxyethyl)amino]propoxy]-9H-xanthen-9-one
-
1.1% inhibition at 0.02 mM
1-hydroxy-3-[2-hydroxy-3-[(3-hydroxypropyl)amino]propoxy]-9H-xanthen-9-one
-
3.5% inhibition at 0.02 mM
1-hydroxy-8-methoxyanthracene-9,10-dione
-
-
1-methyl-3-(2-hydroxypropan-2-yl)-2-(5-methoxy-9H-beta-carbolin-1-yl)-cyclopentanol
-
-
1-[2-(dimethylamino)ethoxy]-8-methoxyanthracene-9,10-dione
-
-
1-[2-(dimethylamino)ethyl]-3-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]quinoxalin-2-amine
-
-
10-methoxy-9-{2-[(2,9,10-trimethoxy-5,6-dihydroisoquino[3,2-a]isoquinolinium-3-yl)oxy]ethoxy}[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium dichloride
-
synthetic protoberberine alkaloid, highly active
10-methoxy-9-{3-[(2,9,10-trimethoxy-5,6-dihydroisoquino[3,2-a]isoquinolinium-3-yl)oxy]propoxy}[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium dichloride
-
synthetic protoberberine alkaloid, highly active
10-methoxy-9-{4-[(2,9,10-trimethoxy-5,6-dihydroisoquino[3,2-a]isoquinolinium-3-yl)oxy]butoxy}[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium dichloride
-
synthetic protoberberine alkaloid, highly active
11-acetyl-10-amino-indolizino[3,2-g]quinoline-5,12-dione
-
-
11-acetyl-10-bromo-indolizino[3,2-g]quinoline-5,12-dione
-
-
11-acetyl-10-chloro-indolizino[3,2-g]quinoline-5,12-dione
-
-
11-acetyl-10-fluoro-indolizino[3,2-g]quinoline-5,12-dione
-
-
11-acetyl-10-hydroxy-indolizino[3,2-g]quinoline-5,12-dione
-
-
11-acetylindolizino[3,2-g]quinoline-5,12-dione
-
-
11-hexyl-5-(4-methylpiperazin-1-yl)-11H-indeno[1,2-c]isoquinolin-11-ol
-
-
11-hydroxy-2-methyl-4H-naphtho[2,3-h]chromene-4,7,12-trione
-
-
11-hydroxy-2-methyl-8-nitro-4H-naphtho[2,3-h]chromene-4,7,12-trione
-
-
11-hydroxy-2-phenyl-4H-naphtho[2,3-h]chromene-4,7,12-trione
-
-
11-methoxy-2-methyl-4H-naphtho[2,3-h]chromene-4,7,12-trione
-
-
11-methoxy-2-phenyl-4H-naphtho[2,3-h]chromene-4,7,12-trione
-
-
11-methyl-5-(4-methylpiperazin-1-yl)-11H-indeno[1,2-c]isoquinolin-11-ol
-
-
11-methylindolizino[3,2-g]quinoline-5,12-dione
-
-
11-[2-(dimethylamino)ethoxy]-2-methyl-4H-naphtho[2,3-h]chromene-4,7,12-trione
-
-
14-chloromethyl-12H-5,11adiazadibenzo[b,h]fluoren-11-one
-
-
17-beta-3-oxo-18-norandrost-4-ene-17-carboxylic acid -4-bromo-benzene sulfonic acid ester
-
partial or complete inhibition of hTopo is only observed at relatively high compound concentrations in the range 5 to 20 microM
17beta-O-[N-(benzyl)carbomyl]-oleanolic acid
-
-
2'-(4-(3,6,9,12,15,18-hexaoxahenicos-20-ynyloxy)phenyl)-6-(4-methylpiperazin-1-yl)-1H,3'H-2,5'-bibenzo[d]imidazole
-
-
2'-(4-ethoxyphenyl)-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole
-
reversibly traps enzyme cleavage complexes with a different and more specific sequence selectivity
2'-(4-ethoxyphenyl)-6-(4-methylpiperazin-1-yl)-1H,3'H,2,5'-bisbenzimidazole
-
Hoechst 33342
2'-(4-hydroxyphenyl)-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole
-
reversibly traps enzyme cleavage complexes with a different and more specific sequence selectivity
2'-[4-([6-[(but-3-yn-1-yl)oxy]hexyl]oxy)phenyl]-6-(4-methylpiperazin-1-yl)-1H,3'H-2,5'-bibenzimidazole
-
-
2'-[4-[(but-3-yn-1-yl)oxy]phenyl]-6-(4-methylpiperazin-1-yl)-1H,3'H-2,5'-bibenzimidazole
-
-
2'-[4-[(heptadec-16-yn-1-yl)oxy]phenyl]-6-(4-methylpiperazin-1-yl)-1H,3'H-2,5'-bibenzimidazole
-
-
2'-[4-[(hex-5-yn-1-yl)oxy]phenyl]-6-(4-methylpiperazin-1-yl)-1H,3'H-2,5'-bibenzimidazole
-
-
2,3-dichloro-5H-isoindolo[2,1-a]quinoxalin-6-one
-
-
2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
2,3-dimethyl-5H-isoindolo[2,1-a]quinoxalin-6-one
-
-
2,4-di(furan-2-yl)-5H-chromeno[4,3-b]pyridine
2,4-di(pyridin-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
2,4-di(thiophen-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
2,4-di(thiophen-3-yl)-5H-chromeno[4,3-b]pyridine
-
-
2,4-diphenyl-5H-chromeno[4,3-b]pyridine
-
-
2-((6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino)acetic acid
-
-
2-((6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino)acetic acid hydrochloride
-
-
2-(4-((1-(2-azidoethyl)-1H-1,2,3-triazol-4-yl)methoxy)-phenyl)-6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazole
-
-
2-(4-(2-(4-(4-ethynylphenyl)-1H-1,2,3-triazol-1-yl)ethoxy)-phenyl)-6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazole
-
-
2-(4-chlorophenyl)-4-(furan-3-yl)-6-(3-methylthiophen-2-yl) pyridine
-
86% inhibition at 0.1 mM
2-(4-chlorophenyl)-6-(5-chlorothiophen-2-yl)-4-(furan-2-yl) pyridine
-
53% inhibition at 0.1 mM
2-(4-ethoxyphenyl)-6-(4-methylpiperazin-1-yl)-1H-benzo[d]-imidazole
-
-
2-(4-hydroxyphenyl)-6-(4-methylpiperazin-1-yl)-1H-benzo-[d]imidazole-4-carboxylic acid
-
-
2-(4-[[1-(6-azidohexyl)-1H-1,2,3-triazol-4-yl]methoxy]phenyl)-6-(4-methylpiperazin-1-yl)-1H-benzimidazole
-
-
2-(5-chlorothiophen-2-yl)-4-(furan-3-yl)-6-(5-methylfuran-2-yl) pyridine
-
13.2% inhibition at 0.1 mM
2-(5-chlorothiophen-2-yl)-4-(furan-3-yl)-6-o-tolylpyridine
-
4.6% inhibition at 0.1 mM
2-(5-chlorothiophen-2-yl)-6-(furan-2-yl)-4-(furan-3-yl)pyridine
-
9.6% inhibition at 0.1 mM
2-(6-methyl-5,7-dioxo-5,6,7,13-tetrahydro-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)-N-[2-methyl-1-(morpholin-4-ylcarbonyl)propyl]acetamide
-
-
2-(6-methyl-5,7-dioxo-5,6,7,13-tetrahydro-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)-N-[3-methyl-1-[(4-methylpiperazin-1-yl)carbonyl]butyl]acetamide
-
-
2-(furan-2-yl)-4-(furan-3-yl)-6-(3-methylthiophen-2-yl)pyridine
-
5.4% inhibition at 0.1 mM
2-(furan-2-yl)-4-(pyridin-2-yl)-5H-chromeno[4,3-b]pyridine
2-(furan-2-yl)-4-(pyridin-3-yl)-5H-chromeno[4,3-b]pyridine
2-(furan-2-yl)-4-(thiophen-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
2-(furan-2-yl)-4-phenyl-5H-chromeno[4,3-b]pyridine
2-(piperidin-1-yl)ethyl5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxylate
-
-
2-(pyridin-2-yl)-4-(pyridin-3-yl)-5H-chromeno[4,3-b]pyridine
2-(pyridin-2-yl)-4-(thiophen-2-yl)-5H-chromeno[4,3-b]pyridine
2-(pyridin-2-yl)ethyl5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxylate
-
-
2-(pyrrolidin-1-yl)ethyl 5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxylate
-
-
2-Amino-1-(1-benzyl-piperidin-4-yl)-4,9-dioxo-3a,4,9,9a-tetrahydro-1H-benzo[f]indole-3-carboxylic acid ethyl ester
-
0.1 mg/ml, 4.1% inhibition of relaxation
2-Amino-1-(2-bromo-ethyl)-4,9-dioxo-3a,4,9,9a-tetrahydro-1H-benzo[f]indole-3-carboxylic acid ethyl ester
-
0.1 mg/ml, 58.7% inhibition of relaxation
2-Amino-1-(2-hydroxy-ethyl)-4,9-dioxo-3a,4,9,9a-tetrahydro-1H-benzo[f]indole-3-carboxylic acid ethyl ester
-
0.1 mg/ml, 27.3% inhibition of relaxation
2-Amino-1-(4-amino-phenyl)-4,9-dioxo-3a,4,9,9a-tetrahydro-1H-benzo[f]indole-3-carboxylic acid ethyl ester
-
0.1 mg/ml, 9.4% inhibition of relaxation
2-Amino-1-(4-fluoro-phenyl)-4,9-dioxo-3a,4,9,9a-tetrahydro-1H-benzo[f]indole-3-carboxylic acid ethyl ester
-
0.1 mg/ml, 67.8% inhibition of relaxation
2-Amino-1-benzyl-4,9-dioxo-3a,4,9,9a-tetrahydro-1H-benzo[f]indole-3-carboxylic acid ethyl ester
-
0.1 mg/ml, 15.7% inhibition of relaxation
2-Amino-1-cyclohexyl-4,9-dioxo-3a,4,9,9a-tetrahydro-1H-benzo[f]indole-3-carboxylic acid ethyl ester
-
0.1 mg/ml, 12.2% inhibition of relaxation
2-Amino-1-isopropyl-4,9-dioxo-3a,4,9,9a-tetrahydro-1H-benzo[f]indole-3-carboxylic acid ethyl ester
-
0.1 mg/ml, 8.6% inhibition of relaxation
2-amino-3-ethoxycarbonyl-N-(4-fluorophenyl)benz[f]indole-4,9-dione
-
potent inhibitor
2-amino-3-ethoxycarbonyl-N-methyl-benz[f]indole-4,9-dione
-
0.1 mg/ml, 5.6% inhibition of relaxation
2-Amino-4,9-dioxo-1-p-tolyl-3a,4,9,9a-tetrahydro-1H-benzo[f]indole-3-carboxylic acid ethyl ester
-
0.1 mg/ml, 4.3% inhibition of relaxation
2-Amino-4,9-dioxo-1-phenyl-3a,4,9,9a-tetrahydro-1H-benzo[f]indole-3-carboxylic acid ethyl ester
-
0.1 mg/ml, 2.9% inhibition of relaxation
2-bromoethyl 5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxylate
-
-
2-hydroxy-3-ethoxycarbonyl-N-(3,4-dimethylphenyl)-benz[f]indole-4,9-dione
-
0.1 mg/ml, 6.6% inhibition of relaxation
2-phenyl-4-(pyridin-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
2-phenyl-4-(pyridin-3-yl)-5H-chromeno[4,3-b]pyridine
-
-
2-phenyl-4-(thiophen-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
2-phenyl-4-(thiophen-3-yl)-5H-chromeno[4,3-b]pyridine
2-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-2-oxoacetic acid
-
-
2-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]-isoquinolin-3-yl)amino]acetic acid
-
-
2-[4-(2-azidoethoxy)phenyl]-6-(4-methylpiperazin-1-yl)-1H-benzimidazole
-
-
2-[4-[(4,11-dihydroxy-5,10-dioxo-5,10-dihydro-1H-naphtho[2,3-f]indol-3-yl)methyl]piperazin-1-yl]ethyl acetate
-
-
20-mercaptocamptothecin
-
weak
20-thio camptothecin
-
analogue of camptothecin, inhibit a modified human topoisomerase I
3,10-dibromo-11-hydroxy-2-methyl-4H-naphtho[2,3-h]chromene-4,7,12-trione
-
-
3,3'-(4-phenylpyridine-2,6-diyl)diphenol
-
67.2% inhibition at 0.1 mM
3,3'-[butane-1,4-diylbis(oxy)]bis(2,9,10-trimethoxy-5,6-dihydroisoquino[3,2-a]isoquinolinium) dichloride
-
synthetic protoberberine alkaloid, highly active
3,3'-[ethane-1,2-diylbis(oxy)]bis(2,9,10-trimethoxy-5,6-dihydroisoquino[3,2-a]isoquinolinium) dichloride
-
synthetic protoberberine alkaloid, highly active. Strongly stabilize the enzyme-DNA binary complex at low concentration (50100microM). From 0.1 to 1 mM, their ability to stabilize is weak
3,3'-[propane-1,3-diylbis(oxy)]bis(2,9,10-trimethoxy-5,6-dihydroisoquino[3,2-a]isoquinolinium) dichloride
-
synthetic protoberberine alkaloid, highly active
3-(1,3-benzoxazol-2-yl)-1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)quinolin-4(1H)-one
-
-
3-(1,3-benzoxazol-2-yl)-1-ethyl-6-fluoro-7-(piperazin-1-yl)-1,8-naphthyridin-4(1H)-one
-
-
3-(1,3-benzoxazol-2-yl)-7-chloro-1-ethyl-6,8-difluoroquinolin-4(1H)-one
-
-
3-(1,3-benzoxazol-2-yl)-7-chloro-1-ethyl-6-fluoroquinolin-4(1H)-one
-
-
3-(1H-benzimidazol-2-yl)-1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)quinolin-4(1H)-one
-
-
3-(1H-benzimidazol-2-yl)-1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)quinolin-4(1H)-one
-
-
3-(1H-benzimidazol-2-yl)-1-ethyl-6-fluoro-7-(piperazin-1-yl)-1,8-naphthyridin-4(1H)-one
-
-
3-(1H-benzimidazol-2-yl)-1-ethyl-6-fluoro-7-(piperazin-1-yl)quinolin-4(1H)-one
-
-
3-(2,3-dimethoxy-5,12-dioxo-5,12-dihydro-6H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinolin-6-yl)propan-1-aminium chloride
-
higher activity than the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
3-(2,6-diphenylpyridin-4-yl)phenol
-
11.5% inhibition at 0.1 mM
3-(2-phenyl-1-benzofuran-3-yl)prop-2-yn-1-yl 3-amino-2,3,6-trideoxy-b-D-arabino-hexopyranoside
-
77.8% inhibition at 0.1 mM
3-(2-phenyl-1-benzothiophen-3-yl)prop-2-yn-1-yl 3-amino-2,3,6-trideoxy-b-D-arabino-hexopyranoside
-
36.9% inhibition at 0.1 mM
3-(2-phenyl-1H-indol-3-yl)prop-2-yn-1-yl 3-amino-2,3,6-trideoxy-b-D-arabino-hexopyranoside
-
8.8% inhibition at 0.1 mM
3-(4,6-diphenylpyridin-2-yl)phenol
-
12.9% inhibition at 0.1 mM
3-(4-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-phenoxy)propan-1-amine
-
-
3-(4-chlorophenyl)-1-(4'-hydroxyphenyl)-2-propen-1-one
-
chalcones (1,3-diaryl-2-propen-1-ones) are alpha, beta-unsaturated ketones with cytotoxic and anticancer properties. Compound has the highest Hammett and log P values (0.23 and 4.21, respectively) and exerted both highest cytotoxicity and strongest DNA topoisomerase I inhibition
3-(4-methylphenyl)-1-(4'-hydroxyphenyl)-2-propen-1-one
-
chalcones (1,3-diaryl-2-propen-1-ones) are alpha, beta-unsaturated ketones with cytotoxic and anticancer properties. Compound shows moderate interference with the DNA topoisomerase I
3-(4-phenyl-2,4'-bipyridin-6-yl)phenol
-
70.4% inhibition at 0.1 mM
3-(6-phenyl-2,2'-bipyridin-4-yl)phenol
-
10.8% inhibition at 0.1 mM
3-(6-phenyl-2,3'-bipyridin-4-yl)phenol
-
8.8% inhibition at 0.1 mM
3-(6-phenyl-2,4'-bipyridin-4-yl)phenol
-
60.8% inhibition at 0.1 mM
3-(imidazolyl-1-propyl)-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline hydrochloride
-
higher activity than the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
3-(piperidin-1-yl)propyl-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxylate
-
-
3-(pyrrolidin-1-yl)propyl-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxylate
-
-
3-amino-4-chloro-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid
-
-
3-amino-6-(3-aminopropyl)-5,6-dihydro-9-methoxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline dihydrochloride
-
-
3-amino-6-(3-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
3-amino-6-(3-azidopropyl)-5,6-dihydro-9-methoxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
-
-
3-bromo-11-hydroxy-2-methyl-4H-naphtho[2,3-h]chromene-4,7,12-trione
-
-
3-bromopropyl 5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxylate
-
-
3-cyano-5,11-dihydro-6-[3-(1H-imidazolyl)propyl]-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinoline
-
-
3-cyano-5,11-dihydro-6-[3-(dimethylamino)propyl]-5,11-dioxoindeno[1,2-c]isquinoline
-
-
3-cyano-6,11-dihydro-5,11-dioxo-6-(3-morpholinylpropyl)-5H-indeno[1,2-c]isoquinoline
-
-
3-cyano-6,11-dihydro-5,11-dioxo-6-[3-(dimethylamino)propyl]-5H-indeno[1,2-c]isoquinoline
-
-
3-iodo-9-methoxy-6-[3-(dimethylamino)propyl]-5H-indeno-[1,2-c]isoquinoline-5,11(6H)-dione
-
-
3-methoxy-5H-isoindolo[2,1-a]quinoxalin-6-one
-
-
3-morpholinopropyl-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxylate
-
-
3-O-(benzenesulfonyloxy)-oleanolic acid
-
-
3-O-[N-(1-naphthyl)-carbamoyl]-17-beta-[N-(1-naphthyl)-carbamoyl]-oleanolic acid
-
-
3-O-[N-(1-naphthyl)-carbamoyl]-oleanolic acid
-
-
3-O-[N-(allyl)carbamoyl]-oleanolic acid
-
-
3-O-[N-(benzyl)carbamoyl]-17beta-O-[N-(benzyl)carbomyl]-oleanolic acid
-
-
3-O-[N-(benzyl)carbamoyl]-oleanolic acid
-
-
3-O-[N-(biphenyl)-p-carbamoyl]-oleanolic acid
-
-
3-O-[N-(phenylsulfonyl)-carbamoyl-17beta-N-(phenylsulfonyl)amide]-oleanolic acid
-
-
3-phenyl-1-(4'-hydroxyphenyl)-2-propen-1-one
-
chalcones (1,3-diaryl-2-propen-1-ones) are alpha, beta-unsaturated ketones with cytotoxic and anticancer properties. Compound shows moderate interference with the DNA topoisomerase I
3-thiiranylmethyloxy-1-hydroxy-5-azaxanthone
-
50% and 27% inhibition at 0.1 mM and 0.02 mM, respectively
3-[(1-azabicyclo[2.2.2]oct-3-ylamino)methyl]-4,11-dihydroxy-1H-naphtho[2,3-f]indole-5,10-dione
-
-
3-[(1-hydroxyethyl-piperazine)-1-propyl]-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
-
similar activity as the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
3-[(1-methylpiperazinyl)-1-propyl]-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
-
weak activity
3-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-3-oxopropanoic acid hydrochloride
-
-
3-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]-isoquinolin-3-yl)amino]-3-oxopropanoic acid
-
-
3-[(dimethylamino)methyl]-4,11-dihydroxy-1H-naphtho[2,3-f]indole-5,10-dione
-
-
3-[(morpholinyl)-1-propyl]-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
-
higher activity than the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
3-[(thiomorpholinyl)-1-propyl]-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
-
similar activity as the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
3-[1-[(4-methylphenyl)sulfonyl]-2-phenyl-1H-indol-3-yl]prop-2-yn-1-yl 3-amino-2,3,6-trideoxy-b-D-arabino-hexopyranoside
-
80.1% inhibition at 0.1 mM
3-[2-(furan-2-yl)-6-phenylpyridin-4-yl]phenol
-
48.8% inhibition at 0.1 mM
3-[2-phenyl-6-(thiophen-2-yl)pyridin-4-yl]phenol
-
9.1% inhibition at 0.1 mM
3-[2-phenyl-6-(thiophen-3-yl)pyridin-4-yl]phenol
-
6.9% inhibition at 0.1 mM
3-[4-phenyl-6-(thiophen-2-yl)pyridin-2-yl]phenol
-
51.2% inhibition at 0.1 mM
3-[4-phenyl-6-(thiophen-3-yl)pyridin-2-yl]phenol
-
75.8% inhibition at 0.1 mM
3-[6-(furan-2-yl)-4-phenylpyridin-2-yl]phenol
-
10.2% inhibition at 0.1 mM
4,11-bis([2-[(2-hydroxyethyl)amino]ethyl]amino)-1H-naphtho[2,3-f]indole-5,10-dione
-
-
4,11-bis[(2-aminoethyl)amino]-1H-naphtho[2,3-f]indole-5,10-dione
-
-
4,11-bis[[2-(dimethylamino)ethyl]amino]-1H-naphtho[2,3-f]indole-5,10-dione
-
-
4,11-bis{[2-(methylamino)ethyl]amino}-1H-naphtho[2,3-f]indole-5,10-dione
-
-
4,11-dihydroxy-3-[(4-methylpiperazin-1-yl)methyl]-1H-naphtho[2,3-f]indole-5,10-dione
-
-
4,4',4'',4'''-porphyrin-5,10,15,20-tetrayltetrabenzoic acid
-
-
4,4',4'',4'''-[1,4-dihydroporphyrin-5,10,15,20-tetrayltetrakis(benzene-4,1-diylmethanediyl)]tetrakis(4-methylmorpholin-4-ium) tetraiodide
-
-
4-(1H-benzo[d]imidazol-2-yl)phenol
-
-
4-(2-hydroxyethyl)-6-([2-[(2-hydroxyethyl)amino]ethyl]amino)-1,2,3,4-tetrahydronaphtho[2,3-f]quinoxaline-7,12-dione
-
-
4-(4,6-diphenylpyridin-2-yl)phenol
-
52.9% inhibition at 0.1 mM
4-(4-phenyl-2,3'-bipyridin-6-yl)phenol
-
44% inhibition at 0.1 mM
4-(5-chlorofuran-2-yl)-2-(3-chlorophenyl)-6-(3-methylthiophen-2-yl) pyridine
-
5.9% inhibition at 0.1 mM
4-(5-chlorofuran-2-yl)-2-(3-chlorophenyl)-6-(5-chlorothiophen-2-yl) pyridine
-
13% inhibition at 0.1 mM
4-(5-chlorofuran-2-yl)-2-(4-chlorophenyl)-6-(3-methylthiophen-2-yl) pyridine
-
5.1% inhibition at 0.1 mM
4-(5-chlorofuran-2-yl)-2-(5-chlorothiophen-2-yl)-6-(furan-2-yl) pyridine
-
23% inhibition at 0.1 mM
4-(5-chlorofuran-2-yl)-2-(5-chlorothiophen-2-yl)-6-p-tolylpyridine
-
14% inhibition at 0.1 mM
4-(5-chlorofuran-2-yl)-2-(furan-2-yl)-6-(3-methylthiophen-2-yl) pyridine
-
7.8% inhibition at 0.1 mM
4-(5-chlorofuran-2-yl)-6-(3-methylthiophen-2-yl)-2,3'-bipyridine
-
21% inhibition at 0.1 mM
4-(6-phenyl-2,4'-bipyridin-4-yl)phenol
-
57.5% inhibition at 0.1 mM
4-(furan-2-yl)-2-(pyridin-2-yl)-5H-chromeno[4,3-b]pyridine
4-(furan-2-yl)-2-(thiophen-2-yl)-5H-chromeno [4,3-b]pyridine
-
9.2% inhibition at 0.1 mM
4-(furan-2-yl)-2-(thiophen-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
4-(furan-2-yl)-2-phenyl-5H-chromeno[4,3-b]pyridine
-
-
4-(furan-3-yl)-2-(thiophen-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
4-(furan-3-yl)-2-phenyl-5H-chromeno[4,3-b]pyridine
-
-
4-(furan-3-yl)-6-(thiophene-2-yl)-[2,4']-bipyridyl
-
shows moderate topoisomerase I inhibitory activities when compared to camptothecin
4-(furan-3-yl)-6-(thiophene-3-yl)-[2,4']-bipyridyl
-
shows moderate topoisomerase I inhibitory activities when compared to camptothecin
4-(pyridin-2-yl)-2-(thiophen-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
4-(pyridin-2-yl)-2-(thiophen-3-yl)-5H-chromeno[4,3-b]pyridine
-
3.3% inhibition at 0.1 mM
4-(thiophene-3-yl)-6-(thiophene-2-yl)-[2,2']-bipyridyl
-
shows significant topoisomerase I inhibitory activities at 20 microM and 100 microM concentration
4-(thiophene-3-yl)-6-(thiophene-2-yl)-[2,4']-bipyridyl
-
shows significant topoisomerase I inhibitory activities at 20 microM and 100 microM concentration
4-chloro-N-[5-imino-1-(quinoxalin-2-yl)-2,5-dihydro-1H-1,2,4-triazol-3-yl]-5-methyl-2-sulfanylbenzenesulfonamide
-
-
4-hydroxy-5-methoxy-1-nitroanthracene-9,10-dione
-
-
4-methyl-5H-isoindolo[2,1-a]quinoxalin-6-one
-
-
4-phenyl-2-(pyridin-2-yl)-5H-chromeno[4,3-b]pyridine
4-phenyl-2-(thiophen-2-yl)-5H-chromeno[4,3-b]pyridine
4-[(6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-4-oxobutanoic acid
-
-
4-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-4-oxobutanoic acid hydrochloride
-
-
4-[2-(furan-2-yl)-6-phenylpyridin-4-yl]phenol
-
5.0% inhibition at 0.1 mM
4-[4-phenyl-6-(thiophen-2-yl)pyridin-2-yl]phenol
-
4.9% inhibition at 0.1 mM
4-[4-phenyl-6-(thiophen-3-yl)pyridin-2-yl]phenol
-
20.4% inhibition at 0.1 mM
4-[5-(4-methyl-1-piperazinyl)-1H,1H'-2,5'-bibenzimidazol-2'-yl]phenol
-
Hoechst 33258
4-[6-(furan-2-yl)-4-phenylpyridin-2-yl]phenol
-
18.6% inhibition at 0.1 mM
4-[[(6-amino-3-methylpyrido[2,3-b]pyrazin-8-yl)amino]methyl]benzenesulfonamide
-
-
5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carbonitrile
-
-
5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxylic acid
-
-
5,12-dioxo-5,12-dihydroindolizino[3,2-g]quinoline-11-carbonitrile
-
-
5,12-dioxo-N-(2-(piperidin-1-yl)ethyl)-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
5,12-dioxo-N-(3-(piperidin-1-yl)propyl)-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
5,12-dioxo-N-(3-(pyrrolidin-1-yl)propyl)-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
5,12-dioxo-N-(3-phenylpropyl)-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
5,12-dioxo-N-phenethyl-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
5,9,11-trimethoxy-2-methyl-4H-naphtho[2,3-h]chromene-4,7,12-trione
-
-
5-(4-ethylpiperazin-1-yl)-11H-indeno[1,2-c]isoquinolin-11-ol
-
-
5-(4-ethylpiperazin-1-yl)-11H-indeno[1,2-c]isoquinolin-11-one
-
-
5-(4-ethylpiperazin-1-yl)-11H-indeno[1,2-c]isoquinoline
-
-
5-(4-methyl-1,4-diazepan-1-yl)-11H-indeno[1,2-c]isoquinolin-11-one
-
-
5-(4-methyl-1,4-diazepan-1-yl)-11H-indeno[1,2-c]isoquinoline
-
-
5-(4-methylpiperazin-1-yl)-11H-indeno[1,2-c]isoquinolin-11-ol
-
-
5-(4-methylpiperazin-1-yl)-11H-indeno[1,2-c]isoquinolin-11-one
-
-
5-(4-methylpiperazin-1-yl)-11H-indeno[1,2-c]isoquinoline
-
-
5-(4-methylpiperazin-1-yl)-2-(4-(6-(prop-2-ynyloxy)-hexyloxy)phenyl)-1H-benzo[d]imidazole
-
-
5-(butylamino)-11H-indeno[1,2-c]isoquinolin-11-one
-
-
5-(morpholin-4-yl)-11H-indeno[1,2-c]isoquinolin-11-ol
-
-
5-(morpholin-4-yl)-11H-indeno[1,2-c]isoquinolin-11-one
-
-
5-(morpholin-4-yl)-11H-indeno[1,2-c]isoquinolin-11-yl acetate
-
-
5-(morpholin-4-yl)-11H-indeno[1,2-c]isoquinoline
-
-
5-(piperazin-1-yl)-11H-indeno[1,2-c]isoquinolin-11-one
-
-
5-deoxy-5-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)-D-arabinitol
-
-
5-phenyl-2'-(indolo-6-yl)bibenzimidazole
-
5P2'IBB
5-[(6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-5-oxopentanoic acid
-
-
5-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-5-oxopentanoic acid hydrochloride
-
-
6'-(thiophene-2-yl)-[3,4',2',4'']-terpyridine
-
shows moderate topoisomerase I inhibitory activities when compared to camptothecin
6'-(thiophene-2-yl)-[4,2',4',4'']-terpyridine
-
shows moderate topoisomerase I inhibitory activities when compared to camptothecin
6-(1-hydroxypropan-2-yl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(2,3-dihydroxypropyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(2-hydroxypropyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-(1H-imidazol-1-yl)propyl)-8-methoxy-3-nitro-5Hindeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-amino-2-hydroxypropyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-aminopropyl)-3-(methylamino)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-aminopropyl)-3-nitro-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-aminopropyl)-5,6-dihydro-8-methoxy-3-nitro-5,11-dioxo-11H-indeno[1,2-c]isoquinoline hydrochloride
-
-
6-(3-aminopropyl)-5,6-dihydro-9-methoxy-3-iodo-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
-
-
6-(3-aminopropyl)-7-methoxy-3-nitro-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-aminopropyl)-9-methoxy-3-nitro-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-azidopropyl)-5,6-dihydro-8-methoxy-3-nitro-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
-
-
6-(3-bromopropyl)-5,6-dihydro-8-methoxy-3-nitro-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
-
-
6-(3-homopiperazinyl-1-propyl)-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline dihydrochloride
-
higher activity than the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
6-(3-hydroxy-2-oxopropyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-hydroxypropyl)-3-nitro-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-piperazinyl-1-propyl)-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline dihydrochloride
-
similar activity as the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
6-(3-thiazolylamino-1-propyl)-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline dihydrochloride
-
higher activity than the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
6-(4-methylpiperazin-1-yl)-2'-(4-(10-(prop-2-ynyloxy)-decyloxy)phenyl)-1H,3'H-2,5'-bibenzo[d]imidazole
-
-
6-(4-methylpiperazin-1-yl)-2'-(4-(12-(prop-2-ynyloxy)-dodecyloxy)phenyl)-1H,3'H-2,5'-bibenzo[d]imidazole
-
-
6-(4-methylpiperazin-1-yl)-2'-(4-(6-(prop-2-ynyloxy)-hexyloxy)phenyl)-1H,3'H-2,5'-bibenzo[d]imidazole
-
-
6-(4-methylpiperazin-1-yl)-2'-(4-(8-(prop-2-ynyloxy)-octyloxy)phenyl)-1H,3'H-2,5'-bibenzo[d]imidazole
-
-
6-(4-methylpiperazin-1-yl)-2-(4-(2-(4-(oct-7-ynyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-1H-benzo[d]imidazole
-
-
6-(4-methylpiperazin-1-yl)-2-[4-[(prop-2-yn-1-yl)oxy]phenyl]-1H-benzimidazole
-
-
6-(4-methylpiperazine-1-carbonyl)indolizino[2,3-g]quinoline-5,12-dione
-
-
6-(furan-2-yl)-4-(furan-3-yl)-[2,2']-bipyridyl
-
shows moderate topoisomerase I inhibitory activities when compared to camptothecin
6-(furan-2-yl)-4-(furan-3-yl)-[2,4']-bipyridyl
-
shows moderate topoisomerase I inhibitory activities when compared to camptothecin
6-(furan-2-yl)-4-(thiophene-2-yl)-[2,4']-bipyridyl
-
shows significant topoisomerase I inhibitory activities at 20 microM and 100 microM concentration
6-(furan-2-yl)-4-(thiophene-3-yl)-[2,4']-bipyridyl
-
shows moderate topoisomerase I inhibitory activities when compared to camptothecin
6-(furan-2-yl)-[3,4',2',4'']-terpyridine
-
shows significant topoisomerase I inhibitory activities at 20 microM and 100 microM concentration
6-(morpholine-4-carbonyl)indolizino[2,3-g]quinoline-5,12-dione
-
-
6-(piperidine-1-carbonyl)indolizino[2,3-g]quinoline-5,12-dione
-
-
6-acetyl-7-amino-indolizino[2,3-g]quinoline-5,12-dione
-
-
6-acetyl-7-bromo-indolizino[2,3-g]quinoline-5,12-dione
-
-
6-acetyl-7-chloro-indolizino[2,3-g]quinoline-5,12-dione
-
-
6-acetyl-7-fluoro-indolizino[2,3-g]quinoline-5,12-dione
-
-
6-acetyl-7-hydroxy-indolizino[2,3-g]quinoline-5,12-dione
-
-
6-acetylindolizino[2,3-g]quinoline-5,12-dione
-
-
6-methylindolizino[2,3-g]quinoline-5,12-dione
-
-
6-N-(1-hydroxymethyl-2-hydroxy)ethylamino-12,13-dihydro-2,10-dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,6(6H)-dione
-
also effective against cancer cells with P-glycoprotein-mediated resistance to adriamycin or taxol
6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosyl)-5G-indolo(2,3-a)pyrrolo(3,4-c)carbarole-5,7(6H)-dione
-
more potent than camptothecin for inhibiting the top1-mediated religation step
6-[(2-chlorobenzyl)sulfanyl]-9-(beta-L-ribofuranosyl)-9H-purin-2-amine
-
-
6-[(2R)-1-hydroxypropan-2-yl]-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-[(2R)-2,3-dihydroxypropyl]-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-[(2R)-2-hydroxypropyl]-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-[(2S)-1-hydroxypropan-2-yl]-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-[(2S)-2,3-dihydroxypropyl]-2,3-dimethoxy-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-[(2S)-2,3-dihydroxypropyl]-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-[(2S)-2-hydroxypropyl]-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-[(3-morpholylethylamino)-1-propyl]-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
-
higher activity than the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
6-[(6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-6-oxohexanoic acid
-
-
6-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-6-oxohexanoic acid hydrochloride
-
-
6-[3-(1H-imidazol-1-yl)propyl]-2,3-dimethoxy-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
higher activity than the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
6-[3-(1H-imidazol-1-yl)propyl]-2,3-dimethoxy-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
-
-
6-[3-(1H-imidazol-1-yl)propyl]-3-nitro-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione hydrochloride
-
higher activity than the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
6-[3-(1H-imidazol-1-yl)propyl]-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
higher activity than the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
6-[3-(3-hydroxypiperidinyl)-1-propyl]-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline hydrochloride
-
higher activity than the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
6-[3-(4-aminopiperidinyl)-1-propyl]-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline dihydrochloride
-
weak activity
6-[3-pyrazolyl-1-propyl]-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
-
similar activity as the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
6-[3-[(2-hydroxyethyl)amino]propyl]-2,3-dimethoxy-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
-
-
6-[3-[2-(1,2,4)]-triazolyl-1-propyl]-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline hydrochloride
-
higher activity than the parent compound 2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
7-(2-furoyl)-10-methoxyhomocamptothecin
-
-
7-(2-naphthoyl)-10-methoxyhomocamptothecin
-
-
7-(2-thenoyl)-10-methoxyhomocamptothecin
-
-
7-(3,5-dimethylbenzoyl)-10-methoxyhomocamptothecin
-
-
7-(4-chlorbenzoyl)-10-methoxyhomocamptothecin
-
-
7-(4-fluorobenzoyl)-10-methoxyhomocamptothecin
-
-
7-(4-methoxylbenzoyl)-10-methoxyhomocamptothecin
-
-
7-(4-toluyl)-10-methoxyhomocamptothecin
-
-
7-(4-triflouromethylbenzoyl)-10-methoxyhomocamptothecin
-
-
7-benzoyl-10-methoxyhomocamptothecin
-
-
7-butyryl-10-methoxyhomocamptothecin
-
-
7-cyclohexyl-10-methoxyhomocamptothecin
-
-
7-cyclohexylcabonyl-10-methoxyhomocamptothecin
-
-
7-cyclopentyl-10-methoxyhomocamptothecin
-
-
7-cyclopentylcabonyl-10-methoxyhomocamptothecin
-
-
7-cyclopropylcabonyl-10-methoxyhomocamptothecin
-
-
7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin
-
strong synergism between irinotecan and 5-fluorouracil
7-heptanoyl-10-methoxyhomocamptothecin
-
-
7-isobutyryl-10-methoxyhomocamptothecin
-
-
7-ketoroyleanone
-
diterpenoid from Orthosiphon wulfenioides
7-pentanoyl-10-methoxyhomocamptothecin
-
-
7-propionyl-10-methoxyhomocamptothecin
-
-
8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-one
-
i.e. ARC-111
8,9-dimethoxy-5-(2-N-methylaminoethyl)-2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-one
-
i.e. Genz-644282
8-bromo-9-cyano-7-(alpha-L-xylofuranosyl)-3,7-dihydroimidazo[1,2-c]pyrrolo[3,2-e]pyrimidin-4-ium
-
-
8-methoxy-6-(3-morpholinopropyl)-3-nitro-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
9,9'-[butane-1,4-diylbis(oxy)]bis(10-methoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium) dichloride
-
synthetic protoberberine alkaloid, highly active
9,9'-[ethane-1,2-diylbis(oxy)]bis(10-methoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium)dichloride
-
synthetic protoberberine alkaloid, highly active
9,9'-[heptane-1,7-diylbis(oxy)]bis(10-methoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium) dichloride
-
synthetic protoberberine alkaloid, highly active
9,9'-[hexane-1,6-diylbis(oxy)]bis(10-methoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium) dichloride
-
synthetic protoberberine alkaloid, highly active
9,9'-[pentane-1,5-diylbis(oxy)]bis(10-methoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium) dichloride
-
synthetic protoberberine alkaloid, highly active
9,9'-[propane-1,3-diylbis(oxy)]bis(10-methoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium) dichloride
-
synthetic protoberberine alkaloid, highly active. Strongly stabilize the enzyme-DNA binary complex at low concentration (50100microM). From 0.1 to 1 mM, their ability to stabilize is weak
9-aminoacridine
-
acts as Top1 poison
9-O-(2-aminoethyl)berberine
-
synthetic protoberberine alkaloid
9-O-(2-hydroxyethyl)berberine
-
synthetic protoberberine alkaloid
9-O-[2-(1H-imidazol-1-yl)ethyl]berberine
-
synthetic protoberberine alkaloid
9-O-[2-(4-methylpiperazin-1-yl)ethyl]berberine
-
synthetic protoberberine alkaloid
actinomycin D
-
traps topoisomerase I-DNA covalent complexes
Aminocatechol A-3253
-
Candida enzyme is more susceptible than the human enzyme
antofine
-
alkaloid from Cynanchum komarovii
berberrubine
-
natural protoberberine alkaloid
beta-octabromo-meso-tetra(4-carboxyl)phenyl porphyrin
-
-
beta-octaphenyl-meso-tetra(4-carboxyl)phenyl porphyrin
-
-
bis(2,2-dichloro-6-[[2-(hydroxy-kO)benzylidene]amino-kN]-4H-1,3,2-benzodioxastannin-4-onato)copper(2+)
-
-
bis(2-hydroxy-5-[[2-(hydroxy-kO)benzylidene]amino-kN]benzoato)copper(2+)
-
-
bis(5,6-dimethyl-1H-benzo[d]imidazol-2-yl)methane
-
-
bis(5-methyl-1H-benzo[d]imidazol-2-yl)methane
-
-
bulgarein
-
stabilize inactive Top1cc
calothrixins
-
weak inhibitors of Top1
chrysin 6-C-beta-D-glucopyranosyl 8-C-alpha-L-arabinopyranoside
-
flavonoid from Scutellaria amoena
cis-2',5,7-trihydroxyflavanonol 3-O-beta-D-glucopyranoside
-
flavonoid from Scutellaria amoena
cisplatin
-
presence of DNA adducts of bifunctional antitumor cisplatin or monodentate [PtCl(dien)]Cl in the substrate DNA inhibits eukaryotic top1 action, the adducts of cisplatin being more effective
colcemid
-
microtubule inhibitor, arrests cells in M phase, followed by induction of apotosis, 1 and 5 ng/ml colcemid display only modest cytotoxic effects. 10, 50 and 100 ng/ml induce pronounced cell death as measured by flow cytometry analysis
coptisine
-
natural protoberberine alkaloid
coralyne
-
potent and selective Top1 inhibitor
corypalline
-
moderate inhibition
dehydrocavidine
-
moderate inhibition
dehydrocheilanthifoline
-
moderate inhibition
dehydrodiscretamine
-
moderate inhibition
diaqua(2,2'-diamino-4,4'-bi-1,3-thiazole)oxosulfato-vanadium(IV) tetrahydrate
-
-
-
dihydrobenzo[a]acridines
-
-
-
dihydrotanshinone I
-
diterpenoid from Salvia castanea f. tomentos
diospyrin
-
promotes protein conformational changes that can affect the kinase activity of Top1 altering SR protein phosphorylation and alternative splicing
erybraedin C
-
binds irreversibly to the enzyme alone, probably in proximity of the active site, without abolishing enzyme binding to the DNA
ethyl 10-amino-5,12-dioxo-5,12-dihydroindolizino[3,2-g]quinoline 11-carboxylate
-
-
ethyl 10-bromo-5,12-dioxo-5,12-dihydroindolizino[3,2-g]quinoline 11-carboxylate
-
-
ethyl 10-chloro-5,12-dioxo-5,12-dihydroindolizino[3,2-g]quinoline 11-carboxylate
-
-
ethyl 10-fluoro-5,12-dioxo-5,12-dihydroindolizino[3,2-g]quinoline 11-carboxylate
-
-
ethyl 10-hydroxy-5,12-dioxo-5,12-dihydroindolizino[3,2-g]quinoline 11-carboxylate
-
-
ethyl 10-methyl-5,12-dioxo-5,12-dihydroindolizino[3,2-g]quinoline 11-carboxylate
-
-
ethyl 2-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl)amino]acetate hydrochloride
-
-
ethyl 2-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]acetate
-
-
ethyl 5,12-dioxo-5,12-dihydroindolizino[2,3-g]isoquinoline-6-carboxylate
-
-
ethyl 5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline 6-carboxylate
-
-
ethyl 5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxylate
-
-
ethyl 5,12-dioxo-5,12-dihydroindolizino[3,2-g]isoquinoline-11-carboxylate
-
-
ethyl 5,12-dioxo-5,12-dihydroindolizino[3,2-g]quinoline 11-carboxylate
-
-
ethyl 6,11-dioxo-6,11-dihydrobenzo[f]-pyrido[1,2-alpha]indole 12-carboxylate
-
-
ethyl 7-amino-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline 6-carboxylate
-
-
ethyl 7-bromo-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline 6-carboxylate
-
-
ethyl 7-chloro-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline 6-carboxylate
-
-
ethyl 7-fluoro-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline 6-carboxylate
-
-
ethyl 7-hydroxy-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline 6-carboxylate
-
-
ethyl 7-methyl-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline 6-carboxylate
-
-
evodiamine
-
EVO, an alkaloidal compound isolated from Evodia rutaecarpa, is able to inhibit supercoiled plasmid DNA relaxation catalyzed by TopI by stabilizing topoisomerase I-DNA cleavable complex
feruloyl agmatine
-
moderate inhibition
fomitellic acid A
-
0.1 mM, 85% inhibition, IC50: 0.06 mM
fomitellic acid B
-
0.1 mM, 85% inhibition
gemcitabine
-
nucleoside analogue
glutathione S-transferase-Par-4
-
-
-
Heliquinomycin
-
at 0.1 mg/ml
indeno[1,2-c]isoquinolinone
-
-
indolizino[2,3-g]quinoline-5,12-dione
-
-
indolizino[3,2-g]quinoline-5,12-dione
-
-
isodiospyrin
-
inhibits by direct binding to htopo I, inhibits relexation activity and kinase activity, antagonizes camptothecin-induced DNA cleavage by htopo I
Jatrorrhizine
-
natural protoberberine alkaloid
jatrorubine
-
natural protoberberine alkaloid
lamellarin D
-
stabilize inactive Top1cc
methyl (7aS,12aS)-5-methylidene-13-oxo-5,7a,12a,13-tetrahydro-7H-[1]benzofuro[3,2-c]benzo[g]chromene-9-carboxylate
-
-
methyl 2-(4-Hydroxyphenyl)-6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazole-4-carboxylate
-
-
methyl 2-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl)amino]-2-oxoacetate
-
-
methyl 2-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-2-oxoacetate
-
-
methyl 3-[(6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-3-oxopropanoate
-
-
methyl 3-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl)amino]-3-oxopropanoate
-
-
methyl 3-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-3-oxopropanoate
-
-
methyl 4-[(6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-4-oxobutanoate
-
-
methyl 4-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl)amino]-4-oxobutanoate
-
-
methyl 4-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-4-oxobutanoate
-
-
methyl 5-[(6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-5-oxopentanoate
-
-
methyl 5-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl)amino]-5-oxopentanoate
-
-
methyl 5-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-5-oxopentanoate
-
-
methyl 6-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl)amino]-6-oxohexanoate
-
-
methyl 6-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-6-oxohexanoate
-
-
methyl N-[(6-methyl-5,7-dioxo-5,6,7,13-tetrahydro-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)acetyl]glycinate
-
-
methyl [[5-carbamoyl-6-(methylsulfanyl)-4-oxo-3-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl]sulfanyl]acetate
-
-
monodentate [PtCl(diethylenetriamine)]Cl
-
presence of DNA adducts of bifunctional antitumor cisplatin or monodentate [PtCl(dien)]Cl in the substrate DNA inhibits eukaryotic top1 action, the adducts of cisplatin being more effective. Inhibition is markedly enhanced by camptothecin. Sequence preference of Pt-DNA adducts in the 161-bp substrate DNA fragment. Inhibition mechanism and interaction analysis, overview
morpholinodoxorubicin
-
traps topoisomerase I-DNA covalent complexes
N,N',N'',N'''-[1,4-dihydroporphyrin-5,10,15,20-tetrayltetrakis(benzene-4,1-diylmethanediyl)]tetrakis(2-hydroxy-N,N-dimethylethanaminium) tetrabromide
-
-
N,N',N'',N'''-[1,4-dihydroporphyrin-5,10,15,20-tetrayltetrakis(benzene-4,1-diylmethanediyl)]tetrakis(N,N-dimethylanilinium) tetrabromide
-
-
N,N',N'',N'''-[1,4-dihydroporphyrin-5,10,15,20-tetrayltetrakis(benzene-4,1-diylmethanediyl)]tetrakis(N-ethyl-N-methylethanaminium) tetrabromide
-
-
N,N',N'',N'''-[1,4-dihydroporphyrin-5,10,15,20-tetrayltetrakis(benzene-4,1-diylmethanediyl)]tetrakis[2-hydroxy-N-(2-hydroxyethyl)-N-methylethanaminium] tetrabromide
-
-
N,N-diethyl-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
N,N-diethyl-9-([2-(1H-indol-3-yl)ethyl]amino)acridine-3-carboxamide
-
-
N-(2-(1H-imidazol-1-yl)ethyl)-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
N-(2-(4-methylpiperazin-1-yl)ethyl)-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
N-(2-(dimethylamino)ethyl)-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
N-(2-(pyrrolidin-1-yl)ethyl)-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
N-(2-morpholinoethyl)-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
N-(3-(4-methylpiperazin-1-yl)propyl)-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
N-(3-(diethylamino)propyl)-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
N-(3-(dimethylamino)propyl)-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
N-(3-morpholinopropyl)-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
N-butyl-11H-indeno[1,2-c]isoquinolin-5-amine
-
-
N-ethyl-5,12-dioxo-5,12-dihydroindolizino[2,3-g]quinoline-6-carboxamide
-
-
N-[1-benzyl-2-(4-ethylpiperazin-1-yl)-2-oxoethyl]-2-(6-methyl-5,7-dioxo-5,6,7,13-tetrahydro-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)acetamide
-
-
N-[1-[(4-ethylpiperazin-1-yl)carbonyl]-3-methylbutyl]-2-(6-methyl-5,7-dioxo-5,6,7,13-tetrahydro-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)acetamide
-
-
N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide
-
-
N-[2-(Dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines
-
-
-
N-[6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl]acetamide
-
-
N-[6-(3-azidopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl]acetamide
-
-
N-[6-(3-hydroxypropyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl]acetamide
-
-
N-[9-acetyl-6-(benzylsulfanyl)-9H-purin-2-yl]acetamide
-
-
nick-containing oligonucleotides
-
inhibit DNA substrate relaxation. Synthesis of and enzyme inhibition by a series of oligonucleotides with various lengths that contain nick and topoisomerase I-binding sites, sequences, overview. The position of the nick as well as the length of the oligonucleotides are crucial factors for the inhibition of the nuclear enzyme
-
nick-containing oligonucleotides s
-
inhibit DNA substrate relaxation. Synthesis of and enzyme inhibition by a series of oligonucleotides with various lengths that contain nick and topoisomerase I-binding sites, sequences, overview. The position of the nick as well as the length of the oligonucleotides are crucial factors for the inhibition of the nuclear enzyme
-
novobiocin
-
inhibits the ATPase activity
NSC 314622
-
cytotoxicity results of its direct action upon topoisomerase 1 in cells
oligo-1,3-thiazolecarboxamides
-
-
-
palmatrubine
-
natural protoberberine alkaloid
Par-4
-
tumor suppressor protein, prostate apoptosis response-4, binds to TOP1, via its leucine zipper domain, and prevents TOP1 interaction with the DNA
-
platinum(II) complex
-
-
-
plukenetione A
-
can inhibit the unwinding activity of Top1
pyrazoloacridine
-
completely suppresses the ability of topoisomerase I to relax supercoiled DNA at a concentration of 0.008 mM, inhibits the enzyme without trapping cleavable complexes
Selenite
-
selenite induces topoisomerase I-DNA complexes in K562 cells
SN38
-
enzyme linker fluctuations can have an impact on SN38 binding by reducing the enzyme affinity for the drug. TOP1 mutations are involved in the development of SN38 resistance
SR proteins
-
inhibition of DNA nicking activity by SR proteins. Inhibition of the DNA nicking activity of Topo I by SRSF1 depends on RNA recognition motifs joined by a spacer, Topo I enzyme inhibition by spacer mutants, overview
-
Tax oncoprotein
-
from HTLV-1, inhibits DNA binding of topoisomerase I, which is the first step of the reaction catalyzed by the enzyme
-
tert-butyl 3-(4-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]-imidazol-2-yl)phenoxy)propylcarbamate
-
-
thiazole-containing oligopeptides
-
inhibitory effect increases with the number of thiazole units. Inhibitory properties of thiazole-containing oligopeptides containing 3 or 4 thiazole units are 3-10tímes better than those of distamycin A
-
Tumor necrosis factor alpha
-
TNFalpha induces receptor-mediated apotosis. Receptor-mediated apoptosis induced by TNFalpha results in a very strong htopoI damage response, further indicating a general involvement of htopoI in apoptosis
-
ursolic acid
-
complete inhibition above 0.2 mM, IC50: 0.25 mM
winchic acid
-
triterpenoid from Winchia calophylla
zinc bis(2-[(E)-[(2,2-dichloro-4-oxo-4H-1,3,2-benzodioxastannin-6-yl)imino]methyl]phenolate)
-
-
zinc bis(2-[(E)-[(3-carboxy-4-hydroxyphenyl)imino]methyl]phenolate)
-
-
[2,2',2'',2''',2'''',2''''',2''''''-([24-((2-[diethyl(methyl)ammonio]ethyl)sulfanyl)-14,19-dihydro-29H,31H-tetrabenzoporphine-2,3,9,10,16,17,23-heptayl-k4N29,N30,N31,N32]heptasulfanediyl)heptakis(N,N,N-trimethylethanaminiumato)(2-)]zinc(8+) octaiodide
-
-
[3-[(E)-2-carboxyethenyl]phenyl](dihydroxy)oxoantimonate(2-)
-
partial or complete inhibition of hTopo is only observed at relatively high compound concentrations in the range 5 to 20 microM
(-)-epigallocatechin
-
(-)-epigallocatechin
i.e. (2R,3R)-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol
(-)-gallocatechin
-
(-)-gallocatechin
i.e. (2R,3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-2,3-dihydro-4H-1-benzopyran-4-one
camptothecin
-
camptothecin
inhibitory effect to wild-type
indenoisoquinoline
-
indenoisoquinoline
NSC314622
irinotecan
-
quercetin
-
quercetin
i.e. 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydro-4H-1-benzopyran-4-one
topotecan
-
(2S,3R,4S,6R)-4-amino-2-methyl-6-(3-(2-phenyl-1H-indol-3-yl)prop-2-ynyloxy)tetrahydro-2H-pyran-3-ol
-
20.2% inhibition at 0.1 mM
(2S,3R,4S,6R)-4-amino-2-methyl-6-(3-(2-phenyl-1H-indol-3-yl)prop-2-ynyloxy)tetrahydro-2H-pyran-3-ol
-
8.2% inhibition at 0.1 mM
1-ethyl-3-(6-nitrobenzoxazol-2-yl)-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4(1H)-quinolone
-
-
1-ethyl-3-(6-nitrobenzoxazol-2-yl)-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4(1H)-quinolone
-
interacts with DNA-Top I complex and induces cancer cell apoptosis to produce antitumor effects, in vivo inhibition of anchorage-dependent colony formation
10-Hydroxycamptothecin
-
-
10-Hydroxycamptothecin
-
camptothecin stabilizes Top1/dsDNA covalent complexes which ultimately results in cell death. Structure-activity-relationships for camptothecin and derivatives, modeling and calculation of interaction energies between bound camptothecin, and derivatives, and Top1/dsDNA, comparisons of different models, e.g. rotated +1 nucleoside and intercalated models, overview
2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
-
-
2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
-
novel functionalities appended to the lactam side chain of the indenoisoquinolines. Development of indenoisoquinoline Top1 inhibitors where the di(methoxy) and methylenedioxy substituents on the aromatic nucleus are combined with previously utilized and novel heterocyclic lactam side chains in an effort to improve the anticancer activity of the indenoisoquinolines
2,3-dimethoxy-6-methyl-5H-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
-
i.e. NSC 314622
2,4-di(furan-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
2,4-di(furan-2-yl)-5H-chromeno[4,3-b]pyridine
-
46.4% inhibition at 0.1 mM#
2-(furan-2-yl)-4-(pyridin-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
2-(furan-2-yl)-4-(pyridin-2-yl)-5H-chromeno[4,3-b]pyridine
-
11.5% inhibition at 0.1 mM
2-(furan-2-yl)-4-(pyridin-3-yl)-5H-chromeno[4,3-b]pyridine
-
-
2-(furan-2-yl)-4-(pyridin-3-yl)-5H-chromeno[4,3-b]pyridine
-
41.6% inhibition at 0.1 mM
2-(furan-2-yl)-4-phenyl-5H-chromeno[4,3-b]pyridine
-
-
2-(furan-2-yl)-4-phenyl-5H-chromeno[4,3-b]pyridine
-
4.9% inhibition at 0.1 mM
2-(pyridin-2-yl)-4-(pyridin-3-yl)-5H-chromeno[4,3-b]pyridine
-
-
2-(pyridin-2-yl)-4-(pyridin-3-yl)-5H-chromeno[4,3-b]pyridine
-
2.6% inhibition at 0.1 mM
2-(pyridin-2-yl)-4-(thiophen-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
2-(pyridin-2-yl)-4-(thiophen-2-yl)-5H-chromeno[4,3-b]pyridine
-
48.2% inhibition at 0.1 mM
2-phenyl-4-(thiophen-3-yl)-5H-chromeno[4,3-b]pyridine
-
-
2-phenyl-4-(thiophen-3-yl)-5H-chromeno[4,3-b]pyridine
-
3.6% inhibition at 0.1 mM
4-(furan-2-yl)-2-(pyridin-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
4-(furan-2-yl)-2-(pyridin-2-yl)-5H-chromeno[4,3-b]pyridine
-
4.4% inhibition at 0.1 mM
4-phenyl-2-(pyridin-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
4-phenyl-2-(pyridin-2-yl)-5H-chromeno[4,3-b]pyridine
-
3.1% inhibition at 0.1 mM
4-phenyl-2-(thiophen-2-yl)-5H-chromeno[4,3-b]pyridine
-
-
4-phenyl-2-(thiophen-2-yl)-5H-chromeno[4,3-b]pyridine
-
5.5% inhibition at 0.1 mM
Berberine
-
moderate inhibition
Berberine
-
natural protoberberine alkaloid
camptothecin
-
-
677937, 681292, 690972, 691137, 691221, 691321, 691728, 691729, 692246, 693067, 693113, 694447, 702579, 702602, 705047, 705973, 714448, 714814, 714900, 714903, 715867, 716380, 727170, 728098, 728293, 728560, 728639, 747693, 748187, 748337, 749223, 750368
camptothecin
-
79% inhibition at 0.1 mM
camptothecin
-
DNA topoisomerase inhibitors are efficient and reversible inducers of premature senescence in normal cells
camptothecin
-
anticancer agent camptothecin (CPT)
camptothecin
-
Camptothecin poisoning of TopIB induces accumulation of positively supercoiled DNA in G1- and S-phase yeast cells. Mechanism of camptothecin-induced toxicity derives from TopIB-dependent accumulation of positive supercoils
camptothecin
-
class I topoisomerase poison. Pentacyclic natural alkaloid produced by the plant Camptotheca accuminata
camptothecin
-
Topoisomerase I inhibitor added for measuring the inhibition of DNA relaxation
camptothecin
-
topoisomerase I poison
camptothecin
-
when CPT is added the cleavage religation equilibrium is shifted toward cleavage
camptothecin
-
a selective inhibitor of DNA topoisomerase I. Camptothecin activates the transcription of low-abundance antisense RNAs at the HIF-1alpha gene locus in human cancer cells in a topoisomerase I-dependent manner, likely due to sustained drug interference with transcription regulation mechanisms leading to a more open chromatin conformation and de-repression/activation of antisense transcription. Top1cc is then a specific DNA damage induced by the drug, damage and repair mechanisms, detailed overview
camptothecin
-
camptothecin stabilizes Top1/dsDNA covalent complexes which ultimately results in cell death. Structure-activity-relationships for camptothecin and derivatives, modeling and calculation of interaction energies between bound camptothecin, and derivatives, and Top1/dsDNA, comparisons of different models, e.g. rotated +1 nucleoside and intercalated models, overview
camptothecin
-
response to camptothecin-based treatment is dependent on hTopI activity, and reduction in activity as well as mutations in hTopI result in camptothecin resistance
camptothecin
-
the natural compound reversibly binds the covalent Top1-DNA complex slowing down the religation of the cleaved DNA strand, thus inducing cell death
doxorubicin
-
-
doxorubicin
-
inhibits the enzyme without trapping cleavable complexes
irinotecan
-
-
irinotecan
-
a prodrug and it is activated by hydrolysis to the biologically active metabolite SN-38
irinotecan
-
i.e. CPT-11, a derivative of camptothecin and an anticancer agent in the treatment of metastatic colon cancer
irinotecan
-
water-soluble camptothecin derivative
palmatine
-
moderate inhibition
palmatine
-
natural protoberberine alkaloid
SN-38
-
-
SN-38
-
active metabolite of CPT-11
topotecan
-
-
691264, 692246, 694447, 705047, 714760, 716380, 727417, 728560, 728639, 747693, 750368
topotecan
-
Camptothecin analogue, induce cell death by poisoning DNA topoisomerase I, topotecan significantly hinders topoisomerase-mediated DNA uncoiling, with a more pronounced effect on the removal of positive (overwound) versus negative supercoils. Significant activity against adult and paediatric solid tumours
topotecan
-
water-soluble camptothecin derivative, topotecan mimics a DNA base-pair and binds at the site of DNA cleavage by intercalating between the upstream (?1) and downstream (+1) base-pairs interacting also with the enzyme, acting as an interfacial uncompetitive inhibitor
additional information
biological results for substituted compounds revealed a disagreement between the structure-activity relationships of monomeric indenoisoquinoline and bisindenoisoquinoline as Top1 inhibitors, but cytotoxicity maintained for both series of compounds. Bisindenoisoquinoline to determine effect of indenoisoquinoline dimerization on cytotoxicity and Top1 inhibition. It is conceivable that it could exert antitumor activity by targeting DNA itself, apart from Top1
-
additional information
-
biological results for substituted compounds revealed a disagreement between the structure-activity relationships of monomeric indenoisoquinoline and bisindenoisoquinoline as Top1 inhibitors, but cytotoxicity maintained for both series of compounds. Bisindenoisoquinoline to determine effect of indenoisoquinoline dimerization on cytotoxicity and Top1 inhibition. It is conceivable that it could exert antitumor activity by targeting DNA itself, apart from Top1
-
additional information
-
-
additional information
cytotoxicities in cancer cells and topoisomerase I inhibitory activities of norindenoisoquinoline derivatives, molecular modeling, overview
-
additional information
-
cytotoxicities in cancer cells and topoisomerase I inhibitory activities of norindenoisoquinoline derivatives, molecular modeling, overview
-
additional information
inhibitor binding in the topoisomerase I-DNA covalent complex, molecular docking and quantum chemical calculations, overview
-
additional information
-
inhibitor binding in the topoisomerase I-DNA covalent complex, molecular docking and quantum chemical calculations, overview
-
additional information
molecular design, synthesis and docking study of benz[b]oxepines and 12-oxobenzo[c]phenanthridinones, inhibitory potencies against topo 1, overview. Cytotoxic activity of inhibitors against human cancer cell lines, overview
-
additional information
synthesis and inhibitory potency of a series of water-soluble aromathecins substituted at position 14 with diaminoalkanes of various lengths, that all show antiproliferative potency. Aromathecins with longer diaminoalkane substituents over 6Cs possess lower anti-top1 activity than their smaller counterparts with 2-4 Cs
-
additional information
-
no substantial inhibitory activity with BAY 50-7952, Ro-61-6653 and BAY 50-7950
-
additional information
-
non-camptothecin DNA topoisomerase I inhibitors in cancer therapy
-
additional information
-
toxicity of drugs targeted against topoisomerase I is directly related to the ability of the drug to stimulate topo I-dependent DNA cleavage
-
additional information
-
10,21-dimercaptocamptothecin is not cytotoxic
-
additional information
-
rebeccamycin and other indolcarbazole derivatives induces significant levels radiosensitization and exhibit efficiency in inducing TOP1-mediated DNA damage
-
additional information
-
biphenyl-3,4'-diylbis(arsonic acid) and 5-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyl-6-[(4-methylphenyl)sulfonyl]tetrahydrofuro[2,3-d][1,3]dioxole show no inhibition even at compound concentrations of 20 microM
-
additional information
-
indenoisoquinoline topoisomerase I (Top1) inhibitors. lactam substituents possessing nitrogen heterocycles can provide highly cytotoxic compounds with potent Top1 inhibition. Molecular modeling of these compounds in complex with DNA and Top1 suggests that some of the lactam substituents are capable of interacting with the DNA base pairs above and below the site of intercalation and/or with Top1 amino acid residues, resulting in increased biological activity
-
additional information
-
series of natural and synthetic protoberberine alkaloid evaluated for their inhibitory activities towards DNA topoisomerase I. Natural, monomeric protoberberine alkaloids and their mono-modified congeners show only minor activities. Most of the dimeric protoberberine alkaloids are highly active
-
additional information
-
to get a rough estimate of the preferred distance between two htopoI molecules a deoxyoligonucleotide with a defined length covalently attached (190 nts, the so-called suicide substrate L193s). Labelling of DNA attached to htopoI with 32P to determine the size of the attached DNA fragment more precisely
-
additional information
-
tumor suppressor p53 not only plays a key role in the regulation of the htopoI response to UV-C irradiation but also to treatment with colcemid
-
additional information
-
3-(4-methoxyphenyl)-1-(4'-hydroxyphenyl)-2-propen-1-one and3-(2-thienyl)-1-(4'-hydroxyphenyl)-2-propen-1-one do not interfere with the enzyme
-
additional information
-
determination for every cell line: GI50 (concentration inhibiting 50% net cell growth), TGI (total growth inhibition), and LC50 (concentration leading to 50% net cell death)
-
additional information
-
a multiple metallation of the short nucleotide sequences on the scissile strand, immediately downstream of the cleavage site impedes the cleavage by top1
-
additional information
-
cytotoxicity and mechanism of action of a series of substituted 9-aminoacridines is evaluated using topoisomerase I and cancer cell growth inhibition assays, overview
-
additional information
-
design and synthesis of 60 2-thienyl-4-furyl-6-aryl pyridine derivatives, inhibitory potency and cytotoxicity analysis using human topoisomerase I and human cancer cell lines MCF-7, HeLa, DU145, and K562. The 2-(5-chlorothiophen-2-yl)-4-(furan-3-yl) moiety has an important role in displaying biological activities. No or poor inhibition by 2-(2-chlorophenyl)-4-(furan-2-yl)-6-(3-methylthiophen-2-yl) pyridine, 2-(4-chlorophenyl)-4-(furan-2-yl)-6-(3-methylthiophen-2-yl) pyridine, 2-(5-chlorothiophen-2-yl)-4-(furan-3-yl)-6-m-tolylpyridine, 2-(5-chlorothiophen-2-yl)-4-(furan-3-yl)-6-p-tolylpyridine, 2-(2-chlorophenyl)-6-(5-chlorothiophen-2-yl)-4-(furan-3-yl) pyridine, 2-(3-chlorophenyl)-6-(5-chlorothiophen-2-yl)-4-(furan-3-yl) pyridine, 2-(4-chlorophenyl)-6-(5-chlorothiophen-2-yl)-4-(furan-3-yl) pyridine, 6-(5-chlorothiophen-2-yl)-4-(furan-3-yl)-2, 2'-bipyridine, 6-(5-chlorothiophen-2-yl)-4-(furan-3-yl)-2,30-bipyridine, and 4-(5-chlorofuran-2-yl)-2-(4-chlorophenyl)-6-(5-chlorothiophen-2-yl) pyridine
-
additional information
-
evodiamine is slightly less cytotoxic than campothecin against breast MCF-7 carcinoma cells
-
additional information
-
inhibition mechanisms of cationic porphyrins and analogues, overview
-
additional information
-
inhibitor design and synthesis, anti-proliferative activity study in human cancer cell lines, effect of quinolone and naphthyridine derivatives on Top I activity, overview
-
additional information
-
inhibitory and cytotoxic potencies of inhibitor compounds, in vivo activity in cancer cell lines, overview. No or poor inhibition by compounds 1-ethyl-3-(benzimidazol-2-yl)-6-fluoro-7-(piperazin-1-yl)-4(1H)-quinolone, 1-ethyl-3-(benzimidazol-2-yl)-6-fluoro-7-(1-piperazin-1-yl)-1,8-naphthyridine-4(1H)-one, 6,8-bis(oxiran-2-ylmethoxy)benzo[b][1,8]naphthyridin-5(10H)-one, 6-hydroxy-8-(thiiran-2-ylmethoxy)benzo[b][1,8]naphthyridin-5(10H)-one, and 8-bis(thiiran-2-ylmethoxy)benzo[b][1,8]naphthyridin-5(10H)-one
-
additional information
-
inhibitory potencies and cytotoxicities versus human cancer cell lines of plant-originated triterpenoids and triterpenoid glycosides isolated from Aesculus pavia, diverse inactive compounds, overview
-
additional information
-
partial inhibition of the Top1-DNAadduct formation upon addition of poly(ADP ribose) polymerase 1 in the absence of NAD+ is shown, whereas in the presence of NAD+ formation of a high molecular weight product, most likely corresponding to poly(ADP) ribosylated Top1-DNA adduct, is observed
-
additional information
-
binding constant values of heterobimetallic complexes including Sn2+ and Cu2+ or Zn2+, and ligand 5-{[(1E)-(2-hydroxyphenyl)methylene]amino}-2-hydroxybenzoic acid with the DNA, NMR and mass spectrometric structure analysis, inhibitory potencies, overview
-
additional information
-
inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines, overview. Hydroxyl substitution at 3- or 3'-position of phenyl ring on 2,4-diphenyl-6-aryl pyridines might be required in order to show significant topo inhibitory activity. No inhibition by 15, 35, and 31
-
additional information
-
molecular docking study, overview. No inhibition by 3-[3-[bis(2-hydroxyethyl)amino]-2-hydroxypropoxy]-1-hydroxy-9H-xanthen-9-one, 1-hydroxy-3-[2-hydroxy-3-[(3-hydroxypropyl)sulfanyl]propoxy]-9H-xanthen-9-one, 1-hydroxy-3-[2-hydroxy-3-[(2-hydroxyethyl)sulfanyl]propoxy]-9H-xanthen-9-one, 1-hydroxy-3-[2-hydroxy-3-(propylamino)propoxy]-9H-xanthen-9-one, 1-hydroxy-3-[2-hydroxy-3-(2-hydroxyethoxy)propoxy]-9H-xanthen-9-one, and 3-[3-[(2-chloroethyl)sulfanyl]-2-hydroxypropoxy]-1-hydroxy-9H-xanthen-9-one
-
additional information
-
synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase II inhibitory activity, cytotoxicity, and structure-activity relationship, overview. 2-Furyl or 2-thienyl at 2- or 4-position of central pyridine is crucial in displaying topo I or II inhibitory activity and cytotoxicity. No inhibition by 18, 19,20, 21, 22, 23, 25, 29, 32, 33, and 35
-
additional information
-
the benz[a]acridine analogues, noncharged bioisosteres of protoberberine alkaloids, are also Top1 inhibitors
-
additional information
-
Top1 can be inhibited by heterocyclic compounds such as indolocarbazoles and indenoisoquinolines. Carbohydrate and hydroxyl-containing side chains are essential for the biological activity of indolocarbazoles. Preparation and inhibitory potency of indenoisoquinolines substituted with short-chain alcohols, diols, and carbohydrates, cytotoxicity, Top1 poisoning activity of diol-substituted indenoisoquinolines is dependent upon stereochemistry, molecular modeling, docking studies, and structure-function relationships, overview. IC50 values for cytotoxic effects in human cancer cell lines, overview
-
additional information
-
topoisomerase I inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans, overview. Analysis of cytotoxocity against three human non-tumor cell lines analyzed by the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) cell viability assay
-
additional information
-
topoisomerase I inhibitors act as anticancer drugs, overview. Bone marrow colony-forming unit, CFU, granulocyte macrophage CFU, and tumor cell CFU activity of topoisomerase I inhibitors, overview. CFU are bipotent hemopoietic stem cells. Human bone marrow colony-forming unit is more sensitive to the Top1 inhibitors than is mouse bone marrow colony-forming unit
-
additional information
-
various 5-amino group-substituted indeno[1,2-c]isoquinolines display potent topoisomerase I inhibitory activity as well as cytotoxicities against five different human tumor cell lines. Molecular modelling and docking using protein structure PDB ID 1SC7
-
additional information
-
7-acyl homocamptothecins as topoisomerase I inhibitors, inhibition of induced DNA cleavage and in vitro cytotoxicity against three cancer cell lines A-549, MDA-MB-435 and HCT-116, overview
-
additional information
-
design, synthesis, and evaluation of indenoisoquinolines that are dual inhibitors of both tyrosyl-DNA phosphodiesterase I and Top1, structure-activity relationships, ctotoxic activities, and molecular modeling, overview
-
additional information
-
inhibitor design and evaluation, DNA cleavage inhibition and cytotoxic activities, docking study, overview
-
additional information
-
isolation of six synthetic isoflavonoid derivatives that dock in the binding site of inhibitors camptothecin and topotecan inside the enzyme, no inhibition by LQB223, docking and molecular dynamics simulations, overview
-
additional information
-
no inhibition by etoposide. Design and semisynthetic reactions preparation of oleanane-type triterpene derivatives of Hibiscus sabdariffa plant-derived oleanolic acid based on docking studies, with topoisomerase I inhibitory activity, NMR spectroscopic structure analysis of the compounds, computer-assisted molecular modeling and docking, overview
-
additional information
-
the detection method termed rolling circle enhanced enzyme activity detection allows measurement of hTopI cleavage-religation activity at the single molecule level, and may be used to detect posttranslational enzymatic differences influencing camptothecin response
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acquired Immunodeficiency Syndrome
Development of pyridine dicoumarols as potent anti HIV-1 leads, targeting HIV-1 associated topoisomeraseII? kinase.
Acquired Immunodeficiency Syndrome
Human topoisomerase I C-terminal domain fragment containing the active site tyrosine is a molten globule: implication for the formation of competent productive complex.
Acquired Immunodeficiency Syndrome
Random diffusion can account for topA-dependent suppression of partition defects in low-copy-number plasmids.
Acro-Osteolysis
Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients.
Acute Kidney Injury
Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.
Adenocarcinoma
A Pilot Evaluation of a Novel Immunohistochemical Assay for Topoisomerase II-alpha and Minichromosome Maintenance Protein 2 Expression (ProEx C) in Cervical Adenocarcinoma In Situ, Adenocarcinoma, and Benign Glandular Mimics.
Adenocarcinoma
AraC-FdUMP[10] (CF10) is a next generation fluoropyrimidine with potent antitumor activity in PDAC and synergy with PARG inhibition.
Adenocarcinoma
Biological activity and molecular docking studies of some new quinolines as potent anticancer agents.
Adenocarcinoma
Cell fixation in zinc salt solution is compatible with DNA damage response detection by phospho-specific antibodies.
Adenocarcinoma
Cinnamomum verum component 2-methoxycinnamaldehyde: a novel antiproliferative drug inducing cell death through targeting both topoisomerase I and II in human colorectal adenocarcinoma COLO 205 cells.
Adenocarcinoma
Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma.
Adenocarcinoma
Cuminaldehyde from Cinnamomum verum Induces Cell Death through Targeting Topoisomerase 1 and 2 in Human Colorectal Adenocarcinoma COLO 205 Cells.
Adenocarcinoma
Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.
Adenocarcinoma
Epidermal Growth Factor Receptor (EGFR) and its Cross-talks with Topoisomerases: Challenges and Opportunities for Multi-Target Anticancer Drugs.
Adenocarcinoma
From Proteomic Analysis to Potential Therapeutic Targets: Functional Profile of Two Lung Cancer Cell Lines, A549 and SW900, Widely Studied in Pre-Clinical Research.
Adenocarcinoma
Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Adenocarcinoma
In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma.
Adenocarcinoma
Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis.
Adenocarcinoma
Mining topoisomerase isoforms in gastric cancer.
Adenocarcinoma
Modulation of DNA topoisomerase I activity by p53.
Adenocarcinoma
Neutral and ionic platinum compounds containing a cyclometallated chiral primary amine: synthesis, antitumor activity, DNA interaction and topoisomerase I-cathepsin B inhibition.
Adenocarcinoma
Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.
Adenocarcinoma
Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Adenocarcinoma
Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas.
Adenocarcinoma
Synthesis, characterization and biological activity of new cyclometallated platinum(iv) complexes containing a para-tolyl ligand.
Adenocarcinoma
The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases.
Adenocarcinoma
The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
Adenocarcinoma
Thymoquinone from Nigella sativa Seeds Promotes the Antitumor Activity of Noncytotoxic Doses of Topotecan in Human Colorectal Cancer Cells in Vitro.
Adenocarcinoma
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
Adenocarcinoma
Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Adenocarcinoma
Toward G-Quadruplex-Based Anticancer Agents: Biophysical and Biological Studies of Novel AS1411 Derivatives.
Adenocarcinoma
Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Adenocarcinoma
[Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo]
Adenocarcinoma in Situ
A Pilot Evaluation of a Novel Immunohistochemical Assay for Topoisomerase II-alpha and Minichromosome Maintenance Protein 2 Expression (ProEx C) in Cervical Adenocarcinoma In Situ, Adenocarcinoma, and Benign Glandular Mimics.
Adenocarcinoma of Lung
Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.
Adenocarcinoma of Lung
Discovery of a Novel Anti-Cancer Agent Targeting Both Topoisomerase I & II as well as Telomerase Activities in Human Lung Adenocarcinoma A549 Cells In Vitro and In Vivo: Cinnamomum verum Component Cuminaldehyde.
Adenocarcinoma of Lung
Identification of key differentially expressed mRNAs and microRNAs in non-small cell lung cancer using bioinformatics analysis.
Adenocarcinoma of Lung
Identification of lung adenocarcinoma biomarkers based on bioinformatic analysis and human samples.
Adenocarcinoma of Lung
Low level phosphorylation of histone H2AX on serine 139 (?H2AX) is not associated with DNA double-strand breaks.
Adenocarcinoma of Lung
Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.
Adenocarcinoma of Lung
Quantitative immunocytochemical assays of topoisomerase II in lung adenocarcinoma cell lines. Correlation to topoisomerase II alpha content and topoisomerase II catalytic activity.
Adenocarcinoma of Lung
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
Adenocarcinoma of Lung
The DNA damage inducible lncRNA SCAT7 regulates genomic integrity and topoisomerase 1 turnover in lung adenocarcinoma.
Adenocarcinoma of Lung
Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Adenoma
Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival.
Adenoma
Expression of Topoisomerase II-? protein in salivary gland tumors.
Adenoma, Islet Cell
Prognostic Significance of p27, Ki-67, and Topoisomerase lla Expression in Clinically Nonfunctioning Pancreatic Endocrine Tumors.
Adenoviridae Infections
Adenovirus infection elevates levels of cellular topoisomerase I.
Adrenal Cortex Neoplasms
Topoisomerase 2? and thymidylate synthase expression in adrenocortical cancer.
Adrenocortical Carcinoma
Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma.
Anemia
Isolation of an 11-kDa protein associated with the topoisomerase I activity from equine infectious anemia virus.
Anemia
Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs.
Anemia
The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells.
Anemia
Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core.
Anemia
Topotecan in the treatment of hematologic malignancies.
Anemia, Refractory
Topotecan in the treatment of hematologic malignancies.
Angelman Syndrome
Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome.
Angelman Syndrome
Human Cerebral Organoids Reveal Early Spatiotemporal Dynamics and Pharmacological Responses of UBE3A.
Anthrax
Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.
Antiphospholipid Syndrome
Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis.
Aortic Aneurysm, Abdominal
Aortic Aneurysm Natural Progression Is Not Influenced By Concomitant Malignancy And Chemotherapy.
Apraxias
The novel human gene aprataxin is directly involved in DNA single-strand-break repair.
Arthralgia
Bone density in Moroccan women with systemic scleroderma and its relationships with disease-related parameters and vitamin D status.
Arthralgia
Mechanical thumb pain in a systemic sclerosis patient: simple first carpometacarpal osteoarthritis?
Arthritis, Rheumatoid
Acute presentation of rheumatoid arthritis following cancer chemotherapy using the topoisomerase I inhibitor irinotecan.
Arthritis, Rheumatoid
DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases.
Arthritis, Rheumatoid
Relationship between natural and infection -induced antibodies in systemic autoimmune diseases (SAD); SLE, SSc and RA.
Arthritis, Rheumatoid
[Anti-idiotypic and natural catalytically active antibodies]
Astrocytoma
Characterization of a novel anti-cancer compound for astrocytomas.
Astrocytoma
Combination value of diffusion-weighted imaging and dynamic susceptibility contrast-enhanced MRI in astrocytoma grading and correlation with GFAP, Topoisomerase II? and MGMT.
Astrocytoma
Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Astrocytoma
Prognostic value of survivin and DNA topoisomerase II? in diffuse and anaplastic astrocytomas.
Astrocytoma
Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan.
Ataxia
Ataxia Telangiectasia-Mutated and Rad3-Related Inhibition and Topoisomerase I Trapping Create a Synthetic Lethality in Cancer Cells.
Ataxia
Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.
Ataxia
Transcription-dependent activation of ataxia telangiectasia-mutated prevents DNA-dependent protein kinase-mediated cell death in response to topoisomerase I poison.
Ataxia Telangiectasia
A defect in DNA topoisomerase II activity in ataxia-telangiectasia cells.
Ataxia Telangiectasia
Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks.
Ataxia Telangiectasia
Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells.
Ataxia Telangiectasia
Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line.
Ataxia Telangiectasia
Disruption of Telomere Integrity and DNA Repair Machineries by KML001 Induces T Cell Senescence, Apoptosis, and Cellular Dysfunctions.
Ataxia Telangiectasia
DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells.
Ataxia Telangiectasia
DNA-dependent protein kinase and Ataxia Telangiectasia Mutated (ATM) promote cell survival in response to NK314, a topoisomerase II? inhibitor.
Ataxia Telangiectasia
Enhanced sensitivity to camptothecin in ataxia-telangiectasia cells and its relationship with the expression of DNA topoisomerase I.
Ataxia Telangiectasia
Genome instability in ataxia telangiectasia (A-T) families: camptothecin-induced damage to replicating DNA discriminates between obligate A-T heterozygotes, A-T homozygotes and controls.
Ataxia Telangiectasia
Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes.
Ataxia Telangiectasia
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Ataxia Telangiectasia
Overexpression of a truncated human topoisomerase III partially corrects multiple aspects of the ataxia-telangiectasia phenotype.
Ataxia Telangiectasia
Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant.
Ataxia Telangiectasia
Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan.
Ataxia Telangiectasia
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Ataxia Telangiectasia
Tethering DNA damage checkpoint mediator proteins topoisomerase IIbeta-binding protein 1 (TopBP1) and Claspin to DNA activates ataxia-telangiectasia mutated and RAD3-related (ATR) phosphorylation of checkpoint kinase 1 (Chk1).
Ataxia Telangiectasia
The ATM protein is required for sustained activation of NF-kappaB following DNA damage.
Ataxia Telangiectasia
The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope.
Ataxia Telangiectasia
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Ataxia Telangiectasia
Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms.
Autoimmune Diseases
An aza-anthrapyrazole negatively regulates Th1 activity and suppresses experimental autoimmune encephalomyelitis.
Autoimmune Diseases
Antibody specificities of Thai and Australian scleroderma sera with topoisomerase I recombinant fusion proteins.
Autoimmune Diseases
DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases.
Autoimmune Diseases
Fused Aryl-Phenazines: Scaffold for the Development of Bioactive Molecules.
Autoimmune Diseases
Synthetic peptides: the future of patient management in systemic rheumatic diseases?
Autoimmune Diseases
[Anti-idiotypic antibodies to topoisomerase I in serum from patients with autoimmune diseases]
Autoimmune Diseases
[Interactions of sera from patients with autoimmune diseases with cDNA expressed fragment of topoisomerase I and monoclonal antibodies against enzyme]
Bacteremia
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
Bacterial Infections
A New-Class Antibacterial-Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV.
Bacterial Infections
Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells.
Bacterial Infections
Chemistry, Biological Properties and Analytical Methods of Levonadifloxacin: A Review.
Bacterial Infections
Design and examination of potent pseudosubstrate-based oligonucleotide inhibitors against bacterial topoisomerase IV.
Bacterial Infections
Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive Staphylococcus aureus.
Bacterial Infections
Identification of an ethyl 5,6-dihydropyrazolo[1,5-c]quinazoline-1-carboxylate as a catalytic inhibitor of DNA gyrase.
Bacterial Infections
Identification of ciprofloxacin resistance by SimpleProbe, High Resolution Melt and Pyrosequencing nucleic acid analysis in biothreat agents: Bacillus anthracis, Yersinia pestis and Francisella tularensis.
Bacterial Infections
Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1.
Bacterial Infections
Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 2.
Bacterial Infections
Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability.
Bacterial Infections
The metabolism and disposition of GSK2140944 in healthy human subjects.
Blast Crisis
The diverse effect of topoisomerase I specific inhibitor (camptothecin) on normal and BCR/ABL-dependent hematopoietic cells proliferation: therapeutic implications.
Blast Crisis
[Killing and proapoptotic effects of topoisomerase I inhibitor on K562 cells]
Bloom Syndrome
Aberrant chromosome morphology in human cells defective for Holliday junction resolution.
Bloom Syndrome
Analysis of m6A RNA Methylation-Related Genes in Liver Hepatocellular Carcinoma and Their Correlation with Survival.
Bloom Syndrome
Association of the Bloom syndrome protein with topoisomerase IIIalpha in somatic and meiotic cells.
Bloom Syndrome
Bloom syndrome complex promotes FANCM recruitment to stalled replication forks and facilitates both repair and traverse of DNA interstrand crosslinks.
Bloom Syndrome
Bloom's syndrome and PICH helicases cooperate with topoisomerase II? in centromere disjunction before anaphase.
Bloom Syndrome
Cleavage of the Bloom's syndrome gene product during apoptosis by caspase-3 results in an impaired interaction with topoisomerase IIIalpha.
Bloom Syndrome
Developing T lymphocytes are uniquely sensitive to a lack of topoisomerase III alpha.
Bloom Syndrome
Mammalian DNA topoisomerase IIIalpha is essential in early embryogenesis.
Bloom Syndrome
RMI, a new OB-fold complex essential for Bloom syndrome protein to maintain genome stability.
Bloom Syndrome
RMI1 contributes to DNA repair and to the tolerance to camptothecin.
Bloom Syndrome
The Bloom syndrome complex senses RPA-coated single-stranded DNA to restart stalled replication forks.
Bloom Syndrome
The Bloom's syndrome gene product interacts with topoisomerase III.
Bloom Syndrome
The Bloom's syndrome helicase stimulates the activity of human topoisomerase IIIalpha.
Bloom Syndrome
Topo IIIalpha and BLM act within the Fanconi anemia pathway in response to DNA-crosslinking agents.
Brain Neoplasms
Chemopotentiation by PARP inhibitors in cancer therapy.
Brain Neoplasms
Chemotherapy for mycosis fungoides and the Sézary syndrome.
Brain Neoplasms
Comparison of topoisomerase I and II expression in primary brain tumor and lung cancer.
Brain Neoplasms
Complications of chemotherapy in neuro-oncology.
Brain Neoplasms
Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
Brain Neoplasms
Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin.
Brain Neoplasms
Expression of DNA topoisomerase I, IIalpha, and IIbeta in human brain tumors.
Brain Neoplasms
Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide.
Brain Neoplasms
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
Brain Neoplasms
Pharmacokinetic considerations in the treatment of CNS tumours.
Brain Neoplasms
Phase II evaluation of topotecan for pediatric central nervous system tumors.
Brain Neoplasms
Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Brain Neoplasms
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Brain Neoplasms
The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration.
Brain Neoplasms
The role of topotecan in the treatment of brain metastases.
Brain Neoplasms
Topoisomerase I inhibitors for the treatment of brain tumors.
Breast Neoplasms
(-)-Xanthatin up-regulation of the GADD45? tumor suppressor gene in MDA-MB-231 breast cancer cells: Role of topoisomerase II? inhibition and reactive oxygen species.
Breast Neoplasms
A novel copper(II) complex identified as a potent drug against colorectal and breast cancer cells and as a poison inhibitor for human topoisomerase II?.
Breast Neoplasms
A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.
Breast Neoplasms
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
Breast Neoplasms
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
Breast Neoplasms
Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
Breast Neoplasms
Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases.
Breast Neoplasms
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
Breast Neoplasms
An electrophoretic mobility shift assay identifies a mechanistically unique inhibitor of protein sumoylation.
Breast Neoplasms
Analyte-driven self-assembly of graphene oxide sheets onto hydroxycamptothecin-functionalized upconversion nanoparticles for the determination of type I topoisomerases in cell extracts.
Breast Neoplasms
Anthracycline vs nonanthracycline adjuvant therapy for breast cancer.
Breast Neoplasms
Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin A in human MCF-7 and MDA-MB-231 breast cancer cells.
Breast Neoplasms
Antitumor activity and pharmacokinetics following oral administration of natural product DNA topoisomerase I inhibitors 10-hydroxycamptothecin and camptothecin in SCID mice bearing human breast cancer xenografts.
Breast Neoplasms
Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways.
Breast Neoplasms
Aromatic analogues of DNA minor groove binders--synthesis and biological evaluation.
Breast Neoplasms
Assessment of DNA Topoisomerase I Unwinding Activity, Radical Scavenging Capacity, and Inhibition of Breast Cancer Cell Viability of N-alkyl-acridones and N,N'-dialkyl-9,9'-biacridylidenes.
Breast Neoplasms
Association between the c.*229C>T polymorphism of the topoisomerase II? binding protein 1 (TopBP1) gene and breast cancer.
Breast Neoplasms
Association between Twist and multidrug resistance gene-associated proteins in Taxol
Breast Neoplasms
BCL-2, topoisomerase II?, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy.
Breast Neoplasms
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Breast Neoplasms
BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
Breast Neoplasms
Benzo[b]tryptanthrin inhibits MDR1, topoisomerase activity, and reverses adriamycin resistance in breast cancer cells.
Breast Neoplasms
Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.
Breast Neoplasms
Caspase activation in MCF7 cells responding to etoposide treatment.
Breast Neoplasms
Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis.
Breast Neoplasms
CD99 correlates with low cyclin D1, high topoisomerase 2? status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma.
Breast Neoplasms
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.
Breast Neoplasms
Changes of Topoisomerase II{alpha} Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival.
Breast Neoplasms
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Breast Neoplasms
Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells.
Breast Neoplasms
Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.
Breast Neoplasms
Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade.
Breast Neoplasms
Cholinergic Receptor Nicotinic Alpha 5 (CHRNA5) RNAi is associated with cell cycle inhibition, apoptosis, DNA damage response and drug sensitivity in breast cancer.
Breast Neoplasms
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.
Breast Neoplasms
Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer.
Breast Neoplasms
Circulating Bone-related Markers and YKL-40 Versus HER2 and TOPO2a in Bone Metastatic and Nonmetastatic Breast Cancer: Diagnostic Implications.
Breast Neoplasms
Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer.
Breast Neoplasms
Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.
Breast Neoplasms
Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20.
Breast Neoplasms
Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas.
Breast Neoplasms
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Breast Neoplasms
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Breast Neoplasms
Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
Breast Neoplasms
Correlations of TOP2A gene aberrations and expression of topoisomerase II? protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
Breast Neoplasms
Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients.
Breast Neoplasms
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Breast Neoplasms
Cytotoxic activity of octahydropyrazin[2,1-a:5,4-a']diisoquinoline derivatives in human breast cancer cells.
Breast Neoplasms
Cytotoxic mechanism of flavonoid from Temu Kunci (Kaempferia pandurata) in cell culture of human mammary carcinoma.
Breast Neoplasms
Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity.
Breast Neoplasms
Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-b]pyridinol Derivatives as Potent Topoisomerase II?-Targeted Chemotherapeutic Agents for Breast Cancer.
Breast Neoplasms
Distribution bias and biochemical characterization of TOP1MT single nucleotide variants.
Breast Neoplasms
DNA Damage and Pulmonary Hypertension.
Breast Neoplasms
DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
Breast Neoplasms
DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity.
Breast Neoplasms
Doxorubicin prevents endoplasmic reticulum stress-induced apoptosis.
Breast Neoplasms
Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.
Breast Neoplasms
Elevations of DNA topoisomerase I in invasive carcinoma of the breast.
Breast Neoplasms
Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest.
Breast Neoplasms
Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer.
Breast Neoplasms
ER, PgR, HER-2, Ki-67, topoisomerase II?, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Breast Neoplasms
Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Breast Neoplasms
Etirinotecan pegol for the treatment of breast cancer.
Breast Neoplasms
Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.
Breast Neoplasms
Expression and functional analyses of breast cancer resistance protein in lung cancer.
Breast Neoplasms
Expression of Topoisomerase II-? in Triple Negative Breast Cancer.
Breast Neoplasms
Expressions of Topo II? and Ki67 in breast cancer and its clinicopathologic features and prognosis.
Breast Neoplasms
Expressions of Topoisomerase II? and BCRP in Metastatic Cells are Associated with Overall Survival in Small Cell Lung Cancer Patients.
Breast Neoplasms
Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, ?-tubulin III, thymidylate synthetase, and topoisomerase II? in breast cancer: Association with clinicopathological characteristics.
Breast Neoplasms
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Breast Neoplasms
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Breast Neoplasms
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability.
Breast Neoplasms
Her-2/neu and topoisomerase II? in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
Breast Neoplasms
HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics.
Breast Neoplasms
Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
Breast Neoplasms
Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer.
Breast Neoplasms
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-? Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel.
Breast Neoplasms
Human neural stem cell tropism to metastatic breast cancer.
Breast Neoplasms
Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
Breast Neoplasms
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.
Breast Neoplasms
Implications of Topoisomerase (TOP1 and TOP2?) Expression in Patients With Breast Cancer.
Breast Neoplasms
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
Breast Neoplasms
Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone.
Breast Neoplasms
Induction of DNA damage, inhibition of DNA synthesis, and suppression of c-myc expression by the topoisomerase I inhibitor, camptothecin, in MCF-7 human breast tumor cells.
Breast Neoplasms
Inhibition of DNA topoisomerase I and II, and growth inhibition of MDA-MB-231 human breast cancer cells by bis-benzimidazole derivatives with alkylating moiety.
Breast Neoplasms
Inhibition of human topoisomerase I and II and anti-proliferative effects on MCF-7 cells by new titanocene complexes.
Breast Neoplasms
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Breast Neoplasms
Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
Breast Neoplasms
L-proline analogues of anthraquinone-2-carboxylic acid: cytotoxic activity in breast cancer MCF-7 cells and inhibitory activity against topoisomerase I and II.
Breast Neoplasms
Loss of O?-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Breast Neoplasms
Mitoxantrone affects topoisomerase activities in human breast cancer cells.
Breast Neoplasms
Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression.
Breast Neoplasms
Multiple molecular targets in breast cancer therapy by betulinic acid.
Breast Neoplasms
New approaches in cancer treatment.
Breast Neoplasms
Nitric oxide inhibits ATPase activity and induces resistance to topoisomerase II-poisons in human MCF-7 breast tumor cells.
Breast Neoplasms
Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses.
Breast Neoplasms
Oxocrebanine: A Novel Dual Topoisomerase inhibitor, Suppressed the Proliferation of Breast Cancer Cells MCF-7 by Inducing DNA Damage and Mitotic Arrest.
Breast Neoplasms
p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Breast Neoplasms
Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer.
Breast Neoplasms
Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
Breast Neoplasms
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
Breast Neoplasms
Phosphorylation and stabilization of topoisomerase II? protein by p38? mitogen-activated protein kinase sensitize breast cancer cells to its poisons.
Breast Neoplasms
Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2? Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.
Breast Neoplasms
Prognostic potential of topoisomerase II? and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.
Breast Neoplasms
Quinacrine has anti-cancer activity in breast cancer cells through inhibition of topoisomerase activity.
Breast Neoplasms
Quinacrine-mediated autophagy and apoptosis in colon cancer cells is through a p53- and p21-dependent mechanism.
Breast Neoplasms
Rapid purification of topoisomerase I from human breast cancer cells by high-performance liquid chromatography.
Breast Neoplasms
Rapid screening of active components group with Topoisomerase I inhibitory activity in Sophora alopecuroides L. based on ultrafiltration coupled with UPLC-QTOF-MS.
Breast Neoplasms
Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.
Breast Neoplasms
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.
Breast Neoplasms
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Breast Neoplasms
RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
Breast Neoplasms
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Breast Neoplasms
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
Breast Neoplasms
Sacituzumab Govitecan: First Approval.
Breast Neoplasms
Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.
Breast Neoplasms
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Breast Neoplasms
Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
Breast Neoplasms
Significance of topoisomerase III? expression in breast ductal carcinomas: strong associations with disease-specific survival and metastasis.
Breast Neoplasms
Spotlight on Geminin.
Breast Neoplasms
Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
Breast Neoplasms
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-?-benzyl ester derivatives as potent topoisomerase II? inhibitors.
Breast Neoplasms
Synthesis and molecular docking studies of some novel Schiff bases incorporating 6-butylquinolinedione moiety as potential topoisomerase II? inhibitors.
Breast Neoplasms
Synthesis and structure-activity relationship of lipo-diterpenoid alkaloids with potential target of topoisomerase II? for breast cancer treatment.
Breast Neoplasms
Targeted therapy in breast cancer: the HER-2/neu gene and protein.
Breast Neoplasms
TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.
Breast Neoplasms
The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
Breast Neoplasms
The Pathological Response to Anthracycline is Associated with Topoisomerase II? Gene Amplification in the HER2 Breast Cancer Subset.
Breast Neoplasms
The potential role of topotecan in the treatment of advanced breast cancer.
Breast Neoplasms
The Predictive and Prognostic Role of Topoisomerase II? and Tissue Inhibitor of Metalloproteinases 1 Expression in Locally Advanced Breast Carcinoma of Egyptian Patients Treated With Anthracycline-based Neoadjuvant Chemotherapy.
Breast Neoplasms
The predictive and prognostic significance of pre- and post-treatment topoisomerase II? in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Breast Neoplasms
The role of topoisomerase II-? (TOPO IIA) as a predictive factor for response to neoadjuvant anthracycline-based chemotherapy in locally advanced breast cancer.
Breast Neoplasms
The role of topoisomerase II? in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
Breast Neoplasms
The selective effect of glycyrrhizin and glycyrrhetinic acid on topoisomerase II? and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells.
Breast Neoplasms
Therapy-related acute leukemia in breast cancer patients: twelve cases treated with a topoisomerase inhibitor.
Breast Neoplasms
Therapy-related acute promyelocytic leukaemia.
Breast Neoplasms
TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Breast Neoplasms
TOP2A Amplification in the Absence of That of HER-2/neu: Toward Individualization of Chemotherapeutic Practice in Breast Cancer.
Breast Neoplasms
Topoisomerase 2? status in invasive breast carcinoma - comparison of its clinical value according to immunohistochemical and fluorescence in situ hybridization methods of evaluation.
Breast Neoplasms
Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
Breast Neoplasms
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer.
Breast Neoplasms
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?
Breast Neoplasms
Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer.
Breast Neoplasms
Topoisomerase II-alpha as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.
Breast Neoplasms
Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas.
Breast Neoplasms
Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.
Breast Neoplasms
Topoisomerase II? levels and G2 radiosensitivity in T-lymphocytes of women presenting with breast cancer.
Breast Neoplasms
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
Breast Neoplasms
Translocation of Bax to mitochondria during apoptosis measured by laser scanning cytometry.
Breast Neoplasms
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Breast Neoplasms
Trastuzumab Deruxtecan: First Approval.
Breast Neoplasms
TREATMENT WITH GEFITINIB OR LAPATINIB INDUCES DRUG RESISTANCE THROUGH DOWNREGULATION OF TOPOISOMERASE II? EXPRESSION.
Breast Neoplasms
Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase II?.
Breast Neoplasms
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.
Breast Neoplasms
Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells.
Breast Neoplasms
Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.
Breast Neoplasms
Using a stem cell-based signature to guide therapeutic selection in cancer.
Breast Neoplasms
Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy.
Breast Neoplasms
[New drugs in metastatic breast cancer--1997]
Breast Neoplasms
[Predictive biomarkers for response to irinotecan, platinum drugs, and taxanes].
Breast Neoplasms
[Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Breast Neoplasms
[Therapeutic effect of Jin Long capsule combined with neoadjuvant chemotherapy on invasive breast cancer and the expression change of multidrug resistance proteins].
Breast Neoplasms
[Topoisomerase inhibitor upregulates MICA/B expression in breast cancer cells through ATM/ATR and NF-?B pathway].
Burkitt Lymphoma
An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine.
Burkitt Lymphoma
Elevated DNA topoisomerase II activity in nitrogen mustard-resistant human cells.
Burkitt Lymphoma
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
Burkitt Lymphoma
Rapid purification and structural study of DNA topoisomerase I from human Burkitt lymphoma Raji cells.
Carcinogenesis
Cancer preventive mechanisms of the green tea polyphenol (-)-epigallocatechin-3-gallate.
Carcinogenesis
Characterization of the topoisomerase I locus in human colorectal cancer.
Carcinogenesis
Chemotherapy-induced secondary malignancies.
Carcinogenesis
Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis.
Carcinogenesis
Spartan deficiency causes accumulation of Topoisomerase 1 cleavage complexes and tumorigenesis.
Carcinogenesis
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.
Carcinogenesis
TopBP1 promotes malignant progression and correlates with poor prognosis in osteosarcoma.
Carcinogenesis
Topoisomerase II-mediated DNA cleavage and mutagenesis activated by nitric oxide underlie the inflammation-associated tumorigenesis.
Carcinogenesis
[Immunohistochemical evaluation of intracranial recurrent meningiomas: correlation of topoisomerase II alpha expression and cell proliferative potential]
Carcinoid Tumor
DNA topoisomerase II-alpha in pulmonary carcinoid tumors.
Carcinoid Tumor
Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells.
Carcinoma
(S)-10-Hydroxycamptothecin Inhibits Esophageal Squamous Cell Carcinoma Growth In Vitro and In Vivo Via Decreasing Topoisomerase I Enzyme Activity.
Carcinoma
10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells.
Carcinoma
A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Carcinoma
A Natural Anticancer Agent Thaspine Targets Human Topoisomerase IB.
Carcinoma
A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors.
Carcinoma
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Carcinoma
A pilot study of topotecan in the treatment of serous carcinoma of the uterus.
Carcinoma
A TOP2A-derived cancer panel drives cancer progression in papillary renal cell carcinoma.
Carcinoma
A type-II DNA topoisomerase and a catenating protein from the transplantable VX2 carcinoma.
Carcinoma
Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function.
Carcinoma
Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells.
Carcinoma
Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Carcinoma
Adenoid cystic carcinomas of the breast have low Topo II? expression but frequently overexpress EGFR protein without EGFR gene amplification.
Carcinoma
All-trans retinoic acid suppresses topoisomerase II? through the proteasomal pathway.
Carcinoma
Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines.
Carcinoma
Anthocyanin-rich blackberry extract suppresses the DNA-damaging properties of topoisomerase I and II poisons in colon carcinoma cells.
Carcinoma
Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.
Carcinoma
Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
Carcinoma
ATM Activation and H2AX Phosphorylation Induced by Genotoxic Agents Assessed by Flow- and Laser Scanning Cytometry.
Carcinoma
BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors.
Carcinoma
Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
Carcinoma
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Carcinoma
Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE.
Carcinoma
Carbohydrate linked organotin(IV) complexes as human topoisomerase I? inhibitor and their antiproliferative effects against the human carcinoma cell line.
Carcinoma
Catalytic inhibition of human DNA topoisomerase by phenolic compounds in Ardisia compressa extracts and their effect on human colon cancer cells.
Carcinoma
Cellular responses to methyl-N-[4-9-acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells.
Carcinoma
Characterization of Oligomeric Proanthocyanidin-Enriched Fractions from Aronia melanocarpa (Michx.) Elliott via High-Resolution Mass Spectrometry and Investigations on Their Inhibitory Potential on Human Topoisomerases.
Carcinoma
Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
Carcinoma
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Carcinoma
Cinnamomum verum ingredient 2-methoxycinnamaldehyde: a new antiproliferative drug targeting topoisomerase I and II in human lung squamous cell carcinoma NCI-H520 cells.
Carcinoma
Combined effects of hyperthermia and CPT-11 on DNA strand breaks in mouse mammary carcinoma FM3A cells.
Carcinoma
Comparative drug screening in NUT midline carcinoma.
Carcinoma
Comparative QSAR studies on substituted bis-(acridines) and bis-(phenazines)-carboxamides: a new class of anticancer agents.
Carcinoma
Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Carcinoma
Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.
Carcinoma
Copper(II) complexes with highly water-soluble L- and D-proline-thiosemicarbazone conjugates as potential inhibitors of Topoisomerase II?.
Carcinoma
Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoetic cell differentiation.
Carcinoma
Cytotoxic mechanism of flavonoid from Temu Kunci (Kaempferia pandurata) in cell culture of human mammary carcinoma.
Carcinoma
Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Carcinoma
Delphinidin Modulates the DNA-Damaging Properties of Topoisomerase II Poisons.
Carcinoma
Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model.
Carcinoma
Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity.
Carcinoma
Design, synthesis, and evaluation of novel 6-chloro-/fluorochromone derivatives as potential topoisomerase inhibitor anticancer agents.
Carcinoma
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Carcinoma
Distribution bias and biochemical characterization of TOP1MT single nucleotide variants.
Carcinoma
DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
Carcinoma
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.
Carcinoma
DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage Repair.
Carcinoma
Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
Carcinoma
Effect of DNA topoisomerase I inhibitor, 10-hydroxycamptothecin, on the structure and function of nuclei and nuclear matrix in bladder carcinoma MBT-2 cells.
Carcinoma
Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs.
Carcinoma
Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells.
Carcinoma
Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells.
Carcinoma
Effect of yerba mate (Ilex paraguariensis) tea on topoisomerase inhibition and oral carcinoma cell proliferation.
Carcinoma
Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Carcinoma
Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies.
Carcinoma
Elevations of DNA topoisomerase I in invasive carcinoma of the breast.
Carcinoma
Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression.
Carcinoma
Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Carcinoma
Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Carcinoma
Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival.
Carcinoma
Expression of DNA topoisomerase II-?: Clinical significance in laryngeal carcinoma.
Carcinoma
Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Carcinoma
Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis.
Carcinoma
Expression of human DNA Topoisomerase II-alpha in squamous cell carcinoma of the larynx and its correlation with clinicopathologic variables.
Carcinoma
Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Carcinoma
Expression of Topoisomerase II-? protein in salivary gland tumors.
Carcinoma
Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, ?-tubulin III, thymidylate synthetase, and topoisomerase II? in breast cancer: Association with clinicopathological characteristics.
Carcinoma
Gastric adenocarcinomas express the glycosphingolipid Gb3/CD77: Targeting of gastric cancer cells with Shiga toxin B-subunit.
Carcinoma
Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas.
Carcinoma
Green tea constituent (--)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells.
Carcinoma
H1 histone sub-type distribution and DNA topoisomerase activity in skeletal muscle of tumour-bearing rats.
Carcinoma
Human DNA topoisomerase II-alpha expression in laparoscopically treated renal cell carcinoma.
Carcinoma
Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
Carcinoma
Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas.
Carcinoma
Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas.
Carcinoma
Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate.
Carcinoma
Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas.
Carcinoma
Impact of Oxidative Metabolism on the Cytotoxic and Genotoxic Potential of Genistein in Human Colon Cancer Cells.
Carcinoma
Improving the Therapeutic Index in Cancer Therapy by Using Antibody-Drug Conjugates Designed with a Moderately Cytotoxic Drug.
Carcinoma
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Carcinoma
In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.
Carcinoma
In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
Carcinoma
Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.
Carcinoma
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Carcinoma
Inhibition of topoisomerase II? sensitizes FaDu cells to ionizing radiation by diminishing DNA repair.
Carcinoma
Inhibitors of topoisomerase II: structure-activity relationships and mechanism of action of podophyllin congeners.
Carcinoma
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Carcinoma
Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
Carcinoma
Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration.
Carcinoma
Lack of prognostic relevance of Her-2/neu, topoisomerase II? and EGFR in advanced ovarian carcinoma.
Carcinoma
Lanostanoids from Fungi: A Group of Potential Anticancer Compounds.
Carcinoma
Limited small-cell lung cancer: a potentially curable disease.
Carcinoma
Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.
Carcinoma
Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review.
Carcinoma
Mucronulatol from Caribbean propolis exerts cytotoxic effects on human tumor cell lines.
Carcinoma
Namitecan: a hydrophilic camptothecin with a promising preclinical profile.
Carcinoma
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
Carcinoma
New perspectives in colon cancer chemotherapy.
Carcinoma
No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer.
Carcinoma
Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells.
Carcinoma
Novel agents that potentially inhibit irinotecan-induced diarrhea.
Carcinoma
Novel antitumor L-arabinose derivative of indolocarbazole with high affinity to DNA.
Carcinoma
Novel assay utilizing fluorochrome-tagged physostigmine (Ph-F) to In situ detect active acetylcholinesterase (AChE) induced during apoptosis.
Carcinoma
Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin.
Carcinoma
p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Carcinoma
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
Carcinoma
Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts.
Carcinoma
Phase II Study of Belotecan (CKD 602) as a Single Agent in Patients with Recurrent or Progressive Carcinoma of Uterine Cervix.
Carcinoma
Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.
Carcinoma
Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
Carcinoma
Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I.
Carcinoma
Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.
Carcinoma
Prognostic importance of survivin, Ki-67, and topoisomerase II? in ovarian carcinoma.
Carcinoma
Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIalpha expression in oral carcinoma.
Carcinoma
Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Carcinoma
Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor.
Carcinoma
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Carcinoma
Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Carcinoma
Protein Expression Profiles Indicative for Drug Resistance of Kidney Carcinoma.
Carcinoma
QSAR analysis of substituted bis[(acridine-4-carboxamide)propyl]methylamines using optimized block-wise variable combination by particle swarm optimization for partial least squares modeling.
Carcinoma
Quantitative microscopy of human DNA topoisomerase II-alpha expression in transitional cell carcinoma of the bladder.
Carcinoma
Quantitative Structure-Activity Relationship Studies on Indenoisoquinoline Topoisomerase I Inhibitors as Anticancer Agents in Human Renal Cell Carcinoma Cell Line SN12C.
Carcinoma
Rapid purification and characterization of DNA topoisomerase I from cultured mouse mammary carcinoma FM3A cells.
Carcinoma
Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.
Carcinoma
Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells.
Carcinoma
Resveratrol modulates the topoisomerase inhibitory potential of doxorubicin in human colon carcinoma cells.
Carcinoma
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Carcinoma
Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.
Carcinoma
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Carcinoma
Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
Carcinoma
Screening for inhibitors of topoisomerase I from Lycoris radiata by combining ultrafiltration with liquid chromatography/mass spectrometry.
Carcinoma
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Carcinoma
Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice.
Carcinoma
Solid phase synthesis of anthraquinone peptides and their evaluation as topoisomerase I inhibitors.
Carcinoma
Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
Carcinoma
Tacrine-Coumarin Derivatives as Topoisomerase Inhibitors with Antitumor Effects on A549 Human Lung Carcinoma Cancer Cell Lines.
Carcinoma
Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
Carcinoma
The activity of topoisomerases is related to the grade and stage in human renal cell carcinoma.
Carcinoma
The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Carcinoma
The c.*229C?>?T gene polymorphism in 3'UTR region of the topoisomerase II? binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma.
Carcinoma
The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells.
Carcinoma
The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase.
Carcinoma
The mammalian DNA replication elongation checkpoint: implication of Chk1 and relationship with origin firing as determined by single DNA molecule and single cell analyses.
Carcinoma
The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.
Carcinoma
The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.
Carcinoma
The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
Carcinoma
The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
Carcinoma
Topoisomerase expression in oral squamous cell carcinoma: relationship with cancer stem cells profiles and lymph node metastasis.
Carcinoma
Topoisomerase I activity in squamous cell carcinoma of the head and neck.
Carcinoma
Topoisomerase I deregulation in laryngeal squamous cell carcinomas based on tissue microarray analysis.
Carcinoma
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Carcinoma
Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11.
Carcinoma
Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
Carcinoma
Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.
Carcinoma
Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
Carcinoma
Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma.
Carcinoma
Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells.
Carcinoma
Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Carcinoma
Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
Carcinoma
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Carcinoma
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.
Carcinoma
Update on the role of topotecan in the treatment of recurrent ovarian cancer.
Carcinoma
Wedelolactone induces growth of breast cancer cells by stimulation of estrogen receptor signalling.
Carcinoma
[Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer]
Carcinoma
[Expression and significance of P-glycoprotein, glutathione S-transferase-pi and Topoisomerase II in gastric carcinomas]
Carcinoma
[Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]
Carcinoma
[Topoisomerase I inhibitor with potential radiosensitizing effect]
Carcinoma, Acinar Cell
Expression of Topoisomerase II-? protein in salivary gland tumors.
Carcinoma, Adenoid Cystic
Adenoid cystic carcinomas of the breast have low Topo II? expression but frequently overexpress EGFR protein without EGFR gene amplification.
Carcinoma, Ductal
Clinical analysis of 21-gene recurrence score test in hormone receptor-positive early-stage breast cancer.
Carcinoma, Ductal
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.
Carcinoma, Ductal
Significance of topoisomerase III? expression in breast ductal carcinomas: strong associations with disease-specific survival and metastasis.
Carcinoma, Embryonal
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Carcinoma, Embryonal
Induction of in vitro differentiation of mouse embryonal carcinoma (F9) cells by inhibitors of topoisomerases.
Carcinoma, Hepatocellular
3,3'-diindolylmethane is a novel topoisomerase IIalpha catalytic inhibitor that induces S-phase retardation and mitotic delay in human hepatoma HepG2 cells.
Carcinoma, Hepatocellular
Association of DNA topoisomerase I and RNA polymerase I: a possible role for topoisomerase I in ribosomal gene transcription.
Carcinoma, Hepatocellular
Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells.
Carcinoma, Hepatocellular
Discovery of a novel anti-cancer agent targeting both topoisomerase I and II in hepatocellular carcinoma Hep 3B cells in vitro and in vivo: Cinnamomum verum component 2-methoxycinnamaldehyde.
Carcinoma, Hepatocellular
DNA topoisomerase II? and Ki67 are prognostic factors in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Effects of cinobufacini injection on cell proliferation and the expression of topoisomerases in human HepG-2 hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Heparin and liver heparan sulfate can rescue hepatoma cells from topotecan action.
Carcinoma, Hepatocellular
Inhibition of phosphorylation of histone H1 and H3 induced by 10-hydroxycamptothecin, DNA topoisomerase I inhibitor, in murine ascites hepatoma cells.
Carcinoma, Hepatocellular
MicroRNA-139 suppresses hepatocellular carcinoma cell proliferation and migration by directly targeting Topoisomerase I.
Carcinoma, Hepatocellular
MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase II? degradation in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Nuclear topoisomerase I and DNase activities in rat diethylnitrosamine-induced hepatoma, in regenerating and fetal liver.
Carcinoma, Hepatocellular
Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Phenolic-containing organic extracts of mulberry (Morus alba L.) leaves inhibit HepG2 hepatoma cells through G2/M phase arrest, induction of apoptosis, and inhibition of topoisomerase II? activity.
Carcinoma, Hepatocellular
Phosphorylation of DNA topoisomerase I is increased during the response of mammalian cells to mitogenic stimuli.
Carcinoma, Hepatocellular
Pinus kesiya Royle ex Gordon induces apoptotic cell death in hepatocellular carcinoma HepG2 cell via intrinsic pathway by PARP and Topoisomerase I suppression.
Carcinoma, Hepatocellular
Potentiation of radioimmunotherapy by inhibition of topoisomerase I.
Carcinoma, Hepatocellular
Sequences and structures at hepadnaviral integration: recombination sites implicate topoisomerase I in hepadnaviral DNA rearrangements and integration.
Carcinoma, Hepatocellular
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.
Carcinoma, Hepatocellular
Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1?.
Carcinoma, Hepatocellular
Topoisomerase I-mediated integration of hepadnavirus DNA in vitro.
Carcinoma, Hepatocellular
[The activity of nuclear endonucleases and topoisomerases in the liver of rats and in diethylnitrosamine-induced tumors]
Carcinoma, Lewis Lung
Cellular responses to methyl-N-[4-9-acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells.
Carcinoma, Lewis Lung
Comparative QSAR studies on substituted bis-(acridines) and bis-(phenazines)-carboxamides: a new class of anticancer agents.
Carcinoma, Lewis Lung
In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.
Carcinoma, Lewis Lung
QSAR analysis of substituted bis[(acridine-4-carboxamide)propyl]methylamines using optimized block-wise variable combination by particle swarm optimization for partial least squares modeling.
Carcinoma, Mucoepidermoid
Expression of Topoisomerase II-? protein in salivary gland tumors.
Carcinoma, Non-Small-Cell Lung
A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines.
Carcinoma, Non-Small-Cell Lung
A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Carcinoma, Non-Small-Cell Lung
Correlation between topoisomerase I and tyrosyl-DNA phosphodiesterase 1 activities in non-small cell lung cancer tissue.
Carcinoma, Non-Small-Cell Lung
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Carcinoma, Non-Small-Cell Lung
DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage Repair.
Carcinoma, Non-Small-Cell Lung
Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
EGCG regulates the cross-talk between JWA and topoisomerase II? in non-small-cell lung cancer (NSCLC) cells.
Carcinoma, Non-Small-Cell Lung
Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells.
Carcinoma, Non-Small-Cell Lung
Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Carcinoma, Non-Small-Cell Lung
HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Long non-coding RNA LALTOP promotes non-small cell lung cancer progression by stabilizing topoisomerase II? mRNA.
Carcinoma, Non-Small-Cell Lung
NF-kappa B activation in topoisomerase I inhibitor-induced apoptotic cell death in human non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.
Carcinoma, Non-Small-Cell Lung
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.
Carcinoma, Non-Small-Cell Lung
Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I.
Carcinoma, Non-Small-Cell Lung
Synthesis and topoisomerase I inhibitory activity of a novel diazaindeno[2,1-b]phenanthrene analogue of Lamellarin D.
Carcinoma, Non-Small-Cell Lung
Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
Carcinoma, Non-Small-Cell Lung
The association of topoisomerase 2? expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients.
Carcinoma, Non-Small-Cell Lung
The Topoisomerase 1 Inhibitor Austrobailignan-1 Isolated from Koelreuteria henryi Induces a G2/M-Phase Arrest and Cell Death Independently of p53 in Non-Small Cell Lung Cancer Cells.
Carcinoma, Non-Small-Cell Lung
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.
Carcinoma, Non-Small-Cell Lung
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Trastuzumab Deruxtecan: First Approval.
Carcinoma, Ovarian Epithelial
Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Carcinoma, Ovarian Epithelial
Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Carcinoma, Ovarian Epithelial
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Carcinoma, Ovarian Epithelial
Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Prognostic importance of survivin, Ki-67, and topoisomerase II? in ovarian carcinoma.
Carcinoma, Ovarian Epithelial
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Carcinoma, Ovarian Epithelial
Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.
Carcinoma, Ovarian Epithelial
Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
Carcinoma, Ovarian Epithelial
The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Carcinoma, Ovarian Epithelial
[Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]
Carcinoma, Renal Cell
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
Carcinoma, Renal Cell
A TOP2A-derived cancer panel drives cancer progression in papillary renal cell carcinoma.
Carcinoma, Renal Cell
Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival.
Carcinoma, Renal Cell
Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Carcinoma, Renal Cell
Human DNA topoisomerase II-alpha expression in laparoscopically treated renal cell carcinoma.
Carcinoma, Renal Cell
Quantitative Structure-Activity Relationship Studies on Indenoisoquinoline Topoisomerase I Inhibitors as Anticancer Agents in Human Renal Cell Carcinoma Cell Line SN12C.
Carcinoma, Renal Cell
The activity of topoisomerases is related to the grade and stage in human renal cell carcinoma.
Carcinoma, Renal Cell
The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
Carcinoma, Renal Cell
Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Carcinoma, Small Cell
A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors.
Carcinoma, Squamous Cell
Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
Carcinoma, Squamous Cell
Cinnamomum verum ingredient 2-methoxycinnamaldehyde: a new antiproliferative drug targeting topoisomerase I and II in human lung squamous cell carcinoma NCI-H520 cells.
Carcinoma, Squamous Cell
DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
Carcinoma, Squamous Cell
Effect of retinoic acid on DNA cleavage and cytotoxicity of topoisomerase II-reactive drugs in a human head and neck squamous carcinoma cell line.
Carcinoma, Squamous Cell
Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Carcinoma, Squamous Cell
Expression of human DNA Topoisomerase II-alpha in squamous cell carcinoma of the larynx and its correlation with clinicopathologic variables.
Carcinoma, Squamous Cell
From Proteomic Analysis to Potential Therapeutic Targets: Functional Profile of Two Lung Cancer Cell Lines, A549 and SW900, Widely Studied in Pre-Clinical Research.
Carcinoma, Squamous Cell
Induction of ubiquitin conjugating enzyme activity for degradation of topoisomerase II alpha during adenovirus E1A-induced apoptosis.
Carcinoma, Squamous Cell
Inhibition of topoisomerase II? sensitizes FaDu cells to ionizing radiation by diminishing DNA repair.
Carcinoma, Squamous Cell
Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393).
Carcinoma, Squamous Cell
Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.
Carcinoma, Squamous Cell
Namitecan: a hydrophilic camptothecin with a promising preclinical profile.
Carcinoma, Squamous Cell
Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.
Carcinoma, Squamous Cell
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Carcinoma, Squamous Cell
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Carcinoma, Squamous Cell
Topoisomerase alpha II, retinoblastoma gene product, and p53: potential relationships with aggressive behavior and malignant transformation in recurrent respiratory papillomatosis.
Carcinoma, Squamous Cell
Topoisomerase I activity in squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Topoisomerase I deregulation in laryngeal squamous cell carcinomas based on tissue microarray analysis.
Carcinoma, Squamous Cell
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Carcinoma, Squamous Cell
Topoisomerase I inhibitors in the treatment of head and neck cancer.
Carcinoma, Transitional Cell
Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression.
Carcinoma, Transitional Cell
Quantitative microscopy of human DNA topoisomerase II-alpha expression in transitional cell carcinoma of the bladder.
Carcinosarcoma
Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas.
Cardiomyopathies
Cardiac Damage in Anthracyclines Therapy: Focus on Oxidative Stress and Inflammation.
Cardiomyopathies
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Cardiotoxicity
A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma.
Cardiotoxicity
A switch in mechanism of action prevents doxorubicin-mediated cardiac damage.
Cardiotoxicity
Adriamycin-associated cardiomyopathy: where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes.
Cardiotoxicity
Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Cardiotoxicity
Anthracycline Chemotherapy and Cardiotoxicity.
Cardiotoxicity
Cardiac Damage in Anthracyclines Therapy: Focus on Oxidative Stress and Inflammation.
Cardiotoxicity
Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase II? activity and cardiac function in a chronic rabbit model.
Cardiotoxicity
Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients.
Cardiotoxicity
Cyclizing-berberine A35 induces G2/M arrest and apoptosis by activating YAP phosphorylation (Ser127).
Cardiotoxicity
Development of Orthogonal Linear Separation Analysis (OLSA) to Decompose Drug Effects into Basic Components.
Cardiotoxicity
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II? inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Cardiotoxicity
DNA damage response by single-strand breaks in terminally differentiated muscle cells and the control of muscle integrity.
Cardiotoxicity
Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Cardiotoxicity
Doxorubicin Redox Biology: Redox Cycling, Topoisomerase Inhibition, and Oxidative Stress.
Cardiotoxicity
Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase II? to II? in human stem cell derived cardiomyocytes.
Cardiotoxicity
Emerging DNA topisomerase inhibitors as anticancer drugs.
Cardiotoxicity
HU-331 is a catalytic inhibitor of topoisomerase II?.
Cardiotoxicity
Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Cardiotoxicity
Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone.
Cardiotoxicity
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II? Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity.
Cardiotoxicity
Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase II? Isoform.
Cardiotoxicity
Method for selective ablation of undifferentiated human pluripotent stem cell populations for cell-based therapies.
Cardiotoxicity
Mitochondrial topoisomerase I (Top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.
Cardiotoxicity
Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib.
Cardiotoxicity
Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Cardiotoxicity
Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Cardiotoxicity
Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase II?.
Cardiotoxicity
The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane.
Cardiotoxicity
Topoisomerase 2?: A Promising Molecular Target for Primary Prevention of Anthracycline-induced Cardiotoxicity.
Cardiotoxicity
Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity.
Cardiotoxicity
Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.
Cardiotoxicity
Twisting and ironing: Doxorubicin cardiotoxicity by mitochondrial DNA damage.
Cardiotoxicity
Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity.
Cardiotoxicity
[?urrent views on predictors and biomarkers of early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer (review of literature).]
Central Nervous System Neoplasms
The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
Central Nervous System Neoplasms
Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.
Central Nervous System Neoplasms
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
Cerebellar Neoplasms
Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma.
Cervical Intraepithelial Neoplasia
A cocktail of MCM2 and TOP2A, p16INK4a and Ki-67 as biomarkers for the improved diagnosis of cervical intraepithelial lesion.
Cervical Intraepithelial Neoplasia
Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling.
Chagas Disease
DNA Topoisomerase 3? Is Involved in Homologous Recombination Repair and Replication Stress Response in Trypanosoma cruzi.
Cholangiocarcinoma
Identification of key genes associated with the progression of intrahepatic cholangiocarcinoma using weighted gene co-expression network analysis.
Cholangiocarcinoma
Inhibition of topoisomerase II? and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives.
Cockayne Syndrome
Fine-tuning of the replisome: Mcm10 regulates fork progression and regression.
Cockayne Syndrome
Mutant Cockayne syndrome group B protein inhibits repair of DNA topoisomerase I-DNA covalent complex.
Collagen Diseases
Antitopoisomerase I antibody in patients with systemic lupus erythematosus/sicca syndrome without a concomitant scleroderma: two case reports.
Colonic Neoplasms
Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
Colonic Neoplasms
Anthocyanin-rich extracts suppress the DNA-damaging effects of topoisomerase poisons in human colon cancer cells.
Colonic Neoplasms
Antitumor Activity of Asperphenin A, a Lipopeptidyl Benzophenone from Marine-Derived Aspergillus sp. Fungus, by Inhibiting Tubulin Polymerization in Colon Cancer Cells.
Colonic Neoplasms
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Colonic Neoplasms
Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model.
Colonic Neoplasms
beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells.
Colonic Neoplasms
Biodegradable Polymeric Micelle-Mediated Delivery of a pH-Activatable Prodrug of 7-Ethyl-10-Hydroxy-Camptothecin (SN-38) to Enhance Anti-Angiogenesis and Anti-Tumor Activity.
Colonic Neoplasms
Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.
Colonic Neoplasms
Camptothecin Induces PD-L1 and Immunomodulatory Cytokines in Colon Cancer Cells.
Colonic Neoplasms
Catalytic inhibition of human DNA topoisomerase by phenolic compounds in Ardisia compressa extracts and their effect on human colon cancer cells.
Colonic Neoplasms
Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.
Colonic Neoplasms
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Colonic Neoplasms
Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
Colonic Neoplasms
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
Colonic Neoplasms
Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
Colonic Neoplasms
Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Colonic Neoplasms
Different Camptothecin Sensitivities in Subpopulations of Colon Cancer Cells Correlate with Expression of Different Phospho-Isoforms of Topoisomerase I with Different Activities.
Colonic Neoplasms
Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Colonic Neoplasms
DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
Colonic Neoplasms
DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.
Colonic Neoplasms
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Colonic Neoplasms
E-pharmacophore guided discovery of pyrazolo[1,5-c]quinazolines as dual inhibitors of topoisomerase-I and histone deacetylase.
Colonic Neoplasms
Effect of 2'-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells.
Colonic Neoplasms
Effects of Ukrain on the activities of DNA-nicking enzymes.
Colonic Neoplasms
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Colonic Neoplasms
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Colonic Neoplasms
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Colonic Neoplasms
Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
Colonic Neoplasms
Expression of BAX in cell nucleus after experimentally induced apoptosis revealed by immunogold and embedment-free electron microscopy.
Colonic Neoplasms
Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Colonic Neoplasms
Fluorescein hydrazones: A series of novel non-intercalative topoisomerase II? catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.
Colonic Neoplasms
Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Colonic Neoplasms
Genistein induces apoptosis and topoisomerase II-mediated DNA breakage in colon cancer cells.
Colonic Neoplasms
Glucose-regulated stresses induce resistance to camptothecin in human cancer cells.
Colonic Neoplasms
Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.
Colonic Neoplasms
Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.
Colonic Neoplasms
Green tea constituent (--)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells.
Colonic Neoplasms
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Colonic Neoplasms
Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins.
Colonic Neoplasms
Hydrogel-mediated delivery of celastrol and doxorubicin induces a synergistic effect on tumor regression via upregulation of ceramides.
Colonic Neoplasms
In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer.
Colonic Neoplasms
Induction of apoptosis in colon cancer cells by a novel topoisomerase I inhibitor TopIn.
Colonic Neoplasms
Irinotecan (Campto) in the treatment of pancreatic cancer.
Colonic Neoplasms
Mad-1 is the exclusive JC virus strain present in the human colon, and its transcriptional control region has a deleted 98-base-pair sequence in colon cancer tissues.
Colonic Neoplasms
Mapping DNA Breaks by Next-Generation Sequencing.
Colonic Neoplasms
MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.
Colonic Neoplasms
Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells.
Colonic Neoplasms
Moguntinones--new selective inhibitors for the treatment of human colorectal cancer.
Colonic Neoplasms
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
Colonic Neoplasms
p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma.
Colonic Neoplasms
Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells.
Colonic Neoplasms
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Colonic Neoplasms
Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Colonic Neoplasms
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.
Colonic Neoplasms
Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
Colonic Neoplasms
Regression of human colon cancer xenografts in SCID mice following oral administration of water-insoluble camptothecins.
Colonic Neoplasms
Replication-deficient adenovirus induces host topoisomerase I activity: implications for adenovirus-mediated gene expression.
Colonic Neoplasms
Resistance to Irinotecan (CPT-11) activates Epidermal Growth Factor Receptor/Nuclear Factor Kappa B and Increases Cellular Metastasis and Autophagy in LoVo Colon Cancer Cells.
Colonic Neoplasms
Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor.
Colonic Neoplasms
Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells.
Colonic Neoplasms
Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan.
Colonic Neoplasms
Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds.
Colonic Neoplasms
Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines.
Colonic Neoplasms
The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1.
Colonic Neoplasms
The Role of Autophagic Cell Death and Apoptosis in Irinotecan-Treated P53 Null Colon Cancer Cells.
Colonic Neoplasms
The use of olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Colonic Neoplasms
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Colonic Neoplasms
Therapy-related acute promyelocytic leukaemia.
Colonic Neoplasms
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer.
Colonic Neoplasms
Topoisomerase II? mediates TCF-dependent epithelial-mesenchymal transition in colon cancer.
Colonic Neoplasms
Topoisomerase-I inhibitors in the management of colon cancer.
Colonic Neoplasms
Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Colonic Neoplasms
Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects.
Colonic Neoplasms
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
Colonic Neoplasms
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan]
Colorectal Neoplasms
A circadian clock transcription model for the personalization of cancer chronotherapy.
Colorectal Neoplasms
A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
Colorectal Neoplasms
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Colorectal Neoplasms
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
Colorectal Neoplasms
A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
Colorectal Neoplasms
A phase-I study of cpt-11, weekly bolus 5-fu and leucovorin in patients with metastatic cancer.
Colorectal Neoplasms
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
Colorectal Neoplasms
A quantitative RT-PCR method to determine topoisomerase I mRNA levels in human tissue samples.
Colorectal Neoplasms
Anti-cancer effect of Indanone-based thiazolyl hydrazone derivative on colon cancer cell lines.
Colorectal Neoplasms
Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Colorectal Neoplasms
Assessment of cyto/genotoxicity of irinotecan in v79 cells using the comet, micronucleus, and chromosome aberration assay.
Colorectal Neoplasms
Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.
Colorectal Neoplasms
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
Colorectal Neoplasms
Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.
Colorectal Neoplasms
Blocking of PI3K/Akt pathway enhances apoptosis induced by SN-38, an active form of CPT-11, in human hepatoma cells.
Colorectal Neoplasms
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
Colorectal Neoplasms
Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.
Colorectal Neoplasms
Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Colorectal Neoplasms
Ceramide involvement in homocamptothecin- and camptothecin-induced cytotoxicity and apoptosis in colon HT29 cells.
Colorectal Neoplasms
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Colorectal Neoplasms
Cetuximab in the treatment of patients with colorectal cancer.
Colorectal Neoplasms
Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications.
Colorectal Neoplasms
Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
Colorectal Neoplasms
Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Colorectal Neoplasms
Characterization of the topoisomerase I locus in human colorectal cancer.
Colorectal Neoplasms
Chemotherapy of advanced gastrointestinal cancer.
Colorectal Neoplasms
Chemotherapy of colorectal cancer: history and new themes.
Colorectal Neoplasms
Clinical applications of the camptothecins.
Colorectal Neoplasms
Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.
Colorectal Neoplasms
Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients.
Colorectal Neoplasms
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
Colorectal Neoplasms
Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers.
Colorectal Neoplasms
CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
Colorectal Neoplasms
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
Colorectal Neoplasms
CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.
Colorectal Neoplasms
Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation.
Colorectal Neoplasms
DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis.
Colorectal Neoplasms
DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner.
Colorectal Neoplasms
E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin.
Colorectal Neoplasms
Effects of camptothecin on double-strand break repair by non-homologous end-joining in DNA mismatch repair-deficient human colorectal cancer cell lines.
Colorectal Neoplasms
EGCG synergizes the therapeutic effect of irinotecan through enhanced DNA damage in human colorectal cancer cells.
Colorectal Neoplasms
EGFR-targeted therapies in colorectal cancer.
Colorectal Neoplasms
Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy.
Colorectal Neoplasms
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Colorectal Neoplasms
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Colorectal Neoplasms
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Colorectal Neoplasms
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Colorectal Neoplasms
Enzyme-Based Electrochemical Biosensor for Therapeutic Drug Monitoring of Anticancer Drug Irinotecan.
Colorectal Neoplasms
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.
Colorectal Neoplasms
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
Colorectal Neoplasms
Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells.
Colorectal Neoplasms
Experience with irinotecan for the treatment of malignant glioma.
Colorectal Neoplasms
Experimental drugs and drug combinations in pancreatic cancer.
Colorectal Neoplasms
Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
Colorectal Neoplasms
Herbal Medicines for Irinotecan-Induced Diarrhea.
Colorectal Neoplasms
Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling.
Colorectal Neoplasms
Improving the Therapeutic Index in Cancer Therapy by Using Antibody-Drug Conjugates Designed with a Moderately Cytotoxic Drug.
Colorectal Neoplasms
In Vitro and In Silico Mechanistic Insights into miR-21-5p-Mediated Topoisomerase Drug Resistance in Human Colorectal Cancer Cells.
Colorectal Neoplasms
In vitro antitumor effect of topoisomerase-I inhibitor, CPT-11, on freshly isolated human gastric and colorectal cancer.
Colorectal Neoplasms
Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation.
Colorectal Neoplasms
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Colorectal Neoplasms
Inhibition of Stat3 by peptide aptamer rS3-PA enhances growth suppressive effects of irinotecan on colorectal cancer cells.
Colorectal Neoplasms
Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer.
Colorectal Neoplasms
Irinotecan in the treatment of colorectal cancer: clinical overview.
Colorectal Neoplasms
Irinotecan induces senescence and apoptosis in colonic cells in vitro.
Colorectal Neoplasms
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Colorectal Neoplasms
Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Colorectal Neoplasms
Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons.
Colorectal Neoplasms
Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.
Colorectal Neoplasms
Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors.
Colorectal Neoplasms
Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort.
Colorectal Neoplasms
Moguntinones--new selective inhibitors for the treatment of human colorectal cancer.
Colorectal Neoplasms
New agents for colon and breast cancer.
Colorectal Neoplasms
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
Colorectal Neoplasms
New promising anticancer agents in development: what comes next?
Colorectal Neoplasms
Non-linear pharmacokinetics of irinotecan in mice.
Colorectal Neoplasms
Personalized Drug Efficacy Monitoring Chip.
Colorectal Neoplasms
Pharmacogenomic Profiling and Pathway Analyses Identify MAPK-Dependent Migration as an Acute Response to SN38 in p53 Null and p53-Mutant Colorectal Cancer Cells.
Colorectal Neoplasms
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Colorectal Neoplasms
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Colorectal Neoplasms
Pregnane x Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
Colorectal Neoplasms
Profiling markers of prognosis in colorectal cancer.
Colorectal Neoplasms
Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
Colorectal Neoplasms
Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage.
Colorectal Neoplasms
Regulation of Tissue-Specific Carboxylesterase Expression by Pregnane X Receptor and Constitutive Androstane Receptor.
Colorectal Neoplasms
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma.
Colorectal Neoplasms
RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.
Colorectal Neoplasms
Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: associations with clinicopathological and molecular features.
Colorectal Neoplasms
Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.
Colorectal Neoplasms
Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Colorectal Neoplasms
St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
Colorectal Neoplasms
Stabilisation in colorectal cancer.
Colorectal Neoplasms
Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion.
Colorectal Neoplasms
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Colorectal Neoplasms
Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles.
Colorectal Neoplasms
The Association Between HSP90/topoisomerase I Immunophenotype and the Clinical Features of Colorectal Cancers in Respect to KRAS Gene Status.
Colorectal Neoplasms
The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway.
Colorectal Neoplasms
The development of new chemotherapeutic agents.
Colorectal Neoplasms
The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studies.
Colorectal Neoplasms
The role of irinotecan in colorectal cancer.
Colorectal Neoplasms
The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
Colorectal Neoplasms
The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Colorectal Neoplasms
The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Colorectal Neoplasms
Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure.
Colorectal Neoplasms
Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
Colorectal Neoplasms
TIMP-1 Increases Expression and Phosphorylation of Proteins Associated with Drug Resistance in Breast Cancer Cells.
Colorectal Neoplasms
Tissue penetration and activity of camptothecins in solid tumor xenografts.
Colorectal Neoplasms
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
Colorectal Neoplasms
Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis.
Colorectal Neoplasms
Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.
Colorectal Neoplasms
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Colorectal Neoplasms
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
Colorectal Neoplasms
Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
Colorectal Neoplasms
Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets.
Colorectal Neoplasms
Topoisomerase I inhibitors in the treatment of colorectal cancer.
Colorectal Neoplasms
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
Colorectal Neoplasms
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
Colorectal Neoplasms
Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy.
Colorectal Neoplasms
Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11.
Colorectal Neoplasms
Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Colorectal Neoplasms
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
Colorectal Neoplasms
Topotecan in advanced colorectal cancer.
Colorectal Neoplasms
Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group.
Colorectal Neoplasms
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Colorectal Neoplasms
Trastuzumab Deruxtecan: First Approval.
Colorectal Neoplasms
Weekly irinotecan plus protracted venous fluorouracil infusion (WI-FI) in advanced colorectal cancer: a phase II study.
Colorectal Neoplasms
[Effect of palliative chemotherapy with topoisomerase inhibitor on the quality of life and survival of patients with advanced colorectal carcinoma]
Colorectal Neoplasms
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer]
Colorectal Neoplasms
[Standard therapy of CPT-11 for colorectal cancer]
Colorectal Neoplasms
[Therapeutic approach for colorectal cancer with topoisomerase as a molecular target]
Communicable Diseases
A patent review of topoisomerase I inhibitors (2016-present).
Communicable Diseases
Inhibitors of DNA Gyrase-GyrB Subunit and/or Topoisomerase IV-ParE Subunit May Treat Infectious Diseases Caused by Antibiotic-Resistant Bacteria.
Community-Acquired Infections
In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class.
Community-Acquired Infections
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
Connective Tissue Diseases
Distinct autoreactive T cell responses to native and fragmented DNA topoisomerase I: influence of APC type and IL-2.
Contracture
Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients.
Contracture
Massive pericardial effusion in scleroderma: a review of five cases.
Cryptorchidism
Changes of enzymes involved in DNA synthesis in the testes of cryptorchid rats.
Cystadenoma
[Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]
Cystic Fibrosis
Ivacaftor, a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator, Enhances Ciprofloxacin Activity Against Pseudomonas aeruginosa.
Cystic Fibrosis
l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor.
Cysts
DNA topoisomerase III? promotes cyst generation by inducing cyst wall protein gene expression in Giardia lamblia.
Decompression Sickness
DNA protection by histone-like protein HU from the hyperthermophilic eubacterium Thermotoga maritima.
Decompression Sickness
The C-terminal domain of DNA gyrase A adopts a DNA-bending beta-pinwheel fold.
Decompression Sickness
Topoisomerase IV bends and overtwists DNA upon binding.
Dengue
Topoisomerase III-? is required for efficient replication of positive-sense RNA viruses.
Dengue
Topoisomerase III-ß is required for efficient replication of positive-sense RNA viruses.
Diabetes Complications
Type 1 diabetes affects topoisomerase I activity and GlcNAcylation in rat organs: kidney liver and pancreas.
Diabetes Mellitus, Type 1
Type 1 diabetes affects topoisomerase I activity and GlcNAcylation in rat organs: kidney liver and pancreas.
Diffuse Intrinsic Pontine Glioma
A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.
dna topoisomerase (atp-hydrolysing) deficiency
Escherichia coli DNA topoisomerase I mutants have compensatory mutations in DNA gyrase genes.
dna topoisomerase (atp-hydrolysing) deficiency
Topoisomerase I Essentiality, DnaA-Independent Chromosomal Replication, and Transcription-Replication Conflict in Escherichia coli.
dna topoisomerase deficiency
An interplay of NOX1-derived ROS and oxygen determines the spermatogonial stem cell self-renewal efficiency under hypoxia.
dna topoisomerase deficiency
Expression of the recA gene is reduced in Escherichia coli topoisomerase I mutants.
dna topoisomerase deficiency
gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.
dna topoisomerase deficiency
Mitochondrial topoisomerase I absence enhances aerobic glycolysis in cancer.
dna topoisomerase deficiency
Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone.
dna topoisomerase deficiency
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.
dna topoisomerase deficiency
Topoisomerase deficiencies subtly enhance global genomic repair of ultraviolet-induced DNA damage in Saccharomyces cerevisiae.
dna topoisomerase deficiency
Topoisomerase I deficiency causes RNA polymerase II accumulation and increases AID abundance in immunoglobulin variable genes.
dna topoisomerase deficiency
Topoisomerase I deficiency results in chromosomal alterations in cervical cancer cells.
dna topoisomerase deficiency
Topoisomerase I Essentiality, DnaA-Independent Chromosomal Replication, and Transcription-Replication Conflict in Escherichia coli.
Drug-Related Side Effects and Adverse Reactions
Drug toxicity in E. coli cells expressing human topoisomerase I.
Drug-Related Side Effects and Adverse Reactions
In vitro sensitivity of human gastric cancer cells (HGC-27) to Helicobacter pylori cytotoxin.
Drug-Related Side Effects and Adverse Reactions
Triple helix-forming oligonucleotides conjugated to indolocarbazole poisons direct topoisomerase I-mediated DNA cleavage to a specific site.
Dysplastic Nevus Syndrome
Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
Encephalomyelitis
Eliminating encephalitogenic T cells without undermining protective immunity.
Encephalomyelitis, Autoimmune, Experimental
Eliminating encephalitogenic T cells without undermining protective immunity.
Endodermal Sinus Tumor
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Endometrial Hyperplasia
Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIalpha expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia.
Endometrial Neoplasms
Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study.
Endometrial Neoplasms
Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIalpha expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia.
Endometrial Neoplasms
Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Endometrial Neoplasms
Topoisomerase II? Binding Protein 1 c.*229C>T (rs115160714) Gene Polymorphism and Endometrial Cancer Risk.
Endometrial Neoplasms
Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.
Endometrial Neoplasms
Treatment options for endometrial cancer: experience with topotecan.
Endometrial Neoplasms
Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.
Endometriosis
Deep Invasive Endometriosis Lesions of the Rectosigmoid May Be Related to Alterations in Cell Kinetics.
Epilepsy
DNA topoisomerase I inhibitors ameliorate seizure-like behaviors and paralysis in a Drosophila model of epilepsy.
Equine Infectious Anemia
Isolation of an 11-kDa protein associated with the topoisomerase I activity from equine infectious anemia virus.
Equine Infectious Anemia
The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells.
Equine Infectious Anemia
Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core.
Esophageal Neoplasms
Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer.
Esophageal Neoplasms
Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Esophageal Neoplasms
Secondary myelodysplastic syndrome after small cell lung cancer and esophageal cancer.
Esophageal Squamous Cell Carcinoma
(S)-10-Hydroxycamptothecin Inhibits Esophageal Squamous Cell Carcinoma Growth In Vitro and In Vivo Via Decreasing Topoisomerase I Enzyme Activity.
Esophageal Squamous Cell Carcinoma
Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis.
Esthesioneuroblastoma, Olfactory
Esthesioneuroblastoma - a clinicopathologic study and role of DNA topoisomerase alpha.
Fanconi Anemia
Cell cycle effects of the DNA topoisomerase inhibitors camptothecin and m-AMSA in lymphoblastoid cell lines from patients with Fanconi anemia.
Fanconi Anemia
Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells.
Fanconi Anemia
Comparison of the effects of DNA topoisomerase inhibitors on lymphoblasts from normal and Fanconi anemia donors.
Fanconi Anemia
Fanconi anemia cells have a normal gene structure for topoisomerase I.
Fanconi Anemia
Fanconi's anemia: anomaly of enzyme passage through the nuclear membrane? Anomalous intracellular distribution of topoisomerase activity in placental extracts in a case of Fanconi's anemia.
Fanconi Anemia
Intracellular distribution of DNA topoisomerase I in fibroblasts from patients with Fanconi's anaemia.
Fanconi Anemia
Rad18 E3 ubiquitin ligase activity mediates fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 Inhibition.
Fanconi Anemia
Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4.
Fanconi Anemia
Replication Fork Protection Factors Controlling R-Loop Bypass and Suppression.
Fanconi Anemia
Topo IIIalpha and BLM act within the Fanconi anemia pathway in response to DNA-crosslinking agents.
Fibrosarcoma
Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Fibrosarcoma
DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives.
Fibrosarcoma
HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Fibrosarcoma
Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo.
Fibrosarcoma
Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I.
Fibrosarcoma
Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
Fragile X Syndrome
Top3? is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation.
Ganglioneuroblastoma
DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
Gastrointestinal Neoplasms
Resveratrol-3-O-glucuronide and resveratrol-4'-O-glucuronide reduce DNA strand breakage but not apoptosis in Jurkat T cells treated with camptothecin.
Gastrointestinal Neoplasms
Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.
Genetic Diseases, Inborn
DNA damage modulates nucleolar interaction of the Werner protein with the AAA ATPase p97/VCP.
Genetic Diseases, Inborn
Evolutionary Comparison of the Mechanism of DNA Cleavage with Respect to Immune Diversity and Genomic Instability.
Genetic Diseases, Inborn
TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage.
Gilbert Disease
Pharmacogenetics: a tool for individualizing antineoplastic therapy.
Glioblastoma
Biological activity and molecular docking studies of some new quinolines as potent anticancer agents.
Glioblastoma
Differential response of human glioblastoma cell lines to combined camptothecin and ionizing radiation treatment.
Glioblastoma
Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Glioblastoma
Fas/CD95-mediated apoptosis in human glioblastoma cells: a target for sensitisation to topoisomerase I inhibitors.
Glioblastoma
Gene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines.
Glioblastoma
Hepatocyte growth factor increases mitochondrial mass in glioblastoma cells.
Glioblastoma
Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Glioblastoma
Karenitecin (bnp1350) and flavopridol as radiosensitizers in malignant glioma.
Glioblastoma
Long-lasting partial regression of glioblastoma multiforme achieved by edotecarin: case report.
Glioblastoma
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.
Glioblastoma
NADPH/quinone oxidoreductase is a priority target of glioblastoma chemotherapy.
Glioblastoma
Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines.
Glioblastoma
p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.
Glioblastoma
Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Glioblastoma
Quantification of DNase type I ends, DNase type II ends, and modified bases using fluorescently labeled ddUTP, terminal deoxynucleotidyl transferase, and formamidopyrimidine-DNA glycosylase.
Glioblastoma
Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.
Glioblastoma
Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells.
Glioblastoma
The effect of iodine-131 beta-particles in combination with A-966492 and Topotecan on radio-sensitization of glioblastoma: An in-vitro study.
Glioblastoma
Topoisomerase I Inhibitors in the Treatment of Primary CNS Malignancies: An Update on Recent Trends.
Glioblastoma
Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends.
Glioblastoma
Topoisomerase II? mediates the resistance of glioblastoma stem cells to replication stress-inducing drugs.
Glioblastoma
Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin.
Glioblastoma
Tyrosyl-DNA Phosphodiesterase 1 and Topoisomerase I Activities as Predictive Indicators for Glioblastoma Susceptibility to Genotoxic Agents.
Glioblastoma
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
Glioma
A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.
Glioma
A systematic review and meta-analysis of topoisomerase inhibition in pre-clinical glioma models.
Glioma
Canine spontaneous glioma: a translational model system for convection-enhanced delivery.
Glioma
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.
Glioma
Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Glioma
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
Glioma
Differential response of human glioblastoma cell lines to combined camptothecin and ionizing radiation treatment.
Glioma
DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival.
Glioma
Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo.
Glioma
Etoposide improves survival in high-grade glioma: a meta-analysis.
Glioma
Gene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines.
Glioma
Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage.
Glioma
In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma.
Glioma
Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.
Glioma
Inhibitory effect of DNA topoisomerase inhibitor isoliquiritigenin on the growth of glioma cells.
Glioma
Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II.
Glioma
Long-term exposure to irinotecan reduces cell migration in glioma cells.
Glioma
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
Glioma
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Glioma
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Glioma
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Glioma
Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Glioma
Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
Glioma
Pyrrolo[2,3-?]carbazole derivatives as topoisomerase I inhibitors that affect viability of glioma and endothelial cells in vitro and angiogenesis in vivo.
Glioma
Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Glioma
Recurrent brainstem gliomas treated with oral VP-16.
Glioma
Regression of Recurrent Malignant Gliomas with Convection-Enhanced Delivery of Topotecan.
Glioma
Resveratrol acts as a topoisomerase II poison in human glioma cells.
Glioma
Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Glioma
Synergistic cytotoxicity, apoptosis and protein-linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorylation.
Glioma
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Glioma
Temozolomide in combination with other cytotoxic agents.
Glioma
The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration.
Glioma
The enhanced antitumor-activity of DNA topoisomerase ii-trapping drugs by natural human tumor-necrosis-factor against human glioma cell-lines in-vitro.
Glioma
Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
Glioma
TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas.
Glioma
Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells.
Glioma
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications.
Glioma
Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells.
Glioma
Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone.
Glioma
Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3 mediated Bid cleavage.
Glioma
[Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11]
Glioma, Subependymal
Therapeutic targets in subependymoma.
Gliosarcoma
Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model.
Gliosarcoma
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Glomerulosclerosis, Focal Segmental
Expression of DNA topoisomerases in chronic proliferative kidney disease.
Gonorrhea
Efficacy of a Novel Tricyclic Topoisomerase Inhibitor in a Murine Model of Neisseria gonorrhoeae Infection.
Gonorrhea
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
Graft vs Host Disease
Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Granuloma
Cellular pharmacology studies of shikonin derivatives.
Head and Neck Neoplasms
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
Head and Neck Neoplasms
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Head and Neck Neoplasms
New cytotoxic and molecular-targeted therapies of head and neck tumors.
Head and Neck Neoplasms
Topoisomerase I inhibitors in the treatment of head and neck cancer.
Head and Neck Neoplasms
Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells.
Hearing Loss
Mutations in TOP2B cause autosomal-dominant hereditary hearing loss via inhibition of the PI3K-Akt signalling pathway.
Heart Failure
A switch in mechanism of action prevents doxorubicin-mediated cardiac damage.
Heart Failure
Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Hemangioma
Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma.
Hematologic Neoplasms
Concomitant use of radiotherapy and two topoisomerase inhibitors to treat adult T-cell leukemia with a radiotherapy-resistant bulky disease: a case series.
Hematologic Neoplasms
Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
Hematologic Neoplasms
Future role of topotecan in the treatment of lung cancer.
Hematologic Neoplasms
New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. Introduction.
Hematologic Neoplasms
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
Hematologic Neoplasms
Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
Hematologic Neoplasms
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Hematologic Neoplasms
Proton Radiotherapy for Pediatric Ewing's Sarcoma: Initial Clinical Outcomes.
Hematologic Neoplasms
Secondary myelodysplastic syndrome after small cell lung cancer and esophageal cancer.
Hematologic Neoplasms
The broken genome: genetic and pharmacologic approaches to breaking DNA.
Hematologic Neoplasms
Topoisomerase I inhibitors in the treatment of head and neck cancer.
Hepatitis
Topoisomerase I-mediated integration of hepadnavirus DNA in vitro.
Hepatitis B
Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2.
Hepatitis B
Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro.
Hepatitis, Chronic
Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
Hepatoblastoma
The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line.
Herpes Simplex
A DNA topoisomerase activity copurifies with the DNA polymerase induced by herpes simplex virus.
Herpes Simplex
Association of type I DNA topoisomerase with herpes simplex virus.
Herpes Simplex
Human topoisomerase 1 messenger RNA is not destabilized by the herpes simplex virus type 2 virion-associated shut-off function.
Herpes Simplex
Identification of KIAA1210 as a novel X-chromosome-linked protein that localizes to the acrosome and associates with the ectoplasmic specialization in testes.
Herpes Simplex
Role of DNA topoisomerase I in the replication of herpes simplex virus type 2.
Herpes Simplex
Studies on DNA topoisomerases I and II in herpes simplex virus type 2-infected cells.
Herpes Simplex
Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Hodgkin Disease
Correspondence re: M. Provencio, et al. the topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin. Cancer Res., 9: 1406-1411, 2003.
Hodgkin Disease
Immunohistochemical staining for DNA topoisomerase IIa in Hodgkin's disease.
Hodgkin Disease
Rearrangement of the Myeloid/Lymphoid Leukemia Gene in Therapy-Related Myelodysplastic Syndrome in Patients Previously Treated with Agents Targeting DNA Topoisomerase II.
Hodgkin Disease
Topoisomerase II{alpha} Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma.
Huntington Disease
Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.
Hypergammaglobulinemia
Clinical influences of anticentromere antibody on primary Sjögren's syndrome in a prospective Korean cohort.
Hyperglycemia
Type 1 diabetes affects topoisomerase I activity and GlcNAcylation in rat organs: kidney liver and pancreas.
Hypersensitivity
Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines.
Hypersensitivity
Cell cycle effects of the DNA topoisomerase inhibitors camptothecin and m-AMSA in lymphoblastoid cell lines from patients with Fanconi anemia.
Hypersensitivity
Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells.
Hypersensitivity
Collaborative roles of gammaH2AX and the Rad51 paralog Xrcc3 in homologous recombinational repair.
Hypersensitivity
Comparison of the effects of DNA topoisomerase inhibitors on lymphoblasts from normal and Fanconi anemia donors.
Hypersensitivity
Contribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniae.
Hypersensitivity
Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs.
Hypersensitivity
Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance.
Hypersensitivity
DNA Ligase IV and Artemis Act Cooperatively to Suppress Homologous Recombination in Human Cells: Implications for DNA Double-Strand Break Repair.
Hypersensitivity
Effects of camptothecin on double-strand break repair by non-homologous end-joining in DNA mismatch repair-deficient human colorectal cancer cell lines.
Hypersensitivity
Enhanced sensitivity to camptothecin in ataxia-telangiectasia cells and its relationship with the expression of DNA topoisomerase I.
Hypersensitivity
gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.
Hypersensitivity
Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA.
Hypersensitivity
Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.
Hypersensitivity
Identification of the MMS22L-TONSL complex that promotes homologous recombination.
Hypersensitivity
Identification of Tyrosyl-DNA Phosphodiesterase as a Novel DNA Damage Repair Enzyme in Arabidopsis.
Hypersensitivity
Isolation of camptothecin-sensitive chinese hamster cell mutants: phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group.
Hypersensitivity
Large-scale analysis of genes that alter sensitivity to the anticancer drug tirapazamine in Saccharomyces cerevisiae.
Hypersensitivity
Mitochondrial topoisomerase I (Top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.
Hypersensitivity
Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone.
Hypersensitivity
Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin.
Hypersensitivity
Overexpression of type I topoisomerases sensitizes yeast cells to DNA damage.
Hypersensitivity
p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.
Hypersensitivity
Pnk1, a DNA kinase/phosphatase required for normal response to DNA damage by gamma-radiation or camptothecin in Schizosaccharomyces pombe.
Hypersensitivity
Quantification of Etoposide Hypersensitivity: A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality.
Hypersensitivity
Sensitivity to camptothecin in Aspergillus nidulans identifies a novel gene, scaA+, related to the cellular DNA damage response.
Hypersensitivity
Tdp1 protects from topoisomerase 1-mediated chromosomal breaks in adult zebrafish but is dispensable during larval development.
Hypersensitivity
The DNA helicase activity of yeast Sgs1p is essential for normal lifespan but not for resistance to topoisomerase inhibitors.
Hypersensitivity
The effect of two topoisomerase inhibitors on low-dose hypersensitivity and increased radioresistance in Chinese hamster V79 cells.
Hypersensitivity
The topoisomerase-related function gene TRF4 affects cellular sensitivity to the antitumor agent camptothecin.
Hypersensitivity
Tyrosyl-DNA phosphodiesterases: rescuing the genome from the risks of relaxation.
Hypersensitivity
[Various novel properties of transcriptionally active mini-chromosomes of the SV40 virus]
Hypertension
Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma.
Hypertension, Pulmonary
Mechanical thumb pain in a systemic sclerosis patient: simple first carpometacarpal osteoarthritis?
Hyperthyroidism
Poly(ADP-ribose) polymerase is affected early by thyroid state during liver regeneration in rats.
Hypertriglyceridemia
Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan.
Infections
55.2, a phage T4 ORFan gene, encodes an inhibitor of Escherichia coli topoisomerase I and increases phage fitness.
Infections
A simplified protocol for high-yield expression and purification of bacterial topoisomerase I.
Infections
Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents.
Infections
Antimicrobial Resistance in Mycoplasma spp.
Infections
Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting.
Infections
Autonomous parvovirus DNA replication requires topoisomerase I and its activity is increased during infection.
Infections
Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
Infections
Chikungunya Virus Infection Alters Expression of MicroRNAs Involved in Cellular Proliferation, Immune Response and Apoptosis.
Infections
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
Infections
Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.
Infections
DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV-1 infection of macrophages.
Infections
DNA damage promotes herpes simplex virus-1 protein expression in a neuroblastoma cell line.
Infections
Effect of bacteriophage T4 DNA topoisomerase gene 39 on level of beta chain of ribonucleoside diphosphate reductase in a T4 nrdB mutant.
Infections
Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B.
Infections
Efficacy of a Novel Tricyclic Topoisomerase Inhibitor in a Murine Model of Neisseria gonorrhoeae Infection.
Infections
Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Infections
Evaluation of a New Chemotherapeutic: Cethromycin-Mediated Protection Against the Plague Pathogen, Yersinia pestis, in a Rat Model of Infection and its Comparison with Levofloxacin.
Infections
Expression of the type I DNA topoisomerase gene in adenovirus-5 infected human cells.
Infections
Human TOP1 residues implicated in species specificity of HIV-1 infection are required for interaction with BTBD2, and RNAi of BTBD2 in old world monkey and human cells increases permissiveness to HIV-1 infection.
Infections
Human topoisomerase 1 messenger RNA is not destabilized by the herpes simplex virus type 2 virion-associated shut-off function.
Infections
Human topoisomerase I promotes HIV-1 proviral DNA synthesis: implications for the species specificity and cellular tropism of HIV-1 infection.
Infections
Identification of smut-responsive genes in sugarcane using cDNA-SRAP.
Infections
Imidazopyrazinones (IPYs): non-quinolone bacterial topoisomerase inhibitors showing partial cross-resistance with quinolones.
Infections
In vitro and in vivo metabolism of 14C-AZ11, a novel inhibitor of bacterial DNA gyrase/type II topoisomerase.
Infections
Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor.
Infections
Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.
Infections
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
Infections
Mycoplasma fermentans Inhibits the Activity of Cellular DNA Topoisomerase I by Activation of PARP1 and Alters the Efficacy of Its Anti-Cancer Inhibitor.
Infections
New aminocoumarin antibiotics as gyrase inhibitors.
Infections
New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV.
Infections
Nonoptimal DNA topoisomerases allow maintenance of supercoiling levels and improve fitness of Streptococcus pneumoniae.
Infections
Novel berberine derivatives: Design, synthesis, antimicrobial effects, and molecular docking studies.
Infections
Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
Infections
Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription.
Infections
Sitafloxacin: antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV.
Infections
Small-Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents.
Infections
Structural alteration of DNA induced by viral protein R of HIV-1 triggers the DNA damage response.
Infections
Studies on DNA topoisomerases I and II in herpes simplex virus type 2-infected cells.
Infections
Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase.
Infections
Targeting Mycobacterium tuberculosis Topoisomerase I by Small-Molecule Inhibitors.
Infections
Temporal Interplay between Efflux Pumps and Target Mutations in Development of Antibiotic Resistance in Escherichia coli.
Infections
The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs.
Infections
The frequency of DNA gyrase and topoisomerase IV mutations, and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
Infections
The role of topoisomerase I in HIV-1 replication.
Infections
Therapeutic targets for the treatment of microsporidiosis in humans.
Infections
Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target.
Infections
Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.
Infections
Type I topoisomerase activity after infection of enucleated, synchronized mouse L cells by vaccinia virus.
Infections
[Mutations of DNA gyrase and topoisomerase IV in clinical isolates of fluoroquinolone-resistant Proteus mirabilis]
Infertility
Development of autoimmunity in mice lacking DNA topoisomerase 3beta.
Infertility
Infertility and aneuploidy in mice lacking a type IA DNA topoisomerase III beta.
Infertility, Male
Proteomic Analysis Reveals that Topoisomerase 2A is Associated with Defective Sperm Head Morphology.
Influenza, Human
A frame shift mutation in a hot spot region of the nuclear autoantigen La (SS-B).
Influenza, Human
Host-directed therapies for antimicrobial resistant respiratory tract infections.
Keloid
Effect of camptothecin on collagen synthesis in fibroblasts from patients with keloid.
Kidney Neoplasms
A potential novel combination therapy targeting survivin in renal cancer cells: Inhibition of survivin expression by topotecan and hexamethylene bisacetamide.
Kidney Neoplasms
Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.
Klatskin Tumor
Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy.
Leiomyomatosis
Topoisomerase I and II consensus sequences in a 17-kb deletion junction of the COL4A5 and COL4A6 genes and immunohistochemical analysis of esophageal leiomyomatosis associated with Alport syndrome.
Leiomyosarcoma
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Leiomyosarcoma
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.
Leishmaniasis
A pentapeptide signature motif plays a pivotal role in Leishmania DNA topoisomerase IB activity and camptothecin sensitivity.
Leishmaniasis
Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani.
Leishmaniasis
Topoisomerase 1B as a Target Against Leishmaniasis.
Leishmaniasis, Cutaneous
Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B.
Leishmaniasis, Visceral
Copper salisylaldoxime (CuSAL) imparts protective efficacy against visceral leishmaniasis by targeting Leishmania donovani topoisomerase IB.
Leishmaniasis, Visceral
Deletion Study of DNA Topoisomerase IB from Leishmania donovani: Searching for a Minimal Functional Heterodimer.
Leishmaniasis, Visceral
Structural insights on the small subunit of DNA topoisomerase I from the unicellular parasite Leishmania donovani.
Leishmaniasis, Visceral
The HIV - 1 protease inhibitor Amprenavir targets Leishmania donovani topoisomerase I and induces oxidative stress-mediated programmed cell death.
Leishmaniasis, Visceral
Topoisomerase IB poisons induce histone H2A phosphorylation as a response to DNA damage in Leishmania infantum.
Leukemia
2- or 6-(1-azidoalkyl)-5,8-dimethoxy-1,4-naphthoquinone: synthesis, evaluation of cytotoxic activity, antitumor activity and inhibitory effect on DNA topoisomerase-I.
Leukemia
3-O-(E)-p-Coumaroyl Tormentic Acid from Eriobotrya japonica Leaves Induces Caspase-Dependent Apoptotic Cell Death in Human Leukemia Cell Line.
Leukemia
A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators.
Leukemia
A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.
Leukemia
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Leukemia
Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.
Leukemia
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Leukemia
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Leukemia
Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
Leukemia
Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia.
Leukemia
ALCAPs induce mitochondrial apoptosis and activate DNA damage response by generating ROS and inhibiting topoisomerase I enzyme activity in K562 leukemia cell line.
Leukemia
Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells.
Leukemia
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.
Leukemia
Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.
Leukemia
Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
Leukemia
Alternative RNA Processing of Topoisomerase II? in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform.
Leukemia
An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.
Leukemia
Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway.
Leukemia
Anion-dependent modulations of DNA topoisomerase II-mediated reactions in potassium-containing solutions.
Leukemia
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Leukemia
Apoptotic response of HL-60 human leukemia cells to the antitumor drug NB-506, a glycosylated indolocarbazole inhibitor of topoisomerase 1.
Leukemia
Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
Leukemia
Automated Extraction of DNA and RNA from a Single Formalin-Fixed Paraffin-Embedded Tissue Section for Analysis of Both Single-Nucleotide Polymorphisms and mRNA Expression.
Leukemia
beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells.
Leukemia
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response.
Leukemia
Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs.
Leukemia
c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosis.
Leukemia
Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells.
Leukemia
Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death.
Leukemia
Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy.
Leukemia
Cell cycle arrest and protein kinase modulating effect of bufalin on human leukemia ML1 cells.
Leukemia
Cell death in leukemia: passenger protein regulation by topoisomerase inhibitors.
Leukemia
Cells lacking DNA topoisomerase II beta are resistant to genistein.
Leukemia
Cellular and biochemical antileukemic mechanisms of the meroterpenoid Oncocalyxone A.
Leukemia
Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.
Leukemia
Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo.
Leukemia
Characterization and mechanisms of chromosomal alterations induced by benzene in mice and humans.
Leukemia
Characterization of a camptothecin-resistant human DNA topoisomerase I.
Leukemia
Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
Leukemia
Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16).
Leukemia
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Leukemia
Chemotherapy-related secondary leukemias: A role for DNA repair by error-prone non-homologous end joining in topoisomerase II - Induced chromosomal rearrangements.
Leukemia
Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites.
Leukemia
Circumvention of resistance by doxorubicin, but not by idarubicin, in a human leukemia cell line containing an intercalator-resistant form of topoisomerase II: evidence for a non-topoisomerase II-mediated mechanism of doxorubicin cytotoxicity.
Leukemia
Comparative QSAR studies on substituted bis-(acridines) and bis-(phenazines)-carboxamides: a new class of anticancer agents.
Leukemia
Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Leukemia
Contributions of the D-Ring to the activity of etoposide against human topoisomerase II?: potential interactions with DNA in the ternary enzyme--drug--DNA complex.
Leukemia
Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC.
Leukemia
Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoetic cell differentiation.
Leukemia
Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
Leukemia
CRISPR/Cas9 Genome Editing of the Human Topoisomerase II? Intron 19 5' Splice Site Circumvents Etoposide Resistance in Human Leukemia K562 Cells.
Leukemia
Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
Leukemia
Cudraflavanone A purified from Cudrania tricuspidata induces apoptotic cell death of human leukemia U937 cells, at least in part, through the inhibition of DNA topoisomerase I and protein kinase C activity.
Leukemia
Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
Leukemia
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Leukemia
Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells.
Leukemia
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives.
Leukemia
Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Leukemia
Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Leukemia
Dietary factors and the risk for acute infant leukemia: evaluating the effects of cocoa-derived flavanols on DNA topoisomerase activity.
Leukemia
Dietary polyphenols influence antimetabolite agents: methotrexate, 6-mercaptopurine and 5-fluorouracil in leukemia cell lines.
Leukemia
Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.
Leukemia
Differential effect of camptothecin treatment on topoisomerase II alpha expression in ML-1 and HL-60 leukemia cell lines.
Leukemia
Differential expression of human topoisomerase IIIalpha during the cell cycle progression in HL-60 leukemia cells and human peripheral blood lymphocytes.
Leukemia
Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors.
Leukemia
Differentiation induction of human promyelocytic leukemia cells by 10-hydroxycamptothecin, a DNA topoisomerase I inhibitor.
Leukemia
Distinct steps in DNA fragmentation pathway during camptothecin-induced apoptosis involved caspase-, benzyloxycarbonyl- and N-tosyl-L-phenylalanylchloromethyl ketone-sensitive activities.
Leukemia
DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles.
Leukemia
DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies.
Leukemia
DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Leukemia
DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.
Leukemia
DNA Topology and Topoisomerases: Teaching a "Knotty" Subject.
Leukemia
Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
Leukemia
Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells.
Leukemia
Early development of acute myeloid leukemia following treatment of osteosarcoma: a case report and review of the literature.
Leukemia
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
Leukemia
Effect of bryostatin 1 on drug-induced, topoisomerase II-mediated DNA cleavage and topoisomerase II gene expression in human leukemia cells.
Leukemia
Effect of difluoromethylornithine, an inhibitor of polyamine biosynthesis, on the topoisomerase II-mediated DNA scission produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide in L1210 murine leukemia cells.
Leukemia
Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Leukemia
Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
Leukemia
Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry.
Leukemia
Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue.
Leukemia
Etoposide, topoisomerase II and cancer.
Leukemia
Etoposide-induced DNA cleavage in human leukemia cells.
Leukemia
Evidence for BLM and Topoisomerase IIIalpha interaction in genomic stability.
Leukemia
Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
Leukemia
Genistein induces topoisomerase IIbeta- and proteasome-mediated DNA sequence rearrangements: Implications in infant leukemia.
Leukemia
Hoechst 33342 induces apoptosis in HL-60 cells and inhibits topoisomerase I in vivo.
Leukemia
Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Leukemia
hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II? in Human Leukemia K562 Cells with Acquired Resistance to Etoposide.
Leukemia
Human LPP gene is fused to MLL in a secondary acute leukemia with a t(3;11) (q28;q23).
Leukemia
Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Leukemia
Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.
Leukemia
Indole alkaloids and other constituents of Rauwolfia serpentina.
Leukemia
Induction of apoptosis by topotecan: implications for the treatment of leukemia.
Leukemia
Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias.
Leukemia
Inhibition of Moloney murine leukemia virus replication by tyrphostins, tyrosine kinase inhibitors.
Leukemia
Inhibition of murine AIDS (MAIDS) development in C57BL/6J mice by tyrphostin AG-1387.
Leukemia
Inhibition of novel GCN5-ATM axis restricts the onset of acquired drug resistance in leukemia.
Leukemia
Inhibitors of topoisomerases as anticancer drugs: problems and prospects.
Leukemia
Initial testing of topotecan by the pediatric preclinical testing program.
Leukemia
Interaction of Deubiquitinase 2A-DUB/MYSM1 with DNA Repair and Replication Factors.
Leukemia
Intercalator-induced, topoisomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites.
Leukemia
Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
Leukemia
Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
Leukemia
Involvement of DNA topoisomerases and DNA topoisomerase inhibitors in the induction of leukemia cell differentiation.
Leukemia
Involvement of hydrogen peroxide in topoisomerase inhibitor beta-lapachone-induced apoptosis and differentiation in human leukemia cells.
Leukemia
Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
Leukemia
Isolation of a mitochondrial DNA topoisomerase from human leukemia cells.
Leukemia
Isolation of an 11-kDa protein associated with the topoisomerase I activity from equine infectious anemia virus.
Leukemia
Lamellarin D: a novel potent inhibitor of topoisomerase I.
Leukemia
Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux.
Leukemia
Leukemias related to treatment with DNA topoisomerase II inhibitors.
Leukemia
MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias.
Leukemia
Mechanism of action and antitumor activity of (S)-10-(2,6-dimethyl-4-pyridinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7 H- pyridol[1,2,3-de]-[1,4]benzothiazine-6-carboxylic acid (WIN 58161).
Leukemia
Mechanism of action of DNA topoisomerase inhibitors.
Leukemia
Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents.
Leukemia
Mechanism of the inhibition of leukemia cell growth and induction of apoptosis through the activation of ATR and PTEN by the topoisomerase inhibitor 3EZ, 20Ac-ingenol.
Leukemia
Methylation profile of the promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma.
Leukemia
Model for MLL translocations in therapy-related leukemia involving topoisomerase II?-mediated DNA strand breaks and gene proximity.
Leukemia
Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites.
Leukemia
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
Leukemia
Multilocus association of genetic variants in MLL, CREBBP, EP300, and TOP2A with childhood acute lymphoblastic leukemia in Hispanics from Texas.
Leukemia
Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.
Leukemia
Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.
Leukemia
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
Leukemia
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Leukemia
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Leukemia
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
Leukemia
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Leukemia
Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation.
Leukemia
Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity.
Leukemia
Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin.
Leukemia
Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.
Leukemia
Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity.
Leukemia
Protease inhibitors induce specific changes in protein tyrosine phosphorylation that correlate with inhibition of apoptosis in myeloid cells.
Leukemia
Purification and characterization of a type I DNA topoisomerase from calf thymus mitochondria.
Leukemia
Rapid increase in the activity of DNA topoisomerase I, but not topoisomerase II, in HL-60 promyelocytic leukemia cells treated with a phorbol diester.
Leukemia
Relation between intracellular acidification and camptothecin-induced apoptosis in leukemia cells.
Leukemia
Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance.
Leukemia
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Leukemia
RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I.
Leukemia
Role of Nitric Oxide in the Chemistry and Anticancer Activity of Etoposide (VP-16,213).
Leukemia
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Leukemia
Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells.
Leukemia
Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells.
Leukemia
Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.
Leukemia
Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis.
Leukemia
Stimulation of topoisomerase II-mediated DNA cleavage by benzene metabolites.
Leukemia
Structural impact of the leukemia drug 1-beta-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex.
Leukemia
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Leukemia
Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.
Leukemia
Structure-mutagenicity relationships in series of 11H-indolo[3,2-c]quinoline-1,4-diones, tetrahydro-11H-indolo[3,2-c]quinoline-1,4-diones and 11H-pyrido[3',4':4,5]pyrrolo[3,2-c]quinoline-1,4-diones with leukemia cytotoxic properties. Relations with topoisomerase I inhibiting properties.
Leukemia
Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Leukemia
Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent.
Leukemia
Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
Leukemia
Synthesis and biological activity of a photoaffinity etoposide probe.
Leukemia
Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
Leukemia
The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells.
Leukemia
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
Leukemia
The effect of staurosporine on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Leukemia
The effect of topoisomerase inhibitors on the expression of differentiation markers and cell cycle progression in human K-562 leukemia cells.
Leukemia
The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA).
Leukemia
The topoisomerase I-binding RING protein, topors, is associated with promyelocytic leukemia nuclear bodies.
Leukemia
Therapy related leukemias: susceptibility, prevention and treatment.
Leukemia
Therapy-related acute leukemia in breast cancer patients: twelve cases treated with a topoisomerase inhibitor.
Leukemia
Thioguanine substitution alters DNA cleavage mediated by topoisomerase II.
Leukemia
Topoisomerase activities in undifferentiated acute myeloblastic leukemias and monocytic differentiated leukemias.
Leukemia
Topoisomerase I dissociates human immunodeficiency virus type 1 reverse transcriptase from genomic RNAs.
Leukemia
Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia
Topoisomerase I-inhibition enhances vitamin D-responsive expression of the receptor for lipopolysaccharide binding protein CD 14.
Leukemia
Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Leukemia
Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Leukemia
Topoisomerase II and leukemia.
Leukemia
Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.
Leukemia
Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells.
Leukemia
Topoisomerase inhibitors potentiate the effect of retinoic acid on cell growth inhibition and induction of differentiation of leukemia HL-60 cells.
Leukemia
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Leukemia
Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage.
Leukemia
[Anthracycline antibiotics and their derivatives--inhibitors of topoisomerase I]
Leukemia
[DNA topoisomerase and telomerase activity with relation to multi-drug resistance in leukemia--review]
Leukemia L1210
DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators.
Leukemia L1210
Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Leukemia L1210
Properties of a purified nuclear topoisomerase from L1210 cells.
Leukemia L1210
Thiol dependent inhibition of mouse leukemia L1210 DNA topoisomerase I by nitracrine.
Leukemia L1210
Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.
Leukemia, Erythroblastic, Acute
Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoetic cell differentiation.
Leukemia, Erythroblastic, Acute
Protein tyrosine phosphatase-dependent activation of beta-globin and delta-aminolevulinic acid synthase genes in the camptothecin-induced IW32 erythroleukemia cell differentiation.
Leukemia, Erythroblastic, Acute
Synergistic induction of erythroid differentiation of mouse erythroleukemia (MEL) cells by inhibitors of topoisomerases and protein tyrosine kinases.
Leukemia, Lymphocytic, Chronic, B-Cell
Topotecan in chronic lymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Leukemia, Myeloid
Activation of PKCalpha downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells.
Leukemia, Myeloid
Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Leukemia, Myeloid
Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells.
Leukemia, Myeloid
Epicatechin and a cocoa polyphenolic extract modulate gene expression in human Caco-2 cells.
Leukemia, Myeloid
Induction of differentiation of human and mouse myeloid leukemia cells by camptothecin.
Leukemia, Myeloid
Phorbol ester-induced down-regulation of topoisomerase II alpha mRNA in a human erythroleukemia cell line. Evidence for a post-transcriptional mechanism.
Leukemia, Myeloid
The S-phase cytotoxicity of camptothecin.
Leukemia, Myeloid
Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells.
Leukemia, Myeloid, Acute
Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
Leukemia, Myeloid, Acute
Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines.
Leukemia, Myeloid, Acute
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Leukemia, Myeloid, Acute
Do children have increased susceptibility for developing secondary acute myelogenous leukemia?
Leukemia, Myeloid, Acute
Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry.
Leukemia, Myeloid, Acute
Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer.
Leukemia, Myeloid, Acute
Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML.
Leukemia, Myeloid, Acute
Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase II? as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin.
Leukemia, Myeloid, Acute
In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil.
Leukemia, Myeloid, Acute
New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA.
Leukemia, Myeloid, Acute
NUP98 is fused to topoisomerase (DNA) IIbeta 180 kDa (TOP2B) in a patient with acute myeloid leukemia with a new t(3;11)(p24;p15).
Leukemia, Myeloid, Acute
Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase II? downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Paclitaxel Induced MDS and AML: A Case Report and Literature Review.
Leukemia, Myeloid, Acute
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
Leukemia, Myeloid, Acute
Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Leukemia, Myeloid, Acute
Potential mechanisms of resistance to cytarabine in AML patients.
Leukemia, Myeloid, Acute
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Leukemia, Myeloid, Acute
Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.
Leukemia, Myeloid, Acute
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Leukemia, Myeloid, Acute
The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Thioguanine substitution alters DNA cleavage mediated by topoisomerase II.
Leukemia, Myeloid, Acute
Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway.
Leukemia, Myeloid, Acute
Topoisomerase activities in undifferentiated acute myeloblastic leukemias and monocytic differentiated leukemias.
Leukemia, Myeloid, Acute
Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.
Leukemia, Myeloid, Acute
XPO1 Inhibition Using Selinexor Synergizes With Chemotherapy in Acute Myeloid Leukemia (AML) by Targeting DNA Repair and Restoring Topoisomerase II? to the Nucleus.
Leukemia, Myelomonocytic, Chronic
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Leukemia, Myelomonocytic, Chronic
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Leukemia, Myelomonocytic, Chronic
Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia, Myelomonocytic, Chronic
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Leukemia, Promyelocytic, Acute
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Leukemia, Promyelocytic, Acute
Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
Leukemia, Promyelocytic, Acute
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
Leukemia, Promyelocytic, Acute
Topoisomerase II levels during granulocytic maturation in vitro and in vivo.
Leukemia, T-Cell
Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis.
Leukemia-Lymphoma, Adult T-Cell
Concomitant use of radiotherapy and two topoisomerase inhibitors to treat adult T-cell leukemia with a radiotherapy-resistant bulky disease: a case series.
Leukemia-Lymphoma, Adult T-Cell
NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase.
Leukopenia
Circadian rhythm of irinotecan tolerability in mice.
Leukopenia
Clinical influences of anticentromere antibody on primary Sjögren's syndrome in a prospective Korean cohort.
Liposarcoma
Doxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with alternative lengthening of telomeres.
Liver Cirrhosis, Biliary
Autoantibodies to topoisomerase I in primary biliary cirrhosis.
Liver Cirrhosis, Biliary
Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.
Liver Neoplasms
Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1?.
Liver Neoplasms
Combating liver cancer through GO-targeted biomaterials.
Liver Neoplasms
DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride.
Liver Neoplasms
Heparin and liver heparan sulfate can rescue hepatoma cells from topotecan action.
Liver Neoplasms
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.
Liver Neoplasms
Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1?.
Liver Neoplasms, Experimental
Phosphorylation of purified Novikoff hepatoma topoisomerase I.
Liver Neoplasms, Experimental
Phosphorylation sites for type N II protein kinase in DNA-topoisomerase I from calf thymus.
Liver Neoplasms, Experimental
Preferential inhibition of DNA polymerases alpha, delta, and epsilon from Novikoff hepatoma cells by inhibitors of cell proliferation.
Liver Neoplasms, Experimental
Topoisomerase I phosphorylation in vitro and in rapidly growing Novikoff hepatoma cells.
Lung Diseases
African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease.
Lung Diseases
Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis.
Lung Diseases, Interstitial
Definition of naturally processed peptides reveals convergent presentation of autoantigenic topoisomerase-I epitopes in scleroderma.
Lung Diseases, Interstitial
Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma.
Lung Neoplasms
A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines.
Lung Neoplasms
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Lung Neoplasms
A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients.
Lung Neoplasms
A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients.
Lung Neoplasms
A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer.
Lung Neoplasms
A review of topoisomerase inhibition in lung cancer.
Lung Neoplasms
Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors.
Lung Neoplasms
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.
Lung Neoplasms
Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Lung Neoplasms
Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.
Lung Neoplasms
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Lung Neoplasms
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Lung Neoplasms
Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis.
Lung Neoplasms
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.
Lung Neoplasms
Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Lung Neoplasms
Chemosensitizing effect of podophyllotoxin acetate on topoisomerase inhibitors leads to synergistic enhancement of lung cancer cell apoptosis.
Lung Neoplasms
Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.
Lung Neoplasms
CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines.
Lung Neoplasms
Cleistanthoside A tetraacetate-induced DNA damage leading to cell cycle arrest and apoptosis with the involvement of p53 in lung cancer cells.
Lung Neoplasms
Clinical pharmacokinetics of topotecan.
Lung Neoplasms
Co-dependency of PKC? and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
Lung Neoplasms
Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells.
Lung Neoplasms
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.
Lung Neoplasms
Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Lung Neoplasms
Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer.
Lung Neoplasms
Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer.
Lung Neoplasms
Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors.
Lung Neoplasms
Comparison of topoisomerase I and II expression in primary brain tumor and lung cancer.
Lung Neoplasms
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Lung Neoplasms
Correlation between topoisomerase I and tyrosyl-DNA phosphodiesterase 1 activities in non-small cell lung cancer tissue.
Lung Neoplasms
Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
Lung Neoplasms
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives.
Lung Neoplasms
Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.
Lung Neoplasms
Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
Lung Neoplasms
Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells.
Lung Neoplasms
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Lung Neoplasms
DNA topoisomerase I drugs and radiotherapy for lung cancer.
Lung Neoplasms
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.
Lung Neoplasms
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Lung Neoplasms
Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
Lung Neoplasms
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Lung Neoplasms
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
Lung Neoplasms
Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines.
Lung Neoplasms
EGCG regulates the cross-talk between JWA and topoisomerase II? in non-small-cell lung cancer (NSCLC) cells.
Lung Neoplasms
Emerging role of topotecan in first-line therapy of small-cell lung cancer.
Lung Neoplasms
Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases.
Lung Neoplasms
ERCC1 and topoisomerase I expression in small cell lung cancer: Prognostic and predictive implications.
Lung Neoplasms
Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells.
Lung Neoplasms
Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Lung Neoplasms
Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Lung Neoplasms
Expression of P-gp, MRP, LRP, GST-? and TopoII? and intrinsic resistance in human lung cancer cell lines.
Lung Neoplasms
Expressions of Topoisomerase II? and BCRP in Metastatic Cells are Associated with Overall Survival in Small Cell Lung Cancer Patients.
Lung Neoplasms
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Lung Neoplasms
Gene-specific damage produced by topoisomerase inhibitors in human lung cancer cells and peripheral mononuclear cells as assayed by polymerase chain reaction-stop assay.
Lung Neoplasms
Herbal Medicines for Irinotecan-Induced Diarrhea.
Lung Neoplasms
HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.
Lung Neoplasms
Higher expression of topoisomerase II in lung cancers than normal lung tissues: different expression pattern from topoisomerase I.
Lung Neoplasms
Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1).
Lung Neoplasms
IFN-? restores the impaired function of RNase L and induces mitochondria-mediated apoptosis in lung cancer.
Lung Neoplasms
In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor.
Lung Neoplasms
Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer.
Lung Neoplasms
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
Lung Neoplasms
Intracellular uptake study of radiolabeled anticancer drug and impedimetric detection of its interaction with DNA.
Lung Neoplasms
Investigation of the mechanism and apoptotic pathway induced by 4? cinnamido linked podophyllotoxins against human lung cancer cells A549.
Lung Neoplasms
Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Lung Neoplasms
Irinotecan and platinums in the treatment of non small-cell lung cancer.
Lung Neoplasms
Irinotecan in small-cell lung cancer: current data.
Lung Neoplasms
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
Lung Neoplasms
Irinotecan plus cisplatin in small-cell lung cancer.
Lung Neoplasms
Irinotecan therapy for small-cell lung cancer.
Lung Neoplasms
Long non-coding RNA LALTOP promotes non-small cell lung cancer progression by stabilizing topoisomerase II? mRNA.
Lung Neoplasms
Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Lung Neoplasms
Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
Lung Neoplasms
Mechanism of action of an imidopiperidine inhibitor of human polynucleotide kinase/phosphatase.
Lung Neoplasms
Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.
Lung Neoplasms
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
Lung Neoplasms
Molecular Insight into the Interaction between Camptothecin and Acyclic Cucurbit[4]urils as Efficient Nanocontainers in Comparison with Cucurbit[7]uril: Molecular Docking and Molecular Dynamics Simulation.
Lung Neoplasms
New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.
Lung Neoplasms
New state of the art in small-cell lung cancer.
Lung Neoplasms
NF-kappa B activation in topoisomerase I inhibitor-induced apoptotic cell death in human non-small cell lung cancer.
Lung Neoplasms
No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer.
Lung Neoplasms
Nuclear Transglutaminase 2 interacts with topoisomerase II? to promote DNA damage repair in lung cancer cells.
Lung Neoplasms
p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.
Lung Neoplasms
Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.
Lung Neoplasms
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
Lung Neoplasms
Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
Lung Neoplasms
Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.
Lung Neoplasms
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Lung Neoplasms
Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
Lung Neoplasms
Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Lung Neoplasms
Phase II study of topotecan in metastatic non-small-cell lung cancer.
Lung Neoplasms
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.
Lung Neoplasms
Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer.
Lung Neoplasms
Phytochemical naphtho[1,2-b] furan-4,5?dione induced topoisomerase II-mediated DNA damage response in human non-small-cell lung cancer.
Lung Neoplasms
Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.
Lung Neoplasms
Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOP?-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide.
Lung Neoplasms
Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer.
Lung Neoplasms
Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis.
Lung Neoplasms
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Lung Neoplasms
Real-Time Positron Emission Tomography Evaluation of Topotecan Brain Kinetics after Ultrasound-Mediated Blood-Brain Barrier Permeability.
Lung Neoplasms
Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
Lung Neoplasms
Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair.
Lung Neoplasms
Reponses to topoisomerase-I inhibitors in extensive small-cell lung cancer: chance or chromosomes?
Lung Neoplasms
RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I.
Lung Neoplasms
Role of topoisomerase I inhibitors in small-cell lung cancer.
Lung Neoplasms
Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.
Lung Neoplasms
Sequential targeted delivery of paclitaxel and camptothecin using a cross-linked "nanosponge" network for lung cancer chemotherapy.
Lung Neoplasms
Serine phosphorylation-dependent coregulation of topoisomerase I by the p14ARF tumor suppressor.
Lung Neoplasms
Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors.
Lung Neoplasms
SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.
Lung Neoplasms
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Lung Neoplasms
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Lung Neoplasms
Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Lung Neoplasms
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-?-benzyl ester derivatives as potent topoisomerase II? inhibitors.
Lung Neoplasms
Synthesis and topoisomerase I inhibitory activity of a novel diazaindeno[2,1-b]phenanthrene analogue of Lamellarin D.
Lung Neoplasms
Targeted therapy in non-small-cell lung cancer.
Lung Neoplasms
Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
Lung Neoplasms
The association of topoisomerase 2? expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients.
Lung Neoplasms
The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells.
Lung Neoplasms
The significance of the sequence of administration of topotecan and etoposide.
Lung Neoplasms
The Topoisomerase 1 Inhibitor Austrobailignan-1 Isolated from Koelreuteria henryi Induces a G2/M-Phase Arrest and Cell Death Independently of p53 in Non-Small Cell Lung Cancer Cells.
Lung Neoplasms
Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Lung Neoplasms
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Lung Neoplasms
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Lung Neoplasms
Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.
Lung Neoplasms
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Lung Neoplasms
Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
Lung Neoplasms
Topoisomerase I inhibitors in the combined modality therapy of lung cancer.
Lung Neoplasms
Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.
Lung Neoplasms
Topoisomerase I targeting agents in small-cell lung cancer.
Lung Neoplasms
Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer.
Lung Neoplasms
Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
Lung Neoplasms
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Lung Neoplasms
topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage.
Lung Neoplasms
Topotecan: An evolving option in the treatment of relapsed small cell lung cancer.
Lung Neoplasms
Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor.
Lung Neoplasms
Trastuzumab Deruxtecan: First Approval.
Lung Neoplasms
Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan.
Lung Neoplasms
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
Lung Neoplasms
Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.
Lung Neoplasms
Update on the role of topotecan in the treatment of non-small cell lung cancer.
Lung Neoplasms
Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells.
Lung Neoplasms
[Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines]
Lung Neoplasms
[Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer]
Lung Neoplasms
[Phase II clinical trials in patients with lung cancer]
Lung Neoplasms
[Preclinical trials from the standpoint of clinical trials]
Lupus Erythematosus, Systemic
Antitopoisomerase I antibody in patients with systemic lupus erythematosus/sicca syndrome without a concomitant scleroderma: two case reports.
Lupus Erythematosus, Systemic
Autoantibodies in the diagnosis of systemic rheumatic diseases.
Lupus Erythematosus, Systemic
Autoantibodies to topoisomerase I in a patient with systemic lupus erythematosus without features of scleroderma.
Lupus Erythematosus, Systemic
Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody.
Lupus Erythematosus, Systemic
DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases.
Lupus Erythematosus, Systemic
Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Relationship between natural and infection -induced antibodies in systemic autoimmune diseases (SAD); SLE, SSc and RA.
Lupus Erythematosus, Systemic
Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis.
Lupus Erythematosus, Systemic
The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis.
Lupus Erythematosus, Systemic
[Anti-idiotypic and natural catalytically active antibodies]
Lupus Nephritis
Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells.
Lupus Nephritis
Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.
Lupus Nephritis
Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
Lupus Nephritis
The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis.
Lymphatic Metastasis
Mitochondrial topoisomerase I absence enhances aerobic glycolysis in cancer.
Lymphatic Metastasis
Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Lymphatic Metastasis
Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
Lymphatic Metastasis
Topoisomerase expression in oral squamous cell carcinoma: relationship with cancer stem cells profiles and lymph node metastasis.
Lymphatic Metastasis
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
Lymphatic Metastasis
[Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer]
Lymphohistiocytosis, Hemophagocytic
Host-directed therapies for antimicrobial resistant respiratory tract infections.
Lymphoma
3EZ, 20Ac-ingenol-induced Apoptosis in Chemoresistant Cancers With Cyclin D1 Accumulation.
Lymphoma
Activation of multidomain and BH3-only pro-apoptotic Bcl-2 family members in p53-defective cells.
Lymphoma
An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.
Lymphoma
Cloning of the TIS gene suppressed by topoisomerase inhibitors.
Lymphoma
Contribution of gene-specific lesions, DNA-replication-associated damage, and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells.
Lymphoma
Correspondence re: M. Provencio, et al. the topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin. Cancer Res., 9: 1406-1411, 2003.
Lymphoma
Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines.
Lymphoma
Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
Lymphoma
Effects of topoisomerase I-targeted drugs on radiation response of L5178Y sublines differentially radiation and drug sensitive.
Lymphoma
Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies.
Lymphoma
Evaluation of DNA topoisomerase IIalpha expression provides independent prognostic information in non-Hodgkin's lymphomas.
Lymphoma
Herbal Medicines for Irinotecan-Induced Diarrhea.
Lymphoma
Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.
Lymphoma
Molecular cloning of the genes suppressed in RVC lymphoma cells by topoisomerase inhibitors.
Lymphoma
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Lymphoma
Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.
Lymphoma
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas.
Lymphoma
Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas.
Lymphoma
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
Lymphoma
Phosphorylation of topoisomerase I in L5178Y-S cells is associated with poly(ADP-ribose) metabolism.
Lymphoma
PKA controls a level of topoisomerase I mRNA in mouse L5178Y lymphoma cells treated with db-cAMP.
Lymphoma
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
Lymphoma
Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin's lymphoma.
Lymphoma
Reduced sensitivity to camptothecin of topoisomerase I from a L5178Y mouse lymphoma subline sensitive to X-radiation.
Lymphoma
Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L.
Lymphoma
Study of DNA topoisomerase II? expression in canine lymphomas and its potential role as a marker of sensitivity to anthracycline-based chemotherapy in dogs.
Lymphoma
The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.
Lymphoma
The sensitivity to camptothecin of DNA topoisomerase I in L5178Y-S lymphoma cells.
Lymphoma
The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lymphoma
The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies.
Lymphoma
Topoisomerase I is differently phosphorylated in two sublines of L5178Y mouse lymphoma cells.
Lymphoma
Topoisomerase levels determine chemotherapy response in vitro and in vivo.
Lymphoma
Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.
Lymphoma
[Immunohistochemical evaluation of topoisomerase IIalpha as proliferation factor in gastric lymphoma]
Lymphoma, B-Cell
Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Molecular docking and dynamics simulation study of bioactive compounds from Ficus carica L. with important anticancer drug targets.
Lymphoma, B-Cell
New approaches in cancer treatment.
Lymphoma, B-Cell
The expression and significance of MRP1, LRP, TOPOII?, and BCL2 in tongue squamous cell carcinoma.
Lymphoma, B-Cell
Therapeutic and cosmetic applications of Evodiamine and its derivatives--A patent review.
Lymphoma, B-Cell, Marginal Zone
[Immunohistochemical evaluation of topoisomerase IIalpha as proliferation factor in gastric lymphoma]
Lymphoma, Large B-Cell, Diffuse
A glass fiber/diethylaminoethyl double filter binding assay that measures apoptotic internucleosomal DNA fragmentation.
Lymphoma, Large B-Cell, Diffuse
Acquisition of cellular resistance to 9-nitro-camptothecin correlates with suppression of transcription factor NF-kappa B activation and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells.
Lymphoma, Large B-Cell, Diffuse
Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Plasma membrane phospholipid asymmetry precedes DNA fragmentation in different apoptotic cell models.
Lymphoma, Large B-Cell, Diffuse
Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.
Lymphoma, Non-Hodgkin
A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study.
Lymphoma, Non-Hodgkin
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Lymphoma, Non-Hodgkin
Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.
Lymphoma, Non-Hodgkin
Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Rearrangement of the Myeloid/Lymphoid Leukemia Gene in Therapy-Related Myelodysplastic Syndrome in Patients Previously Treated with Agents Targeting DNA Topoisomerase II.
Lymphoma, Non-Hodgkin
Response of DNA repair enzymes in murine fibrosarcoma, lymphosarcoma and ascites cells following gamma irradiation.
Lymphoma, Non-Hodgkin
The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.
Lymphoma, Non-Hodgkin
Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide.
Lymphoma, T-Cell
Expression of growth-related genes and drug-resistance genes in HTLV-I-positive and HTLV-I-negative post-thymic T-cell malignancies.
Malabsorption Syndromes
Bone density in Moroccan women with systemic scleroderma and its relationships with disease-related parameters and vitamin D status.
Malaria
Detection of the Malaria causing Plasmodium Parasite in Saliva from Infected Patients using Topoisomerase I Activity as a Biomarker.
Malaria
Effects of camptothecin, a topoisomerase I inhibitor, on Plasmodium falciparum.
Malaria
In Vitro and In Silico Characterization of an Antimalarial Compound with Antitumor Activity Targeting Human DNA Topoisomerase IB.
Malaria
Optimized Detection of Plasmodium falciparum Topoisomerase I Enzyme Activity in a Complex Biological Sample by the Use of Molecular Beacons.
Malaria
Radicicol-Mediated Inhibition of Topoisomerase VIB-VIA Activity of the Human Malaria Parasite Plasmodium falciparum.
Malaria
Specific detection of topoisomerase I from the malaria causing P. falciparum parasite using isothermal rolling circle amplification.
Malaria
The gene encoding topoisomerase I from the human malaria parasite Plasmodium falciparum.
Malaria
Theoretical and Experimental Studies of New Modified Isoflavonoids as Potential Inhibitors of Topoisomerase I from Plasmodium falciparum.
Mastocytoma
A protein factor that enhances amsacrine-mediated formation of topoisomerase II-DNA complexes in murine mastocytoma cell nuclei.
Mastocytoma
Evidence that a protein kinase enhances amsacrine mediated formation of topoisomerase II-DNA complexes in murine mastocytoma cell nuclei.
Mastocytoma
Evidence that mAMSA induces topoisomerase action.
Mastocytoma
Regulation of topoisomerase II by murine mastocytoma cells.
Medulloblastoma
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
Medulloblastoma
Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms.
Medulloblastoma
Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
Medulloblastoma
Geminin deficiency enhances survival in a murine medulloblastoma model by inducing apoptosis of preneoplastic granule neuron precursors.
Medulloblastoma
Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Medulloblastoma
Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Medulloblastoma
Topoisomerase II? immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer Group.
Melanoma
3-O-(E)-p-Coumaroyl Tormentic Acid from Eriobotrya japonica Leaves Induces Caspase-Dependent Apoptotic Cell Death in Human Leukemia Cell Line.
Melanoma
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
Melanoma
Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.
Melanoma
Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents.
Melanoma
Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells.
Melanoma
Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
Melanoma
Chemosensitivity testing as an aid to anti-cancer drug and regimen development.
Melanoma
Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC.
Melanoma
Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
Melanoma
Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
Melanoma
Distribution bias and biochemical characterization of TOP1MT single nucleotide variants.
Melanoma
DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Melanoma
Dual inhibition of topoisomerases enhances apoptosis in melanoma cells.
Melanoma
Ex vivo activity of XR5000 against solid tumors.
Melanoma
Exploring the DNA binding/cleavage, cellular accumulation and topoisomerase inhibition of 2-hydroxy-3-(aminomethyl)-1,4-naphthoquinone Mannich bases and their platinum(II) complexes.
Melanoma
Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma.
Melanoma
Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines.
Melanoma
Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I.
Melanoma
Interaction of Deubiquitinase 2A-DUB/MYSM1 with DNA Repair and Replication Factors.
Melanoma
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
Melanoma
Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells.
Melanoma
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Melanoma
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.
Melanoma
RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1.
Melanoma
Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
Melanoma
Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis.
Melanoma
Topoisomerase I inactivation by reticulol and its in vivo cytotoxicity against B16F10 melanoma.
Melanoma
Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.
Melanoma
Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells.
Melanoma
Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma.
Meningioma
Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas.
Meningioma
DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
Meningioma
DNA topoisomerase II? and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.
Meningioma
Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays.
Meningioma
Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.
Meningitis, Cryptococcal
Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target.
Mesothelioma
Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase II?, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
Microsporidiosis
Therapeutic targets for the treatment of microsporidiosis in humans.
Mitochondrial Diseases
Controlling the topology of mammalian mitochondrial DNA.
Molluscum Contagiosum
DNA contacts by protein domains of the molluscum contagiosum virus type-1B topoisomerase.
Molluscum Contagiosum
DNA contacts stimulate catalysis by a poxvirus topoisomerase.
Molluscum Contagiosum
Lamellarins, from A to Z: a family of anticancer marine pyrrole alkaloids.
Molluscum Contagiosum
Molluscum contagiosum virus topoisomerase: purification, activities, and response to inhibitors.
Molluscum Contagiosum
Pyrrolo[2,1-alpha]isoquinoline as a skeleton for the synthesis of bioactive lamellarin H.
Mouth Neoplasms
Comparative and Mechanistic Study on the Anticancer Activity of Quinacrine-Based Silver and Gold Hybrid Nanoparticles in Head and Neck Cancer.
Mouth Neoplasms
Dichloromethane fraction from Gardenia jasminoides: DNA topoisomerase 1 inhibition and oral cancer cell death induction.
Mouth Neoplasms
Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer.
Mouth Neoplasms
PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade.
Mucositis
Circadian variation of topoisomerase II-alpha in human rectal crypt epithelium: implications for reduction of toxicity of chemotherapy.
Mucositis
Irinotecan-induced mucositis is associated with changes in intestinal mucins.
Multiple Myeloma
Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
Multiple Myeloma
Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells.
Multiple Myeloma
Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells.
Multiple Myeloma
Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein.
Multiple Myeloma
nm23, TOP2A and VEGF expression: Potential prognostic biologic factors in peripheral T-cell lymphoma, not otherwise specified.
Multiple Myeloma
Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.
Multiple Myeloma
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Multiple Myeloma
Psorospermin structural requirements for P-glycoprotein resistance reversal.
Multiple Myeloma
The use of topoisomerase I inhibitors in multiple myeloma.
Myelodysplastic Syndromes
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Myelodysplastic Syndromes
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Myelodysplastic Syndromes
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Myelodysplastic Syndromes
Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy.
Myelodysplastic Syndromes
Paclitaxel Induced MDS and AML: A Case Report and Literature Review.
Myelodysplastic Syndromes
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
Myelodysplastic Syndromes
Possible role of edotecarin, a novel topoisomerase I inhibitor, in therapy-related myelodysplastic syndrome.
Myelodysplastic Syndromes
The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
Myelodysplastic Syndromes
Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
Myelodysplastic Syndromes
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Myositis
Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity.
Myositis
Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis.
Nasopharyngeal Carcinoma
[Apoptosis of nasopharyngeal carcinoma cells induced by topoisomerase I inhibitor]
Nasopharyngeal Carcinoma
[Experimental studies on treatment of nasopharyngeal carcinoma with combination regimen of hydroxycamptothecin and etoposide]
Nasopharyngeal Carcinoma
[The effect of EB virus bhrfl gene expressing on the topoisomerase I expression in nasopharyngeal carcinoma cell line]
Nasopharyngeal Neoplasms
[Zn(phen)(O,N,O)(H(2)O)] and [Zn(phen)(O,N)(H(2)O)] with O,N,O is 2,6-dipicolinate and N,O is L-threoninate: synthesis, characterization, and biomedical properties.
Neoplasm Metastasis
A model of Primary Culture of Colorectal Cancer and Liver Metastasis to Predict Chemosensitivity.
Neoplasm Metastasis
Cerebral metastases--a therapeutic update.
Neoplasm Metastasis
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
Neoplasm Metastasis
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.
Neoplasm Metastasis
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase.
Neoplasm Metastasis
Mitochondrial topoisomerase I absence enhances aerobic glycolysis in cancer.
Neoplasm Metastasis
Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer.
Neoplasm Metastasis
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
Neoplasm Metastasis
Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Neoplasm Metastasis
Shiquandabutangjiaweibang inhibits tumor metastasis and angiogenesis via regulation of topoisomerase-1.
Neoplasm Metastasis
Significance of topoisomerase III? expression in breast ductal carcinomas: strong associations with disease-specific survival and metastasis.
Neoplasm Metastasis
Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
Neoplasm Metastasis
The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.
Neoplasm Metastasis
Topoisomerase expression in oral squamous cell carcinoma: relationship with cancer stem cells profiles and lymph node metastasis.
Neoplasm Metastasis
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Neoplasm Metastasis
Topoisomerase I inactivation by reticulol and its in vivo cytotoxicity against B16F10 melanoma.
Neoplasm Metastasis
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
Neoplasm Metastasis
[Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer]
Neoplasm Metastasis
[New drugs in metastatic breast cancer--1997]
Neoplasm, Residual
The predictive and prognostic significance of pre- and post-treatment topoisomerase II? in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Neoplasms
(-)-Xanthatin up-regulation of the GADD45? tumor suppressor gene in MDA-MB-231 breast cancer cells: Role of topoisomerase II? inhibition and reactive oxygen species.
Neoplasms
10th Conference on DNA Topoisomerases in therapy.
Neoplasms
2"-Substituted 5-phenylterbenzimidazoles as topoisomerase I poisons.
Neoplasms
2',5,7-Trihydroxy-4',5'-(2,2-dimethylchromeno)-8-(3-hydroxy-3-methylbutyl) flavanone purified from Cudrania tricuspidata induces apoptotic cell death of human leukemia U937 cells.
Neoplasms
2,2'-Methylenebis (6-tert-butyl 4-methylphenol) enhances the antitumor efficacy of belotecan, a derivative of camptothecin, by inducing autophagy.
Neoplasms
2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents.
Neoplasms
2,4,6-Trisubstituted pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Neoplasms
2,4-Diaryl-5,6-dihydro-1,10-phenanthroline and 2,4-diaryl-5,6-dihydrothieno[2,3-h] quinoline derivatives for topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
Neoplasms
2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study.
Neoplasms
2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines.
Neoplasms
2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
Neoplasms
2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model.
Neoplasms
2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
Neoplasms
3-Arylisoquinolines as novel topoisomerase I inhibitors.
Neoplasms
9-Nitrocamptothecin inhibits tumor recrosis factor-mediated activation of human immunodeficiency virus type 1 and enhances apoptosis in a latently infected T cell clone.
Neoplasms
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Neoplasms
?-Elemene Inhibits Cell Proliferation by Regulating the Expression and Activity of Topoisomerases I and II? in Human Hepatocarcinoma HepG-2 Cells.
Neoplasms
?V?3-Targeted Delivery of Camptothecin-Encapsulated Carbon Nanotube-Cyclic RGD in 2D and 3D Cancer Cell Culture.
Neoplasms
A Bioactive l-Phenylalanine-Derived Arene in Multitargeted Organoruthenium Compounds: Impact on the Antiproliferative Activity and Mode of Action.
Neoplasms
A cocktail of MCM2 and TOP2A, p16INK4a and Ki-67 as biomarkers for the improved diagnosis of cervical intraepithelial lesion.
Neoplasms
A comprehensive review on anticancer mechanisms of the main carotenoid of saffron, crocin.
Neoplasms
A cysteine-reactive alkyl hydroquinone modifies topoisomerase II?, enhances DNA breakage, and induces apoptosis in cancer cells.
Neoplasms
A Dual Topoisomerase Inhibitor of Intense Pro-Apoptotic and Antileukemic Nature for Cancer Treatment.
Neoplasms
A dual topoisomerase inhibitor, TAS-103, induces apoptosis in human cancer cells.
Neoplasms
A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines.
Neoplasms
A model for tumor cell killing by topoisomerase poisons.
Neoplasms
A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Neoplasms
A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships.
Neoplasms
A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study.
Neoplasms
A new topoisomerase II inhibitor, BE-22179, produced by a streptomycete. I. Producing strain, fermentation, isolation and biological activity.
Neoplasms
A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
Neoplasms
A novel chromatin tether domain controls topoisomerase II? dynamics and mitotic chromosome formation.
Neoplasms
A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
Neoplasms
A novel microfluidic liposomal formulation for the delivery of the SN-38 camptothecin: characterization and in vitro assessment of its cytotoxic effect on two tumor cell lines.
Neoplasms
A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
Neoplasms
A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.
Neoplasms
A novel topoisomerase 2a inhibitor, cryptotanshinone, suppresses the growth of PC3 cells without apparent cytotoxicity.
Neoplasms
A novel topoisomerase I inhibitor DIA-001 induces DNA damage mediated cell cycle arrest and apoptosis in cancer cell.
Neoplasms
A patent review of topoisomerase I inhibitors (2016-present).
Neoplasms
A PCR-aided transcript titration assay (PATTY) to measure topoisomerase I gene expression in human tumor specimens.
Neoplasms
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Neoplasms
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Neoplasms
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Neoplasms
A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors.
Neoplasms
A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcoma.
Neoplasms
A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Neoplasms
A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
Neoplasms
A phase II single institution single arm prospective study with paclitaxel, ifosfamide and cisplatin (TIP) as first-line chemotherapy in high-risk germ cell tumor patients with more than ten years follow-up and retrospective correlation with ERCC1, Topoisomerase 1, 2A, p53 and HER-2 expression.
Neoplasms
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
Neoplasms
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
Neoplasms
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
Neoplasms
A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours.
Neoplasms
A phase II trial of irinotecan in hormone-refractory prostate cancer.
Neoplasms
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
Neoplasms
A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339).
Neoplasms
A pilot study of topotecan in the treatment of serous carcinoma of the uterus.
Neoplasms
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
Neoplasms
A protein factor from Xenopus oocytes with simian virus 40 large tumor antigen-like DNA supercoiling activity.
Neoplasms
A quantitative RT-PCR method to determine topoisomerase I mRNA levels in human tissue samples.
Neoplasms
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
Neoplasms
A study of topoisomerase activity in human testicular cancers.
Neoplasms
A supramolecular vesicle of camptothecin for its water dispersion and controllable releasing.
Neoplasms
A switch in mechanism of action prevents doxorubicin-mediated cardiac damage.
Neoplasms
A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy.
Neoplasms
A terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: a potential mechanism for topoisomerase I poisoning.
Neoplasms
A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2.
Neoplasms
Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation.
Neoplasms
Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells.
Neoplasms
Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells.
Neoplasms
Activation of a PGC-1-related Coactivator (PRC)-dependent Inflammatory Stress Program Linked to Apoptosis and Premature Senescence.
Neoplasms
Activation of camptothecin derivatives by conjugation to triple helix-forming oligonucleotides.
Neoplasms
Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): correlation with DNA fragmentation.
Neoplasms
Activation of chymotrypsin-like serine protease(s) during apoptosis detected by affinity-labeling of the enzymatic center with fluoresceinated inhibitor.
Neoplasms
Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells.
Neoplasms
Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis.
Neoplasms
Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
Neoplasms
Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Neoplasms
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
Neoplasms
Acute presentation of rheumatoid arthritis following cancer chemotherapy using the topoisomerase I inhibitor irinotecan.
Neoplasms
Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Neoplasms
Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model.
Neoplasms
Allosteric inhibition of topoisomerase I by pinostrobin: Molecular docking, spectroscopic and topoisomerase I activity studies.
Neoplasms
Alpha, beta-unsaturated lactones 2-furanone and 2-pyrone induce cellular DNA damage, formation of topoisomerase I- and II-DNA complexes and cancer cell death.
Neoplasms
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
Neoplasms
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.
Neoplasms
Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan.
Neoplasms
An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Neoplasms
An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies.
Neoplasms
An Insight into the Mechanism of Holamine- and Funtumine-Induced Cell Death in Cancer Cells.
Neoplasms
An overview of topoisomerase I-targeting agents.
Neoplasms
Analogues of distamycin--synthesis and biological evaluation of new aromatic oligopeptides, potential anticancer agents.
Neoplasms
Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
Neoplasms
Analysis of common gene expression patterns in four human tumor cell lines exposed to camptothecin using cDNA microarray: identification of topoisomerase-mediated DNA damage response pathways.
Neoplasms
Analysis of plant-derived phytochemicals as anti-cancer agents targeting cyclin dependent kinase-2, human topoisomerase IIa and vascular endothelial growth factor receptor-2.
Neoplasms
Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines.
Neoplasms
Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway.
Neoplasms
Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host.
Neoplasms
Anthracyclines.
Neoplasms
Anti-cancer agents in Saudi Arabian herbals revealed by automated high-content imaging.
Neoplasms
Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan.
Neoplasms
Anti-lung cancer activity and inhibitory mechanisms of a novel Calothrixin A derivative.
Neoplasms
Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.
Neoplasms
Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma.
Neoplasms
Antiangiogenesis response of endothelial cells to the antitumour drug 10-methoxy-9-nitrocamptothecin.
Neoplasms
Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.
Neoplasms
Anticancer Activity of BIM-46174, a New Inhibitor of the Heterotrimeric G{alpha}/G{beta}{gamma} Protein Complex.
Neoplasms
Anticancer Activity of Indeno[1,2-b]-Pyridinol Derivative as a New DNA Minor Groove Binding Catalytic Inhibitor of Topoisomerase II?.
Neoplasms
Anticancer and Antiviral Properties of Cardiac Glycosides: A Review to Explore the Mechanism of Actions.
Neoplasms
Anticancer and Cytotoxic activities of [Cu(C6H16N2O2)2][Ni(CN)4] and [Cu(C6H16N2O2)Pd(CN)4] Cyanidometallate Compounds on HT29, HeLa, C6 and Vero Cell Lines.
Neoplasms
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
Neoplasms
Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?
Neoplasms
Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas.
Neoplasms
Anticancer effects of CKD-602 (Camtobell(®)) via G2/M phase arrest in oral squamous cell carcinoma cell lines.
Neoplasms
Anticancer Properties of Lamellarins.
Neoplasms
Anticarcinogenic Effects of Dietary Phytoestrogens and Their Chemopreventive Mechanisms.
Neoplasms
Antiproliferation in human EA.hy926 endothelial cells and inhibition of VEGF expression in PC-3 cells by topotecan.
Neoplasms
Antiproliferative activity of O4-benzo[c]phenanthridine alkaloids against HCT-116 and HL-60 tumor cells.
Neoplasms
Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.
Neoplasms
Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Neoplasms
Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
Neoplasms
Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB.
Neoplasms
Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
Neoplasms
Antitumor Activity of Asperphenin A, a Lipopeptidyl Benzophenone from Marine-Derived Aspergillus sp. Fungus, by Inhibiting Tubulin Polymerization in Colon Cancer Cells.
Neoplasms
Antitumor activity of edotecarin in breast carcinoma models.
Neoplasms
Antitumor activity of palmitic acid found as a selective cytotoxic substance in a marine red alga.
Neoplasms
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Neoplasms
Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Neoplasms
Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice.
Neoplasms
Antitumor potential of a novel camptothecin derivative, ZBH-ZM-06.
Neoplasms
Antitumor triptycene analogs directly interact with isolated mitochondria to rapidly trigger markers of permeability transition.
Neoplasms
Antitumor triptycene bisquinones induce a caspase-independent release of mitochondrial cytochrome c and a caspase-2-mediated activation of initiator caspase-8 and -9 in HL-60 cells by a mechanism which does not involve Fas signaling.
Neoplasms
Antitumor triptycene bisquinones: a novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities.
Neoplasms
Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor.
Neoplasms
Antitumour activity of DX-8951f: a new camptothecin derivative.
Neoplasms
Antitumour drug design: DNA-binding ligands, which inhibit the topoisomerase I.
Neoplasms
Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
Neoplasms
Apoptosis by genetic engineering.
Neoplasms
Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Neoplasms
Apoptosis is the most efficient death-pathway in tumor cells after topoisomerase II inhibition.
Neoplasms
Apoptosis of S-phase HL-60 cells induced by DNA topoisomerase inhibitors: detection of DNA strand breaks by flow cytometry using the in situ nick translation assay.
Neoplasms
Application of topoisomerase assays in the evaluation of natural products as antitumor agents.
Neoplasms
ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation.
Neoplasms
Assessing the interaction of irradiation with etoposide or idarubicin.
Neoplasms
Assessment of topoisomerase II-alpha gene status by dual color chromogenic
Neoplasms
Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells.
Neoplasms
Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.
Neoplasms
Ataxia Telangiectasia-Mutated and Rad3-Related Inhibition and Topoisomerase I Trapping Create a Synthetic Lethality in Cancer Cells.
Neoplasms
ATM mediates cytotoxicity of a mutant telomerase RNA in human cancer cells.
Neoplasms
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Neoplasms
B-ring-aryl substituted luotonin A analogues with a new binding mode to the topoisomerase 1-DNA complex show enhanced cytotoxic activity.
Neoplasms
BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors.
Neoplasms
Barking up the wrong genome - we are not alone.
Neoplasms
Basal-like subtype and BRCA1 dysfunction in breast cancers.
Neoplasms
BCL-2, topoisomerase II?, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy.
Neoplasms
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Neoplasms
BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix.
Neoplasms
Benzoxazines as new human topoisomerase I inhibitors and potential poisons.
Neoplasms
Beyond the unwinding: role of TOP1MT in mitochondrial translation.
Neoplasms
Beyond topoisomerase inhibition: antitumor 1,4-naphthoquinones as potential inhibitors of human monoamine oxidase.
Neoplasms
BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response.
Neoplasms
Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.
Neoplasms
Biochemical modulation of cytotoxic drugs by cytokines: molecular mechanisms in experimental oncology.
Neoplasms
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.
Neoplasms
Biological activity and molecular docking studies of some new quinolines as potent anticancer agents.
Neoplasms
Biological activity of the tryprostatins and their diastereomers on human carcinoma cell lines.
Neoplasms
Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase II? inhibitors.
Neoplasms
Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions.
Neoplasms
Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development.
Neoplasms
BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
Neoplasms
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Neoplasms
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
Neoplasms
Brostallicin: a new concept in minor groove DNA binder development.
Neoplasms
Bufalin influences the repair of X-ray-induced DNA breaks in Chinese hamster cells.
Neoplasms
Caffeic acid and quercitrin purified from Houttuynia cordata inhibit DNA topoisomerase I activity.
Neoplasms
Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma.
Neoplasms
Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
Neoplasms
Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.
Neoplasms
Camptothecin and 9-nitrocamptothecin (9NC) as anti-cancer, anti-HIV and cell-differentiation agents. Development of resistance, enhancement of 9NC-induced activities and combination treatments in cell and animal models.
Neoplasms
Camptothecin and taxol: historic achievements in natural products research.
Neoplasms
Camptothecin antitumor agents.
Neoplasms
Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Neoplasms
Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Neoplasms
Camptothecin in sterically stabilized phospholipid nano-micelles: a novel solvent pH change solubilization method.
Neoplasms
Camptothecin induces c-Myc- and Sp1-mediated hTERT expression in LNCaP cells: Involvement of reactive oxygen species and PI3K/Akt.
Neoplasms
Camptothecin post-treatments inhibit the biochemical events linked to the tumor-promoting component of carcinogenesis in mouse epidermis in vivo.
Neoplasms
Camptothecin promotes the production of nitric oxide that triggers subsequent S-nitrosoproteome-mediated signaling cascades in endothelial cells.
Neoplasms
Camptothecin Resistance in Cancer: Insights into the Molecular Mechanisms of a DNA damaging Drug.
Neoplasms
Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.
Neoplasms
Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise.
Neoplasms
Camptothecins: a review of their chemotherapeutic potential.
Neoplasms
Camptothecins: a review of their development and schedules of administration.
Neoplasms
Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin d.
Neoplasms
Cancer chemopreventive potential of aromathecins and phenazines, novel natural product derivatives.
Neoplasms
Cancer Essential Genes Stratified Lung Adenocarcinoma Patients with Distinct Survival Outcomes and Identified a Subgroup from the Terminal Respiratory Unit Type with Different Proliferative Signatures in Multiple Cohorts.
Neoplasms
Cancer Targeted Enzymatic Theranostic Prodrug: Precise Diagnosis and Chemotherapy.
Neoplasms
Cancer-Stroma Targeting Therapy by Cytotoxic Immunoconjugate Bound to the Collagen 4 Network in the Tumor Tissue.
Neoplasms
Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis.
Neoplasms
Cardiac glycosides in cancer research and cancer therapy.
Neoplasms
Catalytic inhibition of eukaryotic topoisomerases I and II by flavonol glycosides extracted from Vicia faba and Lotus edulis.
Neoplasms
CD117, CK20, TTF-1, and DNA topoisomerase II-alpha antigen expression in small cell tumors.
Neoplasms
Cell-based assays for profiling activity and safety properties of cancer drugs.
Neoplasms
Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy.
Neoplasms
Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.
Neoplasms
Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
Neoplasms
Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.
Neoplasms
Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.
Neoplasms
Cellular stress triggers the human topoisomerase I damage response independently of DNA damage in a p53 controlled manner.
Neoplasms
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Neoplasms
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.
Neoplasms
Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
Neoplasms
Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells.
Neoplasms
Characterization of novel Checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors.
Neoplasms
Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
Neoplasms
Characterization of the 3' region of the human DNA topoisomerase I gene.
Neoplasms
Characterization of the antitumor-promoting activity of camptothecin in SENCAR mouse skin.
Neoplasms
Characterization of topotecan-mediated redistribution of DNA topoisomerase I by digital imaging microscopy.
Neoplasms
Checkpoint inhibition of origin firing prevents DNA topological stress.
Neoplasms
Chemopotentiation by PARP inhibitors in cancer therapy.
Neoplasms
Chemosensitivity testing--present and future in Japan.
Neoplasms
Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
Neoplasms
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Neoplasms
Chiral ruthenium(II) complexes with phenolic hydroxyl groups as dual poisons of topoisomerases I and II?.
Neoplasms
Chitosan-Dextran sulfate coated doxorubicin loaded PLGA-PVA-nanoparticles caused apoptosis in doxorubicin resistance breast cancer cells through induction of DNA damage.
Neoplasms
Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites.
Neoplasms
Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones.
Neoplasms
Circadian rhythm of irinotecan tolerability in mice.
Neoplasms
Circumventing multidrug resistance in cancer by beta-galactoside binding protein, an antiproliferative cytokine.
Neoplasms
Circumvention of atypical multidrug resistance with tumor necrosis factor.
Neoplasms
Cisplatin and irinotecan in upper gastrointestinal malignancies.
Neoplasms
Cisplatin enhances the p53-independent apoptosis induced by a topoisomerase I inhibitor (CPT-11) in the lens epithelial tumors in transgenic mice.
Neoplasms
CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.
Neoplasms
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Neoplasms
Clinical applications of the camptothecins.
Neoplasms
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
Neoplasms
Clinical pharmacokinetics of irinotecan.
Neoplasms
Clinical pharmacokinetics of topotecan.
Neoplasms
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
Neoplasms
Clinical resistance to topoisomerase-targeted drugs.
Neoplasms
Clinical status and optimal use of topotecan.
Neoplasms
Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance.
Neoplasms
Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20.
Neoplasms
Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas.
Neoplasms
Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs.
Neoplasms
Collateral sensitivity of natural products in drug-resistant cancer cells.
Neoplasms
Combating liver cancer through GO-targeted biomaterials.
Neoplasms
Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.
Neoplasms
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.
Neoplasms
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Neoplasms
Combination Treatment of CI-994 With Etoposide Potentiates Anticancer Effects Through a Topoisomerase II-Dependent Mechanism in Atypical Teratoid/Rhabdoid Tumor (AT/RT).
Neoplasms
Combinational effect of topotecan and octreotide on murine leukemia cells in vivo and in vitro.
Neoplasms
Comparative drug screening in NUT midline carcinoma.
Neoplasms
Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells.
Neoplasms
Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis.
Neoplasms
Computational screening of chalcones acting against topoisomerase II? and their cytotoxicity towards cancer cell lines.
Neoplasms
Computational Study of Anticancer Drug Resistance Caused by 10 Topisomerase I Mutations, Including 7 Camptothecin Analogs and Lucanthone.
Neoplasms
Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Neoplasms
Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy.
Neoplasms
Conjugation with polyamines enhances the antitumor activity of naphthoquinones against human glioblastoma cells.
Neoplasms
Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations.
Neoplasms
Contribution of immunohistochemistry in prognostic assessment of epithelial ovarian carcinoma --review of the literature I.
Neoplasms
Controlled release of 9-nitro-20(S)-camptothecin from methoxy poly(ethylene glycol)-poly(D,L-lactide) micelles.
Neoplasms
Convenient synthesis of indeno[1,2-c]isoquinolines as constrained forms of 3-arylisoquinolines and docking study of a topoisomerase I inhibitor into DNA-topoisomerase I complex.
Neoplasms
Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC.
Neoplasms
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II.
Neoplasms
Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers.
Neoplasms
Correction: Cytocidal Activities of Topoisomerase 1 Inhibitors and 5-Azacytidine against Pheochromocytoma/Paraganglioma Cells in Primary Human Tumor Cultures and Mouse Cell Lines.
Neoplasms
Correction: The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor.
Neoplasms
Correspondence re: M. Provencio, et al. the topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin. Cancer Res., 9: 1406-1411, 2003.
Neoplasms
Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
Neoplasms
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
Neoplasms
CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.
Neoplasms
CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
Neoplasms
CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype.
Neoplasms
CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.
Neoplasms
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Neoplasms
Cross-sensitivity to x-radiation and type-I and type-ii DNA topoisomerase inhibitors in a range of human and rodent cell-lines.
Neoplasms
Crystal structure of the Geobacillus stearothermophilus carboxylesterase Est55 and its activation of prodrug CPT-11.
Neoplasms
CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.
Neoplasms
Cucurbitane triterpenes from the fruiting bodies and cultivated mycelia of Leucopaxillus gentianeus.
Neoplasms
Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
Neoplasms
Current status and perspectives in the development of camptothecins.
Neoplasms
Current updates on microRNAs as regulators of chemoresistance.
Neoplasms
Cyanobacterial Metabolite Calothrixins: Recent Advances in Synthesis and Biological Evaluation.
Neoplasms
Cyclane-aminol 10-hydroxycamptothecin analogs as novel DNA topoisomerase I inhibitors induce apoptosis selectively in tumor cells.
Neoplasms
Cyclometalated gold(iii) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons.
Neoplasms
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Neoplasms
Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy.
Neoplasms
Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines.
Neoplasms
Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
Neoplasms
Cytotoxic compounds from Annonaceus species as DNA topoisomerase I poisons.
Neoplasms
Cytotoxic mechanism of flavonoid from Temu Kunci (Kaempferia pandurata) in cell culture of human mammary carcinoma.
Neoplasms
Cytotoxic pyrroloiminoquinones from four new species of South African latrunculid sponges.
Neoplasms
Cytotoxicity and preliminary mode of action studies of novel 2-aryl-4-thiopyrone-based organometallics.
Neoplasms
Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells.
Neoplasms
Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
Neoplasms
Decreased serum levels of carboxylesterase-2 in patients with ovarian cancer.
Neoplasms
Degradation of DNA topoisomerase I by a novel trypsin-like serine protease in proliferating human T lymphocytes.
Neoplasms
Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
Neoplasms
Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model.
Neoplasms
Design and synthesis of conformationally constrained hydroxylated 4-phenyl-2-aryl chromenopyridines as novel and selective topoisomerase II-targeted antiproliferative agents.
Neoplasms
Design and synthesis of N-methylmaleimide indolocarbazole bearing modified 2-acetamino acid moieties as Topoisomerase I inhibitors.
Neoplasms
Design and synthesis of novel 2,4-diaryl-5H-indeno[1,2-b]pyridine derivatives, and their evaluation of topoisomerase inhibitory activity and cytotoxicity.
Neoplasms
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives.
Neoplasms
Design of topoisomerase inhibitors to overcome MDR1-mediated drug resistance.
Neoplasms
Design, synthesis and biological evaluation of 3-nitro-1,8-naphthalimides as potential antitumor agents.
Neoplasms
Design, Synthesis and Cytotoxicity Evaluation of New 3, 5-Disubstituted-2-Thioxoimidazolidinones.
Neoplasms
Design, synthesis and docking study of 5-amino substituted indeno[1,2-c]isoquinolines as novel topoisomerase I inhibitors.
Neoplasms
Design, synthesis and topoisomerase II inhibition activity of 4'-demethylepipodophyllotoxin-lexitropsin conjugates.
Neoplasms
Design, synthesis, and antitumor evaluation of 2,4,6-triaryl pyridines containing chlorophenyl and phenolic moiety.
Neoplasms
Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.
Neoplasms
Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
Neoplasms
Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen.
Neoplasms
Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.
Neoplasms
Design, synthesis, and evaluation of psorospermin/quinobenzoxazine hybrids as structurally novel antitumor agents.
Neoplasms
Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs.
Neoplasms
Determination of 9-nitrocamptothecin by precolumn derivatization and its metabolite 9-aminocamptothecin in a biological fluid using reversed-phase high-performance liquid chromatography with fluorescence detection.
Neoplasms
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Neoplasms
Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography.
Neoplasms
Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors.
Neoplasms
Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
Neoplasms
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
Neoplasms
Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis.
Neoplasms
Development of New ADC Technology with Topoisomerase I Inhibitor.
Neoplasms
Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells.
Neoplasms
Diazoniapolycyclic ions inhibit the activity of topoisomerase I and the growth of certain tumor cell lines.
Neoplasms
Dietary phytoestrogens.
Neoplasms
Differences between latent and clinical prostate carcinomas: lower cell proliferation activity in latent cases.
Neoplasms
Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.
Neoplasms
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
Neoplasms
Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
Neoplasms
Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.
Neoplasms
Differential effect of camptothecin treatment on topoisomerase II alpha expression in ML-1 and HL-60 leukemia cell lines.
Neoplasms
Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: detected by RNA/PCR-based quantitation assay.
Neoplasms
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Neoplasms
Differential increase in topoisomerase II in simian virus 40-infected cells.
Neoplasms
Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
Neoplasms
Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation.
Neoplasms
Differentiated Human Colorectal Cancer Cells Protect Tumor-Initiating Cells from Irinotecan.
Neoplasms
Differentiation-inducing activity of lupane triterpenes on a mouse melanoma cell line.
Neoplasms
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Neoplasms
Dihydroxylated 2,4,6-triphenyl pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
Neoplasms
Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and II? dual inhibitors with DNA non-intercalative catalytic activity.
Neoplasms
Dioscin, a natural steroid saponin, induces apoptosis and DNA damage through reactive oxygen species: A potential new drug for treatment of glioblastoma multiforme.
Neoplasms
Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-b]pyridinol Derivatives as Potent Topoisomerase II?-Targeted Chemotherapeutic Agents for Breast Cancer.
Neoplasms
Discovery of 5-(or 6)-benzoxazoles and oxazolo[4,5-b]pyridines as novel candidate antitumor agents targeting hTopo II?.
Neoplasms
Discovery of Camptothecin based Topoisomerase I Inhibitors: Identification Using an Atom based 3D-QSAR, Pharmacophore Modeling, Virtual Screening and Molecular Docking Approach.
Neoplasms
Discovery of cell-permeable inhibitors that target the BRCT domain of BRCA1 protein by using a small-molecule microarray.
Neoplasms
Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products.
Neoplasms
Discovery of Novel Sultone Fused Berberine Derivatives as Promising Tdp1 Inhibitors.
Neoplasms
Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.
Neoplasms
Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: Implications for physiological and therapeutic modulation of enzyme activity.
Neoplasms
Distinct requirements for the Rad32(Mre11) nuclease and Ctp1(CtIP) in the removal of covalently bound topoisomerase I and II from DNA.
Neoplasms
Distribution bias and biochemical characterization of TOP1MT single nucleotide variants.
Neoplasms
DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Neoplasms
DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH.
Neoplasms
DNA damage modulates nucleolar interaction of the Werner protein with the AAA ATPase p97/VCP.
Neoplasms
DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.
Neoplasms
DNA Polymerase theta (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse.
Neoplasms
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Neoplasms
DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.
Neoplasms
DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
Neoplasms
DNA topoisomerase i as a transcription protein and a lethal cellular toxin.
Neoplasms
DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives.
Neoplasms
DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?
Neoplasms
DNA topoisomerase I inhibitor, ergosterol peroxide from Penicillium oxalicum.
Neoplasms
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.
Neoplasms
DNA topoisomerase I phosphorylation in murine fibroblasts treated with 12-O-tetradecanoylphorbol-13-acetate and in vitro by protein kinase.
Neoplasms
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Neoplasms
DNA topoisomerase II as a potential factor in drug resistance of human malignancies.
Neoplasms
DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy.
Neoplasms
DNA topoisomerase II mutations and resistance to anti-tumor drugs.
Neoplasms
DNA Topoisomerase II-alpha as a marker of cell proliferation in endocrine and other neoplasms.
Neoplasms
DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival.
Neoplasms
DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
Neoplasms
DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides.
Neoplasms
DNA topoisomerase II? and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.
Neoplasms
DNA Topoisomerase III Alpha Regulates p53-Mediated Tumor Suppression.
Neoplasms
DNA topoisomerase-targeting antitumor agents and drug resistance.
Neoplasms
DNA topoisomerases and the DNA lesion in human genetic instability syndromes.
Neoplasms
DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.
Neoplasms
DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.
Neoplasms
DNA topoisomerases in therapy--tenth conference. 6-8 October 1999, Amsterdam, The Netherlands.
Neoplasms
DNA Topology and Topoisomerases: Teaching a "Knotty" Subject.
Neoplasms
DNA-interactive agents.
Neoplasms
DNA-topoisomerase I activity and content in epithelial ovarian cancer.
Neoplasms
Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Neoplasms
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer.
Neoplasms
Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
Neoplasms
Drugging topoisomerases: lessons and challenges.
Neoplasms
Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Neoplasms
Dual topoisomerase I/II inhibitors in cancer therapy.
Neoplasms
Dual-acting histone deacetylase-topoisomerase I inhibitors.
Neoplasms
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
Neoplasms
DX-8951f: summary of phase I clinical trials.
Neoplasms
E-pharmacophore guided discovery of pyrazolo[1,5-c]quinazolines as dual inhibitors of topoisomerase-I and histone deacetylase.
Neoplasms
EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs.
Neoplasms
ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice.
Neoplasms
Effect of chlorine substituent on cytotoxic activities: Design and synthesis of systematically modified 2,4-diphenyl-5H-indeno[1,2-b]pyridines.
Neoplasms
Effect of Pterostilbene, a Natural Derivative of Resveratrol, in the Treatment of Colorectal Cancer through Top1/Tdp1-Mediated DNA Repair Pathway.
Neoplasms
Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo.
Neoplasms
Effects of albaconol from the basidiomycete Albatrellus confluens on DNA topoisomerase II-mediated DNA cleavage and relaxation.
Neoplasms
Effects of camptothecin, an inhibitor of DNA topoisomerase I on ribosomal gene structure and function in TG cells.
Neoplasms
Effects of cinobufacini injection on cell proliferation and the expression of topoisomerases in human HepG-2 hepatocellular carcinoma cells.
Neoplasms
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
Neoplasms
Effects of inhibitors of topoisomerases-I and topoisomerases-ii on DNA methylation and DNA-synthesis in human colonic adenocarcinoma cells-invitro.
Neoplasms
Effects of minor groove binding drugs on camptothecin-induced DNA lesions in L1210 nuclei.
Neoplasms
Effects of plant phenolics and grape extracts from Greek varieties of Vitis vinifera on Mitomycin C and topoisomerase I-induced nicking of DNA.
Neoplasms
Effects of resveratrol on topoisomerase II-? activity: induction of micronuclei and inhibition of chromosome segregation in CHO-K1 cells.
Neoplasms
Effects of topoisomerases inhibitors protoberberine on Leishmania donovani growth, macrophage function, and infection.
Neoplasms
Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells.
Neoplasms
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Neoplasms
EGCG regulates the cross-talk between JWA and topoisomerase II? in non-small-cell lung cancer (NSCLC) cells.
Neoplasms
Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy.
Neoplasms
Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Neoplasms
Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy.
Neoplasms
Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies.
Neoplasms
Elevations of DNA topoisomerase I in invasive carcinoma of the breast.
Neoplasms
Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression.
Neoplasms
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Neoplasms
Elucidation of Mechanisms of Topotecan-Induced Cell Death in Human Breast MCF-7 Cancer Cells by Gene Expression Analysis.
Neoplasms
Emerging DNA topisomerase inhibitors as anticancer drugs.
Neoplasms
Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
Neoplasms
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Neoplasms
Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Neoplasms
Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Neoplasms
Enhanced malignant transformation is accompanied by increased survival recovery after ionizing radiation in Chinese hamster embryo fibroblasts.
Neoplasms
Enhanced Stability of the Pharmacologically Active Lactone Form of 10-Hydroxycamptothecin by Self-Microemulsifying Drug Delivery Systems.
Neoplasms
Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Neoplasms
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
Neoplasms
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Neoplasms
Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs.
Neoplasms
Environment-Sensitive Polymeric Micelles Encapsulating SN-38 Potently Suppress Growth of Neuroblastoma Cells Exhibiting Intrinsic and Acquired Drug Resistance.
Neoplasms
Enzymatic O-Glycosylation of Etoposide Aglycone by Exploration of the Substrate Promiscuity for Glycosyltransferases.
Neoplasms
Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer.
Neoplasms
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.
Neoplasms
ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells.
Neoplasms
Establishment and characterization of 18 human colorectal cancer cell lines.
Neoplasms
Etirinotecan pegol for the treatment of breast cancer.
Neoplasms
Etoposide induction of tumor immunity in Lewis lung cancer.
Neoplasms
Etoposide, topoisomerase II and cancer.
Neoplasms
Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies.
Neoplasms
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Neoplasms
Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.
Neoplasms
Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.
Neoplasms
Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
Neoplasms
Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer.
Neoplasms
Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study.
Neoplasms
Evodiamine and rutaecarpine alkaloids as highly selective transient receptor potential vanilloid 1 agonists.
Neoplasms
Evolutionary trace analysis of eukaryotic DNA topoisomerase I superfamily: identification of novel antitumor drug binding site.
Neoplasms
Ex vivo activity of XR5000 against solid tumors.
Neoplasms
Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors.
Neoplasms
Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer.
Neoplasms
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Neoplasms
Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC).
Neoplasms
Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron.
Neoplasms
Experience with irinotecan for the treatment of malignant glioma.
Neoplasms
Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
Neoplasms
Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.
Neoplasms
Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
Neoplasms
Exploring the cellular activity of camptothecin-triple-helix-forming oligonucleotide conjugates.
Neoplasms
Exploring the DNA binding/cleavage, cellular accumulation and topoisomerase inhibition of 2-hydroxy-3-(aminomethyl)-1,4-naphthoquinone Mannich bases and their platinum(II) complexes.
Neoplasms
Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines.
Neoplasms
Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
Neoplasms
Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.
Neoplasms
Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Neoplasms
Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival.
Neoplasms
Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma.
Neoplasms
Expression of DNA topoisomerase IIalpha in oligodendroglioma.
Neoplasms
Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas.
Neoplasms
Expression of growth-related genes and drug-resistance genes in HTLV-I-positive and HTLV-I-negative post-thymic T-cell malignancies.
Neoplasms
Expression of meiotic genes in the germline progenitors of Drosophila embryos.
Neoplasms
Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer.
Neoplasms
Expression of multidrug resistance-related genes (mdrl, MRP, GST-pi and DNA topoisomerase II) in urothelial cancers.
Neoplasms
Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase II?) in borderline ovarian tumors: Correlation with clinicopathological features.
Neoplasms
Expression of resistance-related proteins in nephroblastoma after chemotherapy.
Neoplasms
Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
Neoplasms
Expression of Topoisomerase II-? protein in salivary gland tumors.
Neoplasms
Expression of topoisomerase IIIalpha in normal and neoplastic tissues determined by immunohistochemistry using a novel monoclonal antibody.
Neoplasms
Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma.
Neoplasms
Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor.
Neoplasms
Extraskeletal Myxoid Chondrosarcoma of the Vulva With PLAG1 Gene Activation: Molecular Genetic Characterization of 2 Cases.
Neoplasms
Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells.
Neoplasms
Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.
Neoplasms
Fine-Tuning the Activation Mode of an 1,3-Indandione-Based Ruthenium(II)-Cymene Half-Sandwich Complex by Variation of Its Leaving Group.
Neoplasms
Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects.
Neoplasms
Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK).
Neoplasms
Formulation of injectable glycyrrhizic acid-hydroxycamptothecin micelles as new generation of DNA topoisomerase I inhibitor for enhanced antitumor activity.
Neoplasms
FPDHP, a novel anticancer agent, induces cell detachment and caspase-dependent apoptosis in Caki cells.
Neoplasms
Functional expression of human DNA topoisomerase I and its subcellular localization in HeLa cells.
Neoplasms
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Neoplasms
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
Neoplasms
Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.
Neoplasms
Geminin deficiency enhances survival in a murine medulloblastoma model by inducing apoptosis of preneoplastic granule neuron precursors.
Neoplasms
Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Neoplasms
Gene expression profiling of adrenal cortical tumors by cDNA macroarray analysis. Results of a preliminary study.
Neoplasms
Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas.
Neoplasms
Genetic toxicity of cytokines.
Neoplasms
Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan.
Neoplasms
Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients.
Neoplasms
Genotoxic effects of topoisomerase poisoning and PARP inhibition on zebrafish embryos.
Neoplasms
Genz-644282, a Novel Non-Camptothecin Topoisomerase I Inhibitor for Cancer Treatment.
Neoplasms
Gimatecan, a novel camptothecin with a promising preclinical profile.
Neoplasms
Gli1 protein regulates the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitors.
Neoplasms
Gold nanoparticles - an optical biosensor for RNA quantification for cancer and neurologic disorders diagnosis.
Neoplasms
Gold(III) complexes of pyridyl- and isoquinolylamido ligands: structural, spectroscopic, and biological studies of a new class of dual topoisomerase I and II inhibitors.
Neoplasms
Green tea constituent (--)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells.
Neoplasms
Green tea constituents (-)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I- and topoisomerase II-DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide.
Neoplasms
Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR.
Neoplasms
H1 histone sub-type distribution and DNA topoisomerase activity in skeletal muscle of tumour-bearing rats.
Neoplasms
Harnessing Solute Carrier Transporters for Precision Oncology.
Neoplasms
Has-miR-30a regulates autophagic activity in cervical cancer upon hydroxycamptothecin exposure.
Neoplasms
HER-2/neu and topoisomerase IIalpha--simultaneous drug targets in cancer.
Neoplasms
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors.
Neoplasms
High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drugs.
Neoplasms
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma.
Neoplasms
Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Neoplasms
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Neoplasms
Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.
Neoplasms
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
Neoplasms
hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II? in Human Leukemia K562 Cells with Acquired Resistance to Etoposide.
Neoplasms
HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Neoplasms
HU-331 is a catalytic inhibitor of topoisomerase II?.
Neoplasms
Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
Neoplasms
Human DNA topoisomerase I poisoning activity of bis-1-aminomethylnaphtalenes. A correlation with their cytotoxic activity.
Neoplasms
Human DNA topoisomerase I: An anticancer drug target present in human sarcomas.
Neoplasms
Human DNA topoisomerase II-alpha expression in laparoscopically treated renal cell carcinoma.
Neoplasms
Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.
Neoplasms
Human DNA topoisomerase-IIalpha expression as a prognostic factor for transitional cell carcinoma of the urinary bladder.
Neoplasms
Human multidrug resistance associated protein 4 confers resistance to camptothecins.
Neoplasms
Human neural stem cells overexpressing a carboxylesterase inhibit bladder tumor growth.
Neoplasms
Human topoisomerase inhibition and DNA/BSA binding of Ru(II)-SCAR complexes as potential anticancer candidates for oral application.
Neoplasms
Human xeroderma pigmentosum group A protein interacts with human replication protein A and inhibits DNA replication.
Neoplasms
Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.
Neoplasms
Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase II? catalytic inhibitor.
Neoplasms
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Neoplasms
Identification and characterization of the sulfate precipitate in GI147211C IV formulation.
Neoplasms
Identification of a caspase-2 isoform that behaves as an endogenous inhibitor of the caspase cascade.
Neoplasms
Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening.
Neoplasms
Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays.
Neoplasms
Identification of a small topoisomerase I-binding peptide that has synergistic antitumor activity with 9-aminocamptothecin.
Neoplasms
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells.
Neoplasms
Identification of early gene expression changes in primary cultured neurons treated with topoisomerase I poisons.
Neoplasms
Identification of functional nuclear export sequences in human topoisomerase IIalpha and beta.
Neoplasms
Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines.
Neoplasms
Identification of novel inhibitors for the tyrosyl-DNA-phosphodiesterase 1 (Tdp1) mutant SCAN1 using virtual screening.
Neoplasms
Identification of sumoylated targets in proliferating mouse spermatogonia and human testicular seminomas.
Neoplasms
Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase I poisons.
Neoplasms
Imatinib-induced apoptosis: a possible link to topoisomerase enzyme inhibition.
Neoplasms
Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas.
Neoplasms
Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas.
Neoplasms
Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas.
Neoplasms
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.
Neoplasms
Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.
Neoplasms
Importance of PIKKs in NF-?B activation by genotoxic stress.
Neoplasms
In vitro action of flavonoids in the canine malignant histiocytic cell line DH82.
Neoplasms
In Vitro and In Vivo Anticancer Activity of Gimatecan against Hepatocellular Carcinoma
Neoplasms
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Neoplasms
In vitro cytotoxicity against different human cancer cell lines of laticifer proteins of Calotropis procera (Ait.) R. Br.
Neoplasms
In vitro pharmacodynamics of CKD-602 in HT-29 cells.
Neoplasms
In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan).
Neoplasms
In Vitro Synergistic Interaction between DTA0100 and Radiation in Human Cancer Cell Lines.
Neoplasms
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Neoplasms
In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites.
Neoplasms
In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1? target genes and decreases tumor angiogenesis.
Neoplasms
In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.
Neoplasms
Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Neoplasms
Indenocinnoline derivatives as G-quadruplex binders, topoisomerase II? inhibitors and antiproliferative agents.
Neoplasms
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
Neoplasms
Indolocarbazole poisons of human topoisomerase I: regioisomeric analogues of ED-110.
Neoplasms
Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short).
Neoplasms
Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.
Neoplasms
Induction of tumor necrosis factor by a camptothecin derivative, irinotecan, in mice and human mononuclear cells.
Neoplasms
Influence of irinotecan and SN-38 on the irradiation response of WHO3 human oesophageal tumour cells under hypoxic conditions.
Neoplasms
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Neoplasms
Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.
Neoplasms
Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells.
Neoplasms
Inhibition of DNA topoisomerase I activity and induction of apoptosis by thiazacridine derivatives.
Neoplasms
Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor.
Neoplasms
Inhibition of DNA topoisomerase I and growth inhibition of human cancer cell lines by an oleanane from Junellia aspera (Verbenaceae).
Neoplasms
Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds.
Neoplasms
Inhibition of gastric cancer by camptothecin involves apoptosis and multiple cellular pathways.
Neoplasms
Inhibition of human DNA topoisomerase IB by a cyclometalated gold III compound: analysis on the different steps of the enzyme catalytic cycle.
Neoplasms
Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons.
Neoplasms
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.
Neoplasms
Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I.
Neoplasms
Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy.
Neoplasms
Inhibition of topoisomerase I activity and efflux drug transporters' expression by xanthohumol. from hops.
Neoplasms
Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells.
Neoplasms
Inhibition of Vascular Calcification.
Neoplasms
Inhibitory effect of conjugated eicosapentaenoic acid on mammalian DNA polymerase and topoisomerase activities and human cancer cell proliferation.
Neoplasms
Inhibitory effects of ?-mangostin on mammalian DNA polymerase, topoisomerase, and human cancer cell proliferation.
Neoplasms
Inhibitory effects of cholesterol derivatives on DNA polymerase and topoisomerase activities, and human cancer cell growth.
Neoplasms
Inhibitory effects of diacylglyceride phospholipids on DNA polymerase and topoisomerase activities, and human cancer cell growth.
Neoplasms
Inhibitory effects of docosyl p-coumarate on DNA topoisomerase activity and human cancer cell growth.
Neoplasms
Inhibitory effects of low molecular weight polyphenolics from Inonotus obliquus on human DNA topoisomerase activity and cancer cell proliferation.
Neoplasms
Inhibitory effects of myricetin on mammalian DNA polymerase, topoisomerase and human cancer cell proliferation.
Neoplasms
Initial testing of topotecan by the pediatric preclinical testing program.
Neoplasms
Insight into eukaryotic topoisomerase II-inhibiting fused heterocyclic compounds in human cancer cell lines by molecular docking.
Neoplasms
Interaction between glucose-regulated destruction domain of DNA topoisomerase IIalpha and MPN domain of Jab1/CSN5.
Neoplasms
Interaction of anticancer drug mitoxantrone with DNA hexamer sequence d-(CTCGAG)2 by absorption, fluorescence and circular dichroism spectroscopy.
Neoplasms
Interaction of ionizing radiation with topotecan in two human tumor cell lines.
Neoplasms
Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells.
Neoplasms
Intrinsic curvature in duplex DNA inhibits Human Topoisomerase I.
Neoplasms
Invasive growth and topoisomerase-switch induced by tumorous extracellular matrix in osteosarcoma cell culture.
Neoplasms
Investigation of Isoindolo[2,1-a]quinoxaline-6-imines as Topoisomerase I Inhibitors With Molecular Modeling Methods.
Neoplasms
Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.
Neoplasms
Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons.
Neoplasms
Involvement of hydrogen peroxide in topoisomerase inhibitor beta-lapachone-induced apoptosis and differentiation in human leukemia cells.
Neoplasms
Involvement of lysosomal cathepsins in the cleavage of DNA topoisomerase I during necrotic cell death.
Neoplasms
Involvement of transcriptional repressor ATF3 in acceleration of caspase protease activation during DNA damaging agent-induced apoptosis.
Neoplasms
Ionizing radiation damage repair: a role for topoisomerases?
Neoplasms
Iridium(iii) complexes as mitochondrial topoisomerase inhibitors against cisplatin-resistant cancer cells.
Neoplasms
Iridoids as DNA topoisomerase I poisons.
Neoplasms
Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Neoplasms
Irinotecan and radiation in vitro and in vivo.
Neoplasms
Irinotecan combined with co-stimulatory molecule blockade prolongs survival of cardiac allografts in alloantigen-primed mice.
Neoplasms
Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer.
Neoplasms
Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.
Neoplasms
Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer.
Neoplasms
Irinotecan in the treatment of colorectal cancer: clinical overview.
Neoplasms
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Neoplasms
Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models.
Neoplasms
Irinotecan-Associated Dysarthria in Patients with Pancreatic Cancer: A Single Site Experience.
Neoplasms
Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer.
Neoplasms
Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells.
Neoplasms
Irinotecan-induced colitis.
Neoplasms
Irinotecan-induced mucositis is associated with changes in intestinal mucins.
Neoplasms
Irinotecan: 25 years of cancer treatment.
Neoplasms
Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.
Neoplasms
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Neoplasms
Isoeugenol is a selective potentiator of camptothecin cytotoxicity in vertebrate cells lacking TDP1.
Neoplasms
Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
Neoplasms
Isolation and biochemical characterization of a new topoisomerase I inhibitor from Ocotea leucoxylon.
Neoplasms
It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.
Neoplasms
Kinetic studies of human tyrosyl-DNA phosphodiesterase, an enzyme in the topoisomerase I DNA repair pathway.
Neoplasms
Kosinostatin, a quinocycline antibiotic with antitumor activity from Micromonospora sp. TP-A0468.
Neoplasms
Ku70 and Rad51 vary in their importance for the repair of doxorubicin- versus etoposide-induced DNA damage.
Neoplasms
Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
Neoplasms
Lanostanoids from Fungi: A Group of Potential Anticancer Compounds.
Neoplasms
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase.
Neoplasms
Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
Neoplasms
Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies.
Neoplasms
Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Neoplasms
Loss of one allele of the p53 gene in the lens epithelial tumor in transgenic mice suppresses apoptosis induced by a topoisomerase I inhibitor (CPT-11).
Neoplasms
Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives.
Neoplasms
Markers of drug resistance in relapsing colon cancer.
Neoplasms
Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents.
Neoplasms
Mechanisms of cancer prevention by tea constituents.
Neoplasms
Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors.
Neoplasms
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Neoplasms
Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors.
Neoplasms
Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs.
Neoplasms
Methylation profile of the promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma.
Neoplasms
Methylenedioxy- and Ethylenedioxy-Fused Indolocarbazoles. Potent Human Topoisomerase I Inhibitors and Antitumor Agents.
Neoplasms
Metnase/SETMAR: a domesticated primate transposase that enhances DNA repair, replication, and decatenation.
Neoplasms
Microvessel Density and Status of p53 Protein as Potential Prognostic Factors for Adjuvant Anthracycline Chemotherapy in Retrospective Analysis of Early Breast Cancer Patients Group.
Neoplasms
Microwave synthesis of novel halogenated ?-enaminonitriles linked 9-bromo-1H-benzo[f]chromene moieties: Induces cell cycle arrest and apoptosis in human cancer cells via dual inhibition of topoisomerase I and II.
Neoplasms
Mining topoisomerase isoforms in gastric cancer.
Neoplasms
Mitochondrial topoisomerase I absence enhances aerobic glycolysis in cancer.
Neoplasms
Mitomycin as a modulator of irinotecan anticancer activity.
Neoplasms
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Neoplasms
Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2.
Neoplasms
Modified 2,4-diaryl-5H-indeno[1,2-b]pyridines with hydroxyl and chlorine moiety: Synthesis, anticancer activity, and structure-activity relationship study.
Neoplasms
Modulation of radiation response by inhibiting topoisomerase II catalytic activity.
Neoplasms
Modulation of topoisomerase activities by tumor necrosis factor.
Neoplasms
Moguntinones--new selective inhibitors for the treatment of human colorectal cancer.
Neoplasms
Molecular design, synthesis and docking study of benz[b]oxepines and 12-oxobenzo[c]phenanthridinones as topoisomerase 1 inhibitors.
Neoplasms
Molecular Docking based analysis to elucidate the DNA Topoisomerase II? as the potential target for the Ganoderic acid, A natural therapeutic agent in cancer therapy.
Neoplasms
Molecular drug design, synthesis and structure elucidation of a new specific target peptide based metallo drug for cancer chemotherapy as topoisomerase I inhibitor.
Neoplasms
Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives.
Neoplasms
MRE11 function in response to topoisomerase poisons is independent of its function in double-strand break repair in Saccharomyces cerevisiae.
Neoplasms
MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma.
Neoplasms
Multifactorial Approach to Predicting Resistance to Anthracyclines.
Neoplasms
Multilevel therapeutic targeting by topoisomerase inhibitors.
Neoplasms
Multiple functions of human single-stranded-DNA binding protein in simian virus 40 DNA replication: single-strand stabilization and stimulation of DNA polymerases alpha and delta.
Neoplasms
Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression.
Neoplasms
Mutagenic activity of topoisomerase I inhibitors
Neoplasms
Mutational analysis of simian virus 40 T-antigen primosome activities in viral DNA replication.
Neoplasms
Mutual regulation of MDM4 and TOP2A in cancer cell proliferation.
Neoplasms
Mycoplasma fermentans Inhibits the Activity of Cellular DNA Topoisomerase I by Activation of PARP1 and Alters the Efficacy of Its Anti-Cancer Inhibitor.
Neoplasms
Myosin VI is differentially regulated by DNA damage in p53- and cell type-dependent manners.
Neoplasms
Namitecan: a hydrophilic camptothecin with a promising preclinical profile.
Neoplasms
Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells.
Neoplasms
Nascent DNA Proteomics Reveals a Chromatin Remodeler Required for Topoisomerase I Loading at Replication Forks.
Neoplasms
Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases.
Neoplasms
Natural Trienoic Acids as Anticancer Agents: First Stereoselective Synthesis, Cell Cycle Analysis, Induction of Apoptosis, Cell Signaling and Mitochondrial Targeting Studies.
Neoplasms
Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II.
Neoplasms
Neoamphimedine circumvents metnase-enhanced DNA topoisomerase II? activity through ATP-competitive inhibition.
Neoplasms
Neurotoxic activity of a Topoisomerase-I inhibitor, camptothecin, in cultured cerebellar granule neurons.
Neoplasms
New advances in fatty acids as antimalarial, antimycobacterial and antifungal agents.
Neoplasms
New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.
Neoplasms
New agents for colon and breast cancer.
Neoplasms
New anthra[2,3-b]furancarboxamides: A role of positioning of the carboxamide moiety in antitumor properties.
Neoplasms
New camptothecin derivatives for generalized oncological chemotherapy: Synthesis, stereochemistry and biology.
Neoplasms
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
Neoplasms
New drugs for patients with pancreatic cancer.
Neoplasms
New heterobimetallic Cu(II)-Sn(2)(IV) complex as potential topoisomerase I inhibitor: In vitro DNA binding, cleavage and cytotoxicity against human cancer cell lines.
Neoplasms
New Insights Into DNA Helicases as Druggable Targets for Cancer Therapy.
Neoplasms
New propylamine oligopyrrole carboxamides linked to a heterocyclic or anthraquinone system: synthesis, DNA binding, topoisomerase I inhibition and cytotoxicity.
Neoplasms
New pyrazoles incorporating pyrazolylpyrazole moiety: synthesis, anti-HCV and antitumor activity.
Neoplasms
New synthetic analogues of natural 5Z,9Z-dienoic acids: Stereoselective synthesis and study of the anticancer activity.
Neoplasms
NF-kappaB activation by double-strand breaks.
Neoplasms
Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
Neoplasms
Nitric oxide inhibits ATPase activity and induces resistance to topoisomerase II-poisons in human MCF-7 breast tumor cells.
Neoplasms
Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Neoplasms
No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer.
Neoplasms
Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy.
Neoplasms
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
Neoplasms
Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone.
Neoplasms
Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
Neoplasms
Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors.
Neoplasms
Novel 4-(4-substituted amidobenzyl)furan-2(5H)-one derivatives as topoisomerase I inhibitors.
Neoplasms
Novel 4-quinoline-thiosemicarbazone derivatives: Synthesis, antiproliferative activity, in vitro and in silico biomacromolecule interaction studies and topoisomerase inhibition.
Neoplasms
Novel 9-(2-(1-arylethylidene)hydrazinyl)acridine derivatives: Target Topoisomerase 1 and growth inhibition of HeLa cancer cells.
Neoplasms
Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis.
Neoplasms
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
Neoplasms
Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
Neoplasms
Novel autoxidative cleavage reaction of 9-fluoredenes discovered during synthesis of a potential DNA-threading indenoisoquinoline.
Neoplasms
Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
Neoplasms
Novel Hybrid Molecules on the Basis of Steroids and (5Z,9Z)-Tetradeca-5,9-dienoic Acid: Synthesis, Anti-Cancer Studies and Human Topoisomerase I Inhibitory Activity.
Neoplasms
Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents.
Neoplasms
Novel insights into the apoptosis mechanism of DNA topoisomerase I inhibitor isoliquiritigenin on HCC tumor cell.
Neoplasms
Novel phosphine sulphide gold(i) complexes: topoisomerase I inhibitors and antiproliferative agents.
Neoplasms
Novel polypyridyl ruthenium complexes acting as high affinity DNA intercalators, potent transcription inhibitors and antitumor reagents.
Neoplasms
Novel securinine derivatives as topoisomerase I based antitumor agents.
Neoplasms
Novel treatment strategies for soft tissue sarcoma.
Neoplasms
Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topote?an on in vivo tumor models.
Neoplasms
NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells.
Neoplasms
NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells.
Neoplasms
Nuclear export of proteins and drug resistance in cancer.
Neoplasms
Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs.
Neoplasms
Nucleic acids therapeutics using PolyPurine Reverse Hoogsteen hairpins.
Neoplasms
Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Neoplasms
O6-benzylguanine-mediated enhancement of chemotherapy.
Neoplasms
Octa-substituted anionic porphyrins: topoisomerase I inhibition and tumor cell apoptosis induction.
Neoplasms
Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis and biological evaluation.
Neoplasms
On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents.
Neoplasms
Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
Neoplasms
Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells.
Neoplasms
Over-expression of TOP2A as a prognostic biomarker in patients with glioma.
Neoplasms
Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.
Neoplasms
Overview of studies on experimental radioimmunotherapy.
Neoplasms
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.
Neoplasms
p53 stimulates human topoisomerase I activity by modulating its DNA binding.
Neoplasms
Palladium(ii) complexes with thiosemicarbazones derived from pyrene as topoisomerase IB inhibitors.
Neoplasms
Paradoxical effects of ethoxidine, a topoisomerase I inhibitor, in the cellular processes leading to angiogenesis on endothelial cells.
Neoplasms
PARP inhibitors for cancer therapy.
Neoplasms
Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitrocamptothecin.
Neoplasms
Pathobiologic characteristics of hereditary breast cancer.
Neoplasms
Pathway Engineering of Anthracyclines: Blazing Trails in Natural Product Glycodiversification.
Neoplasms
Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Neoplasms
Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide.
Neoplasms
Personalized Drug Efficacy Monitoring Chip.
Neoplasms
PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy.
Neoplasms
pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine.
Neoplasms
Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Neoplasms
Pharmacogenetics of irinotecan.
Neoplasms
Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin.
Neoplasms
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
Neoplasms
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Neoplasms
Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.
Neoplasms
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
Neoplasms
Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
Neoplasms
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
Neoplasms
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Neoplasms
Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Neoplasms
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Neoplasms
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Neoplasms
Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.
Neoplasms
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
Neoplasms
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Neoplasms
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
Neoplasms
Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide.
Neoplasms
Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Neoplasms
Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
Neoplasms
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Neoplasms
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Neoplasms
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Neoplasms
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.
Neoplasms
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Neoplasms
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Neoplasms
Phase I study of docetaxel and topotecan in patients with solid tumors.
Neoplasms
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas.
Neoplasms
Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors.
Neoplasms
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
Neoplasms
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.
Neoplasms
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
Neoplasms
Phase II data on paclitaxel and docetaxel in gastrointestinal malignancies.
Neoplasms
Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
Neoplasms
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Neoplasms
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
Neoplasms
Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group.
Neoplasms
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
Neoplasms
Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
Neoplasms
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
Neoplasms
Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study.
Neoplasms
Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.
Neoplasms
Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex.
Neoplasms
Phosphate ester derivatives of homocamptothecin: synthesis, solution stabilities and antitumor activities.
Neoplasms
Phospholipid Fatty Acid Composition and Diamine Oxidase Activity of Intestinal Mucosa From Rats Treated With Irinotecan Hydrochloride (CPT-11) under Vegetable Oil-Enriched Diets: Comparison Between Perilla Oil and Corn Oil.
Neoplasms
Phosphorylation of DNA topoisomerase I is increased during the response of mammalian cells to mitogenic stimuli.
Neoplasms
Phosphorylation of human topoisomerase I by protein kinase C in vitro and in phorbol 12-myristate 13-acetate-activated HL-60 promyelocytic leukaemia cells.
Neoplasms
Photochemical properties of camptothecin in the presence of copper(II) ions: the role of radicals as prospective species in photodynamic therapy.
Neoplasms
Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.
Neoplasms
Poly(D,L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin.
Neoplasms
Potent and sustained inhibition of HIF-1? and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Neoplasms
Potent cytotoxic arylnaphthalene lignan lactones from Phyllanthus poilanei.
Neoplasms
Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Neoplasms
Potential use of Pichia pastoris strain SMD1168H expressing DNA topoisomerase I in the screening of potential anti?breast cancer agents.
Neoplasms
Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
Neoplasms
Potentiation of radioimmunotherapy by inhibition of topoisomerase I.
Neoplasms
Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.
Neoplasms
Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
Neoplasms
Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
Neoplasms
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.
Neoplasms
Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies.
Neoplasms
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
Neoplasms
Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling.
Neoplasms
Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Neoplasms
Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Neoplasms
Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.
Neoplasms
Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-kappaB activation in drug resistance.
Neoplasms
Pro-Angiogenic Effects of Low Dose Ethoxidine in a Murine Model of Ischemic Hindlimb: Correlation between Ethoxidine Levels and Increased Activation of the Nitric Oxide Pathway.
Neoplasms
Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Neoplasms
Prognostic Significance of p27, Ki-67, and Topoisomerase lla Expression in Clinically Nonfunctioning Pancreatic Endocrine Tumors.
Neoplasms
Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor.
Neoplasms
Proliferative markers in diagnosis of thyroid tumors: a comparative study of MIB-1 and topoisomerase II-a immunostaining.
Neoplasms
Promising new developments in cancer chemotherapy.
Neoplasms
Prostaglandins Isolated from the Octocoral Plexaura homomalla: In Silico and In Vitro Studies Against Different Enzymes of Cancer.
Neoplasms
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Neoplasms
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Neoplasms
Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Neoplasms
Protein Expression Profiles Indicative for Drug Resistance of Kidney Carcinoma.
Neoplasms
Protein kinase C phosphorylates DNA topoisomerase I.
Neoplasms
Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines.
Neoplasms
Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison.
Neoplasms
Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor.
Neoplasms
Proteomic Analysis of Nuclei Isolated from Cancer Cell Lines Treated with Indenoisoquinoline NSC 724998, a Novel Topoisomerase I Inhibitor.
Neoplasms
Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin's lymphoma.
Neoplasms
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
Neoplasms
Pyranicin, a non-classical annonaceous acetogenin, is a potent inhibitor of DNA polymerase, topoisomerase and human cancer cell growth.
Neoplasms
Pyrrolo[2,3-?]carbazole derivatives as topoisomerase I inhibitors that affect viability of glioma and endothelial cells in vitro and angiogenesis in vivo.
Neoplasms
QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase II?.
Neoplasms
QSAR modeling on benzo[c]phenanthridine analogues as topoisomerase I inhibitors and anti-cancer agents.
Neoplasms
Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
Neoplasms
Quantitative microscopy of human DNA topoisomerase II-alpha expression in transitional cell carcinoma of the bladder.
Neoplasms
Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies.
Neoplasms
Quinazolinecarboline alkaloid evodiamine as scaffold for targeting topoisomerase I and sirtuins.
Neoplasms
Quinolino[3,4-b]quinoxalines and pyridazino[4,3-c]quinoline derivatives: Synthesis, inhibition of topoisomerase II?, G-quadruplex binding and cytotoxic properties.
Neoplasms
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Neoplasms
Radiological and Pathological Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Brief Literature Review.
Neoplasms
Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
Neoplasms
Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species.
Neoplasms
Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers.
Neoplasms
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Neoplasms
Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
Neoplasms
Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies.
Neoplasms
Real-time investigation of human topoisomerase I reaction kinetics using an optical sensor: a fast method for drug screening and determination of active enzyme concentrations.
Neoplasms
Rearrangement of the Myeloid/Lymphoid Leukemia Gene in Therapy-Related Myelodysplastic Syndrome in Patients Previously Treated with Agents Targeting DNA Topoisomerase II.
Neoplasms
Recapitulation of Werner syndrome sensitivity to camptothecin by limited knockdown of the WRN helicase/exonuclease.
Neoplasms
Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy.
Neoplasms
Recent Development in Nano-sized Dosage Forms of Plant Alkaloid Camptothecin-Derived Drugs.
Neoplasms
Recent developments in mushrooms as anti-cancer therapeutics: a review.
Neoplasms
Recent Developments in Oxazole Derivatives as Anticancer Agents: Review on Synthetic Strategies, Mechanism of Action and SAR studies.
Neoplasms
Recent developments in topoisomerase-targeted cancer chemotherapy.
Neoplasms
Recent Developments on Thiourea Based Anticancer Chemotherapeutics.
Neoplasms
Recifin A, Initial Example of the Tyr-Lock Peptide Structural Family, Is a Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I.
Neoplasms
RecQ helicases and topoisomerase III in cancer and aging.
Neoplasms
Recurrent Glioblastomas Exhibit Higher Expression of Biomarkers with Stem-like Properties.
Neoplasms
Redox responsive 7-ethyl-10-hydroxycamptothecin (SN38) lysophospholipid conjugate: synthesis, assembly and anticancer evaluation.
Neoplasms
Regulation of p14ARF through subnuclear compartmentalization.
Neoplasms
Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts.
Neoplasms
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Neoplasms
Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.
Neoplasms
Replication-deficient adenovirus induces host topoisomerase I activity: implications for adenovirus-mediated gene expression.
Neoplasms
Replication-dependent and transcription-dependent mechanisms of DNA double-strand break induction by the topoisomerase 2-targeting drug etoposide.
Neoplasms
Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.
Neoplasms
Resistance-associated signatures in breast cancer.
Neoplasms
Resveratrol acts as a topoisomerase II poison in human glioma cells.
Neoplasms
Resveratrol-3-O-glucuronide and resveratrol-4'-O-glucuronide reduce DNA strand breakage but not apoptosis in Jurkat T cells treated with camptothecin.
Neoplasms
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Neoplasms
Ring fusion strategy for the synthesis of anthra[2,3-d]oxazole-2-thione-5,10-dione homologues as DNA topoisomerase inhibitors and as antitumor agents.
Neoplasms
Robustadial A and B from Eucalyptus globulus Labill. and their anticancer activity as selective tyrosyl-DNA phosphodiesterase 2 inhibitors.
Neoplasms
Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells.
Neoplasms
Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide.
Neoplasms
Role of folylpolygutamate synthetase (FPGS) in antifolate chemotherapy; a biochemical and clinical update.
Neoplasms
Role of human topoisomerase IB on ionizing radiation induced damage.
Neoplasms
Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents.
Neoplasms
Role of nucleotide excision repair proteins in response to DNA damage induced by topoisomerase II inhibitors.
Neoplasms
Role of the protein in the DNA sequence specificity of the cleavage site stabilized by the camptothecin topoisomerase IB inhibitor: a metadynamics study.
Neoplasms
Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: associations with clinicopathological and molecular features.
Neoplasms
Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.
Neoplasms
Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells.
Neoplasms
Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Neoplasms
Ruthenium(II) Diphosphine Complexes with Mercapto Ligands That Inhibit Topoisomerase IB and Suppress Tumor Growth In Vivo.
Neoplasms
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
Neoplasms
Sacituzumab Govitecan: First Approval.
Neoplasms
Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Neoplasms
Sarcoma chemotherapy.
Neoplasms
Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
Neoplasms
Screening of mammalian DNA polymerase and topoisomerase inhibitors from Garcinia mangostana L. and analysis of human cancer cell proliferation and apoptosis.
Neoplasms
Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis.
Neoplasms
Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I.
Neoplasms
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.
Neoplasms
Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor.
Neoplasms
Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells.
Neoplasms
Self-resistance guided genome mining uncovers new topoisomerase inhibitors from myxobacteria.
Neoplasms
Semi-quantitative analysis of DNA topoisomerase-I mRNA level using reverse transcription-polymerase chain reaction in cancer cell lines: its relation to cytotoxicity against camptothecin derivative.
Neoplasms
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Neoplasms
Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression.
Neoplasms
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Neoplasms
Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules.
Neoplasms
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.
Neoplasms
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Neoplasms
Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.
Neoplasms
Serine phosphorylation-dependent coregulation of topoisomerase I by the p14ARF tumor suppressor.
Neoplasms
Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer.
Neoplasms
Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.
Neoplasms
Silicon-containing analogs of camptothecin as anticancer agents.
Neoplasms
Silver Nanoparticles Potentiates Cytotoxicity and Apoptotic Potential of Camptothecin in Human Cervical Cancer Cells.
Neoplasms
Simian virus 40 (SV40) DNA replication: SV40 large T antigen unwinds DNA containing the SV40 origin of replication.
Neoplasms
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Neoplasms
SLFN11: Achilles' Heel or Troublemaker.
Neoplasms
SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy.
Neoplasms
Special Issue "Anticancer Drugs".
Neoplasms
Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.
Neoplasms
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Neoplasms
STEALTH liposomal CKD-602, a topoisomerase II inhibitor, improves the therapeutic index in human tumor xenograft models.
Neoplasms
Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
Neoplasms
Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes.
Neoplasms
Structural and mechanistic bases of the anticancer activity of natural aporphinoid alkaloids.
Neoplasms
Structural modification of 3-arylisoquinolines to isoindolo[2,1-b]isoquinolinones for the development of novel topoisomerase 1 inhibitors with molecular docking study.
Neoplasms
Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Neoplasms
Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.
Neoplasms
Structure and function of DNA-binding proteins.
Neoplasms
Structure-based discovery of cytotoxic dimeric tetrahydroxanthones as potential topoisomerase I inhibitors from a marine-derived fungus.
Neoplasms
Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase II?.
Neoplasms
Studies on the initiation and elongation reactions in the simian virus 40 DNA replication system.
Neoplasms
Studies on the initiation of simian virus 40 replication in vitro: RNA primer synthesis and its elongation.
Neoplasms
Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
Neoplasms
Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status.
Neoplasms
Substituted dibenzo[c,h]cinnolines: topoisomerase I-targeting anticancer agents.
Neoplasms
Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts.
Neoplasms
Suppression of Reserve MCM Complexes Chemosensitizes to Gemcitabine and 5-Fluorouracil.
Neoplasms
Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro.
Neoplasms
Suzuki coupling based synthesis and in vitro cytotoxic evaluation of 7-heteroaryl-substituted camptothecin analogs.
Neoplasms
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Neoplasms
Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.
Neoplasms
Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity.
Neoplasms
Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864).
Neoplasms
Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Neoplasms
Synergistic enhancement of topotecan-induced cell death by ascorbic acid in human breast MCF-7 tumor cells.
Neoplasms
Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
Neoplasms
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Neoplasms
Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II.
Neoplasms
Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Neoplasms
Syntheses and antiproliferative activities of 7-azarebeccamycin analogues bearing one 7-azaindole moiety.
Neoplasms
Syntheses, molecular targets and antitumor activities of novel triptycene bisquinones and 1,4-anthracenedione analogs.
Neoplasms
Synthesis and Anticancer Activity Evaluation of Novel Phenanthridine Derivatives.
Neoplasms
Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.
Neoplasms
Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2.
Neoplasms
Synthesis and antiproliferative evaluation of certain indolo[3,2-c]quinoline derivatives.
Neoplasms
Synthesis and antitumor activity of novel 10-substituted camptothecin analogues.
Neoplasms
Synthesis and antitumor activity of some indeno[1,2-b]quinoline-based bis carboxamides.
Neoplasms
Synthesis and antitumor characterization of pyrazolic analogues of the marine pyrroloquinoline alkaloids: wakayin and tsitsikammamines.
Neoplasms
Synthesis and bioevaluation of 22-hydroxyacuminatine analogs.
Neoplasms
Synthesis and biological activity of 2,4-di-p-phenolyl-6-2-furanyl-pyridine as a potent topoisomerase II poison.
Neoplasms
Synthesis and biological activity of ferrocenyl indeno[1,2-c]isoquinolines as topoisomerase II inhibitors.
Neoplasms
Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.
Neoplasms
Synthesis and biological evaluation of 2-phenol-4-chlorophenyl-6-aryl pyridines as topoisomerase II inhibitors and cytotoxic agents.
Neoplasms
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-?-benzyl ester derivatives as potent topoisomerase II? inhibitors.
Neoplasms
Synthesis and characterization of Cu(II)-based anticancer chemotherapeutic agent targeting topoisomerase I?: in vitro DNA binding, pBR322 cleavage, molecular docking studies and cytotoxicity against human cancer cell lines.
Neoplasms
Synthesis and crystal structure determination of copper(II)-complex: In vitro DNA and HSA binding, pBR322 plasmid cleavage, cell imaging and cytotoxic studies.
Neoplasms
SYNTHESIS AND CYTOTOXIC ACTIVITY OF NEW 5H-INDOLO[2,3-B]QUINOLINE O-AMINOGLYCOSIDES.
Neoplasms
Synthesis and cytotoxic activity of substituted 7-aryliminomethyl derivatives of camptothecin.
Neoplasms
Synthesis and evaluation of ether-linked demethylepipodophyllotoxin dimers.
Neoplasms
Synthesis and Evaluation of New Naphthalene and Naphthoquinone Derivatives as Anticancer Agents.
Neoplasms
Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
Neoplasms
Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis.
Neoplasms
Synthesis and SAR study of new hydroxy and chloro-substituted 2,4-diphenyl 5H-chromeno[4,3-b]pyridines as selective topoisomerase II?-targeting anticancer agents.
Neoplasms
Synthesis and structure-activity relationship study of potent cytotoxic analogues of the marine alkaloid Lamellarin D.
Neoplasms
Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Neoplasms
Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Neoplasms
Synthesis of a DNA-targeting nickel (II) complex with testosterone thiosemicarbazone which exhibits selective cytotoxicity towards human prostate cancer cells (LNCaP).
Neoplasms
Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons.
Neoplasms
Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer.
Neoplasms
Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model.
Neoplasms
Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.
Neoplasms
Synthesis of novel C5-curcuminoid-fatty acid conjugates and mechanistic investigation of their anticancer activity.
Neoplasms
Synthesis of podophyllotoxin congeners as potential DNA topoisomerase II inhibitors.
Neoplasms
Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors.
Neoplasms
Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
Neoplasms
Synthesis, cytotoxicity and topoisomerase inhibition properties of multifarious aminoalkylated indeno[1,2-c]isoquinolin-5,11-diones.
Neoplasms
Synthesis, Resolution, and Biological Evaluation of Atropisomeric (aR)- and (aS)-16-Methyllamellarins N: Unique Effects of the Axial Chirality on the Selectivity of Protein Kinases Inhibition.
Neoplasms
Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of 2-phenyl- or hydroxylated 2-phenyl-4-aryl-5H-indeno[1,2-b]pyridines.
Neoplasms
Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines.
Neoplasms
Synthesis, topoisomerase I inhibition and antitumor cytotoxicity of 2,2':6',2"-, 2,2':6',3"- and 2,2':6',4"-terpyridine derivatives.
Neoplasms
Synthetic Cytotoxicity: Digenic Interactions with TEL1/ATM Mutations Reveal Sensitivity to Low Doses of Camptothecin.
Neoplasms
Tacrine-Coumarin Derivatives as Topoisomerase Inhibitors with Antitumor Effects on A549 Human Lung Carcinoma Cancer Cell Lines.
Neoplasms
Tailored immunoconjugate therapy depending on a quantity of tumor stroma.
Neoplasms
Targeted radiosensitization with DNA topoisomerase I drugs.
Neoplasms
Targeting cell cycle by ?-carboline alkaloids in vitro: Novel therapeutic prospects for the treatment of cancer.
Neoplasms
Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies.
Neoplasms
Targeting DNA Topoisomerase I with Non-Camptothecin Poisons.
Neoplasms
Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer.
Neoplasms
Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
Neoplasms
Targeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin.
Neoplasms
Targeting topoisomerase I to inhibit hypoxia inducible factor 1.
Neoplasms
Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors.
Neoplasms
Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
Neoplasms
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
Neoplasms
TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy.
Neoplasms
Tdp1 processes chromate-induced single-strand DNA breaks that collapse replication forks.
Neoplasms
Template supercoiling during ATP-dependent DNA helix tracking: studies with simian virus 40 large tumor antigen.
Neoplasms
Terbenzimidazoles: influence of 2"-, 4-, and 5-substituents on cytotoxicity and relative potency as topoisomerase I poisons.
Neoplasms
Thapsigargin enhances camptothecin-induced apoptosis in cardiomyocytes.
Neoplasms
The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration.
Neoplasms
The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase II?.
Neoplasms
The antileukemia activity of natural product HQ17(3) is possibly associated with downregulation of miR-17-92 cluster.
Neoplasms
The antitumor and antimetastatic effects of N-trimethyl chitosan-encapsulated camptothecin on ovarian cancer with minimal side effects.
Neoplasms
The Association Between HSP90/topoisomerase I Immunophenotype and the Clinical Features of Colorectal Cancers in Respect to KRAS Gene Status.
Neoplasms
The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Neoplasms
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
Neoplasms
The broken genome: genetic and pharmacologic approaches to breaking DNA.
Neoplasms
The chemosensitivity profile of retinoblastoma.
Neoplasms
The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells.
Neoplasms
The collective nuclear migration of p53 and phosphorylated S473 of Akt during ellipticine-mediated apoptosis in human lung epithelial cancer cells.
Neoplasms
The combination of A-966492 and Topotecan for effective radiosensitization on glioblastoma spheroids.
Neoplasms
The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes.
Neoplasms
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
Neoplasms
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
Neoplasms
The development of camptothecin analogs in childhood cancers.
Neoplasms
The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells.
Neoplasms
The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.
Neoplasms
The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.
Neoplasms
The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53.
Neoplasms
The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells.
Neoplasms
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
Neoplasms
The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases.
Neoplasms
The effects of camptothecin on RNA polymerase II transcription: roles of DNA topoisomerase I.
Neoplasms
The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells.
Neoplasms
The expression and significance of MRP1, LRP, TOPOII?, and BCL2 in tongue squamous cell carcinoma.
Neoplasms
The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11.
Neoplasms
The genetic consequences of ablating helicase activity and the Top3 interaction domain of Sgs1.
Neoplasms
The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumor-bearing mice.
Neoplasms
The Human Tyrosyl-DNA Phosphodiesterase 1 (hTdp1) Inhibitor NSC120686 as an Exploratory Tool to Investigate Plant Tdp1 Genes.
Neoplasms
The impact of tumor physiology on camptothecin-based drug development.
Neoplasms
The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
Neoplasms
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
Neoplasms
The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
Neoplasms
The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.
Neoplasms
The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase.
Neoplasms
The interaction between CtIP and BRCA1 is not essential for resection-mediated DNA repair or tumor suppression.
Neoplasms
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.
Neoplasms
The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1? activity by changing miR expression patterns in human cancer cells.
Neoplasms
The p14ARF alternate reading frame protein enhances DNA binding of topoisomerase I by interacting with the serine 506-phosphorylated core domain.
Neoplasms
The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
Neoplasms
The predictive and prognostic significance of pre- and post-treatment topoisomerase II? in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Neoplasms
The relation of pituitary adenomas invasiveness and the proliferative index measured by immunoexpression of topoisomerase II?.
Neoplasms
The relationship between the molecular structure of natural acetogenins and their inhibitory activities which affect DNA polymerase, DNA topoisomerase and human cancer cell growth.
Neoplasms
The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes.
Neoplasms
The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.
Neoplasms
The Role of the MAPK Signaling, Topoisomerase and Dietary Bioactives in Controlling Cancer Incidence.
Neoplasms
The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
Neoplasms
The role of topoisomerase II? in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
Neoplasms
The significance of the sequence of administration of topotecan and etoposide.
Neoplasms
The Structure of DNA-Bound Human Topoisomerase II Alpha: Conformational Mechanisms for Coordinating Inter-Subunit Interactions with DNA Cleavage.
Neoplasms
The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
Neoplasms
The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
Neoplasms
The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor.
Neoplasms
The topoisomerase II-inhibitor NC-190 reduces the level of thymidine kinase mRNA in murine tumor cells.
Neoplasms
The tumor suppressor protein p53 stimulates the formation of the human topoisomerase I double cleavage complex in vitro.
Neoplasms
The use of olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Neoplasms
The use of topoisomerase I inhibitors in multiple myeloma.
Neoplasms
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Neoplasms
Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.
Neoplasms
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond.
Neoplasms
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Neoplasms
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
Neoplasms
Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment.
Neoplasms
Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
Neoplasms
Therapeutic targets in subependymoma.
Neoplasms
Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma.
Neoplasms
Therapy-related acute myeloid leukemia following HIV-associated lymphoma.
Neoplasms
Therapy-related acute promyelocytic leukaemia.
Neoplasms
Therapy-related acute promyelocytic leukemia.
Neoplasms
Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl- secretion in isolated rat colon.
Neoplasms
Thymoquinone-chemotherapeutic combinations: new regimen to combat cancer and cancer stem cells.
Neoplasms
TIMP-1 Increases Expression and Phosphorylation of Proteins Associated with Drug Resistance in Breast Cancer Cells.
Neoplasms
TOP2? Is Essential for Ovarian Follicles That Are Hypersensitive to Chemotherapeutic Drugs.
Neoplasms
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Neoplasms
TOP2A Promotes Lung Adenocarcinoma Cells' Malignant Progression and Predicts Poor Prognosis in Lung Adenocarcinoma.
Neoplasms
TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53.
Neoplasms
TopBP1 promotes malignant progression and correlates with poor prognosis in osteosarcoma.
Neoplasms
TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.
Neoplasms
Topo II? gene alterations correlated with survival in patients with diffuse large B-cell lymphoma.
Neoplasms
Topoisomerase 1 inhibition reversibly impairs synaptic function.
Neoplasms
Topoisomerase 1 inhibitors and cancer therapy.
Neoplasms
Topoisomerase 1B poisons: Over a half-century of drug leads, clinical candidates, and serendipitous discoveries.
Neoplasms
Topoisomerase 2? and thymidylate synthase expression in adrenocortical cancer.
Neoplasms
Topoisomerase 2alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia.
Neoplasms
Topoisomerase activity associated with polyoma virus large tumor antigen.
Neoplasms
Topoisomerase activity associated with SV40 large tumor antigen.
Neoplasms
Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Neoplasms
Topoisomerase enzymes as therapeutic targets for cancer chemotherapy.
Neoplasms
Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.
Neoplasms
Topoisomerase expression in cancer cell lines and clinical samples.
Neoplasms
Topoisomerase expression in oral squamous cell carcinoma: relationship with cancer stem cells profiles and lymph node metastasis.
Neoplasms
Topoisomerase I activity in squamous cell carcinoma of the head and neck.
Neoplasms
Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis.
Neoplasms
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer.
Neoplasms
Topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of dihydroxylated 2,6-diphenyl-4-aryl pyridines.
Neoplasms
Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.
Neoplasms
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Neoplasms
Topoisomerase I deregulation in laryngeal squamous cell carcinomas based on tissue microarray analysis.
Neoplasms
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.
Neoplasms
Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
Neoplasms
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Neoplasms
Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types.
Neoplasms
Topoisomerase I inactivation by reticulol and its in vivo cytotoxicity against B16F10 melanoma.
Neoplasms
Topoisomerase I inhibition and cytotoxicity of licochalcones A and E from Glycyrrhiza inflata.
Neoplasms
Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic.
Neoplasms
Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets.
Neoplasms
Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues.
Neoplasms
Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity.
Neoplasms
Topoisomerase I inhibitors in the combined modality therapy of lung cancer.
Neoplasms
Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.
Neoplasms
Topoisomerase I Inhibitors in the Treatment of Primary CNS Malignancies: An Update on Recent Trends.
Neoplasms
Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends.
Neoplasms
Topoisomerase I Inhibitors.
Neoplasms
Topoisomerase I interactive drugs in children with cancer.
Neoplasms
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
Neoplasms
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.
Neoplasms
Topoisomerase I poisoning results in PARP-mediated replication fork reversal.
Neoplasms
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
Neoplasms
Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy.
Neoplasms
Topoisomerase I targeting agents in small-cell lung cancer.
Neoplasms
Topoisomerase I, II{alpha} and II{beta} mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results.
Neoplasms
Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11.
Neoplasms
Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
Neoplasms
Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.
Neoplasms
Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.
Neoplasms
Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy.
Neoplasms
Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.
Neoplasms
Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy.
Neoplasms
Topoisomerase II-alpha as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.
Neoplasms
Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.
Neoplasms
Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.
Neoplasms
Topoisomerase II-mediated DNA damage of episomes in tumor-bearing mice.
Neoplasms
Topoisomerase II? immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer Group.
Neoplasms
Topoisomerase II? in chromosome instability and personalized cancer therapy.
Neoplasms
Topoisomerase II? promotes activation of RNA polymerase I transcription by facilitating pre-initiation complex formation.
Neoplasms
Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.
Neoplasms
Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
Neoplasms
Topoisomerase inhibitor coralyne photosensitizes DNA, leading to elicitation of Chk2-dependent S-phase checkpoint and p53-independent apoptosis in cancer cells.
Neoplasms
Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy.
Neoplasms
Topoisomerase Inhibitors Conference, University of Maryland Cancer Center. Proceedings. Monterey, California, 27-30 October 1993.
Neoplasms
Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells.
Neoplasms
Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells.
Neoplasms
Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway.
Neoplasms
Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
Neoplasms
Topoisomerase inhibitors: Pharmacology and emerging nanoscale delivery systems.
Neoplasms
Topoisomerase levels determine chemotherapy response in vitro and in vivo.
Neoplasms
Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Neoplasms
Topoisomerase-I inhibitors in gynaecologic tumours.
Neoplasms
Topoisomerase-I inhibitors in gynecologic tumors.
Neoplasms
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Neoplasms
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
Neoplasms
Topoisomerase-targeting antitumor drugs.
Neoplasms
Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck.
Neoplasms
topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage.
Neoplasms
Topotecan in combination chemotherapy.
Neoplasms
Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study.
Neoplasms
Topotecan in the treatment of non-small cell lung cancer.
Neoplasms
Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Neoplasms
Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice.
Neoplasms
Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3 mediated Bid cleavage.
Neoplasms
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
Neoplasms
Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Neoplasms
Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival.
Neoplasms
Topotecan. A review of its potential in advanced ovarian cancer.
Neoplasms
Topotecan: Incorporating It Into the Treatment of Solid Tumors.
Neoplasms
Toxicity of the topoisomerase I inhibitors.
Neoplasms
Transcription-associated DNA breaks and cancer: A matter of DNA topology.
Neoplasms
Transcription-dependent activation of ataxia telangiectasia-mutated prevents DNA-dependent protein kinase-mediated cell death in response to topoisomerase I poison.
Neoplasms
Transcription-dependent DNA double-strand breaks and human disease.
Neoplasms
Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid.
Neoplasms
Trastuzumab Deruxtecan: First Approval.
Neoplasms
Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.
Neoplasms
Trifluoromethyl-promoted homocamptothecins: Synthesis and biological activity.
Neoplasms
Triggering of Suicidal Erythrocyte Death by Topotecan.
Neoplasms
Triple helix-forming oligonucleotides conjugated to indolocarbazole poisons direct topoisomerase I-mediated DNA cleavage to a specific site.
Neoplasms
Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.
Neoplasms
Tumor Physiology and Charge Dynamics of Anticancer Drugs: Implications for Camptothecin-based Drug Development.
Neoplasms
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Neoplasms
Tumor- and stromal cell-specific expression of topoisomerase II? and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study.
Neoplasms
Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity.
Neoplasms
Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent.
Neoplasms
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.
Neoplasms
Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors.
Neoplasms
Tyrosyl-DNA phosphodiesterase 1 targeting for modulation of camptothecin-based treatment.
Neoplasms
Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
Neoplasms
Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.
Neoplasms
Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide.
Neoplasms
Unique Polyhalogenated Peptides from the Marine Sponge Ircinia sp.
Neoplasms
Untangling trapped topoisomerases with tyrosyl-DNA phosphodiesterases.
Neoplasms
Update on the treatment of cervical and uterine carcinoma: focus on topotecan.
Neoplasms
Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development.
Neoplasms
Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy-Modulators of Cellular Entry or Pharmacokinetics?
Neoplasms
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
Neoplasms
VIRTUAL SCREENING FOR THE DEVELOPMENT OF DUAL-INHIBITORS TARGETING TOPOISOMERASE IB AND TYROSYL-DNA PHOSPHODIESTERASE 1.
Neoplasms
Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism.
Neoplasms
Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
Neoplasms
Werner Syndrome Protein Expression in Breast Cancer.
Neoplasms
When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy.
Neoplasms
WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Neoplasms
Xanthocidin derivatives as topoisomerase II? enzymatic inhibitors.
Neoplasms
Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction.
Neoplasms
ZD9331 in combination with topotecan: phase I and II experience.
Neoplasms
[Activity of topoisomerase I and endonucleases in cells transfected by a ras oncogene]
Neoplasms
[Advance on study in anti-tumor mechamism of bererine (Ber)]
Neoplasms
[Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent--the in vitro evaluation]
Neoplasms
[DNA topoisomerase inhibitor]
Neoplasms
[DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance]
Neoplasms
[Drug resistance mediated by ABC transporters]
Neoplasms
[Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo]
Neoplasms
[Effects of hydroxycamptothecin and teniposide on proliferation and apoptosis of gastric cancer cell line BGC-823]
Neoplasms
[Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer]
Neoplasms
[Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma]
Neoplasms
[Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]
Neoplasms
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Neoplasms
[Immunohistochemical evaluation of topoisomerase IIalpha as proliferation factor in gastric lymphoma]
Neoplasms
[Inhibition of mixture of lucid garoderma and lucid garoderma spore on tumor cell in vitro and in vivo]
Neoplasms
[Inhibitors of DNA topoisomerases]
Neoplasms
[Inhibitory effect of galangin on DNA topoisomerases in lung cancer cells].
Neoplasms
[Late sequelae of oncologic treatment in children]
Neoplasms
[Mechanisms of acquired resistance to DNA topoisomerase I inhibitors]
Neoplasms
[Multidrug resistance]
Neoplasms
[New cytotoxics in the treatment of bronchial cancers]
Neoplasms
[Pharmacology of camptothecin and its derivatives]
Neoplasms
[Preclinical trials from the standpoint of clinical trials]
Neoplasms
[Preliminary study of apoptosis of human hepatocarcinoma cell line HepG2 induced by topotecan]
Neoplasms
[Preliminary study of lyophilized 10-hydroxycamptothecin in advanced or recurrent malignancies]
Neoplasms
[Principles of drug therapy of malignant tumors: determinants of the efficacy of cytostatic agents]
Neoplasms
[Recent trend on the development of new anticancer drugs]
Neoplasms
[Response of metastatic colorectal cancers to treatment with CPT11 (irinotecan): implications of the mismatched base repair system]
Neoplasms
[Synthesis of camptothecin glycosides by phase transfer-catalysis and its inhibitory activity against topo I]
Neoplasms
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials]
Neoplasms
[The activity of nuclear endonucleases and topoisomerases in the liver of rats and in diethylnitrosamine-induced tumors]
Neoplasms
[The synergistic antitumor effects of berberine alpha-hydroxy-beta-decanoylethyl sulfonate with hydroxycamptothecine and its effect on topoisomerase].
Neoplasms
[Topotecan for pediatric patients with resistant and recurrent solid tumors]
Neoplasms
[Treatment of small-cell lung cancer].
Neoplasms, Germ Cell and Embryonal
A phase II single institution single arm prospective study with paclitaxel, ifosfamide and cisplatin (TIP) as first-line chemotherapy in high-risk germ cell tumor patients with more than ten years follow-up and retrospective correlation with ERCC1, Topoisomerase 1, 2A, p53 and HER-2 expression.
Neoplasms, Germ Cell and Embryonal
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Neoplasms, Second Primary
Childhood cancer: improved prospects for survival but is prevention possible?
Neoplasms, Second Primary
Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
Neoplasms, Squamous Cell
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
Neoplasms, Squamous Cell
CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.
Neoplasms, Squamous Cell
The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11.
Neoplastic Cells, Circulating
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.
Nephritis, Hereditary
Topoisomerase I and II consensus sequences in a 17-kb deletion junction of the COL4A5 and COL4A6 genes and immunohistochemical analysis of esophageal leiomyomatosis associated with Alport syndrome.
Nerve Sheath Neoplasms
Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors.
Nervous System Diseases
Gold nanoparticles - an optical biosensor for RNA quantification for cancer and neurologic disorders diagnosis.
Nervous System Diseases
Transcription-dependent DNA double-strand breaks and human disease.
Nervous System Neoplasms
Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor.
Neuroblastoma
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
Neuroblastoma
A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines.
Neuroblastoma
Antibody-drug conjugate efficacy in neuroblastoma - role of payload, resistance mechanisms, target density, and antibody internalization.
Neuroblastoma
BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors.
Neuroblastoma
Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma.
Neuroblastoma
Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.
Neuroblastoma
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Neuroblastoma
DNA damage promotes herpes simplex virus-1 protein expression in a neuroblastoma cell line.
Neuroblastoma
DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
Neuroblastoma
Dual inhibition of MAGL and type II topoisomerase by N-phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth.
Neuroblastoma
Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma.
Neuroblastoma
Efficacy of oral irinotecan against neuroblastoma xenografts.
Neuroblastoma
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Neuroblastoma
Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.
Neuroblastoma
Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor.
Neuroblastoma
In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.
Neuroblastoma
No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
Neuroblastoma
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Neuroblastoma
Suppressive effect of topoisomerase inhibitors on JC polyomavirus propagation in human neuroblastoma cells.
Neuroblastoma
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Neuroblastoma
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Neuroblastoma
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Neuroblastoma
[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
Neurodegenerative Diseases
A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage.
Neurodegenerative Diseases
Chromatin remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability.
Neurodegenerative Diseases
Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC).
Neuroectodermal Tumors, Primitive, Peripheral
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Neurofibroma
Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours - A prognostic test after surgical resection.
Neurofibrosarcoma
Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors.
Neurofibrosarcoma
Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours - A prognostic test after surgical resection.
Neutropenia
Circadian rhythm of irinotecan tolerability in mice.
Neutropenia
Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11.
Neutropenia
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
Neutropenia
Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
Neutropenia
Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitor.
Neutropenia
Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs.
Neutropenia
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan]
Nevus
Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
Nevus, Pigmented
Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.
Oligodendroglioma
The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas.
Oligospermia
Decrease of topoisomerase I activity in the testes of infertile men with varicocele.
Onychomycosis
Evaluation of PCR for the diagnosis of dermatophytes in nail specimens from patients with suspected onychomycosis.
Opportunistic Infections
Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
Osteosarcoma
Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.
Osteosarcoma
Different types of DNA cleavage involved in osteosarcoma cell death.
Osteosarcoma
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Osteosarcoma
Parathyroid hormone regulates the expression of rat osteoblast and osteosarcoma nuclear matrix proteins.
Osteosarcoma
pRb suppresses camptothecin-induced apoptosis in human osteosarcoma Saos-2 cells by inhibiting c-Jun N-terminal kinase.
Osteosarcoma
Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse.
Ovarian Neoplasms
A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients.
Ovarian Neoplasms
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Ovarian Neoplasms
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
Ovarian Neoplasms
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
Ovarian Neoplasms
Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.
Ovarian Neoplasms
Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells.
Ovarian Neoplasms
Altered phosphorylation of topoisomerase I following overexpression in an ovarian cancer cell line.
Ovarian Neoplasms
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Ovarian Neoplasms
Chemosensitivity testing as an aid to anti-cancer drug and regimen development.
Ovarian Neoplasms
Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
Ovarian Neoplasms
Circumvention of atypical multidrug resistance with tumor necrosis factor.
Ovarian Neoplasms
Clinical applications of the camptothecins.
Ovarian Neoplasms
Clinical pharmacokinetics of topotecan.
Ovarian Neoplasms
Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells.
Ovarian Neoplasms
Cytoprotective activity of amifostine on cultured human lymphocytes exposed to irinotecan.
Ovarian Neoplasms
Daurinol, a catalytic inhibitor of topoisomerase II?, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase.
Ovarian Neoplasms
Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance.
Ovarian Neoplasms
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
Ovarian Neoplasms
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Ovarian Neoplasms
DNA-topoisomerase I activity and content in epithelial ovarian cancer.
Ovarian Neoplasms
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer.
Ovarian Neoplasms
EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs.
Ovarian Neoplasms
Efficacy and Toxicity of Belotecan With and Without Cisplatin in Patients With Recurrent Ovarian Cancer.
Ovarian Neoplasms
Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.
Ovarian Neoplasms
Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents.
Ovarian Neoplasms
Ex vivo activity of XR5000 against solid tumors.
Ovarian Neoplasms
Glucose-regulated stresses induce resistance to camptothecin in human cancer cells.
Ovarian Neoplasms
Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas.
Ovarian Neoplasms
Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Ovarian Neoplasms
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.
Ovarian Neoplasms
Irinotecan in epithelial ovarian cancer.
Ovarian Neoplasms
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Ovarian Neoplasms
New non-cytotoxic approaches to ovarian cancer.
Ovarian Neoplasms
New options for the treatment of advanced ovarian cancer.
Ovarian Neoplasms
Ovarian cancer, from the laboratory to the clinic: challenges for the future.
Ovarian Neoplasms
Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.
Ovarian Neoplasms
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Ovarian Neoplasms
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.
Ovarian Neoplasms
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
Ovarian Neoplasms
Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Ovarian Neoplasms
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
Ovarian Neoplasms
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.
Ovarian Neoplasms
Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.
Ovarian Neoplasms
Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
Ovarian Neoplasms
Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.
Ovarian Neoplasms
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
Ovarian Neoplasms
Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.
Ovarian Neoplasms
Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks.
Ovarian Neoplasms
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Ovarian Neoplasms
Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer.
Ovarian Neoplasms
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
Ovarian Neoplasms
The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.
Ovarian Neoplasms
The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
Ovarian Neoplasms
The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Ovarian Neoplasms
Topoisomerase 1 inhibitors and cancer therapy.
Ovarian Neoplasms
Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples.
Ovarian Neoplasms
Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study.
Ovarian Neoplasms
Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer.
Ovarian Neoplasms
Topotecan in the treatment of gynecologic cancer.
Ovarian Neoplasms
Transcriptome analysis of stem wood of Nothapodytes nimmoniana (Graham) Mabb. identifies genes associated with biosynthesis of camptothecin, an anti-carcinogenic molecule.
Ovarian Neoplasms
Triapine Disrupts CtIP-Mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors.
Ovarian Neoplasms
Tumor- and stromal cell-specific expression of topoisomerase II? and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study.
Ovarian Neoplasms
[DNA topoisomerase I inhibitor in the treatment of ovarian neoplasm]
Ovarian Neoplasms
[Promising new drugs for gynecological cancer]
Ovarian Neoplasms
[Topotecan: prospects for using it in combination therapy for ovarian carcinoma]
Ovarian Neoplasms
[Treatment of recurrent ovarian cancer]
Pancreatic Neoplasms
First-Line Treatment for Advanced Pancreatic Cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Pancreatic Neoplasms
Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Pancreatic Neoplasms
Irinotecan: 25 years of cancer treatment.
Pancreatic Neoplasms
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors.
Pancreatic Neoplasms
Phase II data on paclitaxel and docetaxel in gastrointestinal malignancies.
Pancreatic Neoplasms
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
Pancreatic Neoplasms
Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Pancreatic Neoplasms
Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures.
Pancreatic Neoplasms
The hydroxyquinoline analog YUM70 inhibits GRP78 to induce ER stress-mediated apoptosis in pancreatic cancer.
Pancreatic Neoplasms
Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Pancreatitis
Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan.
Papilloma
Human topoisomerase II-alpha is highly expressed in sinonasal-inverted papilloma, but not in inflammatory polyp.
Papilloma
Topoisomerase alpha II, retinoblastoma gene product, and p53: potential relationships with aggressive behavior and malignant transformation in recurrent respiratory papillomatosis.
Paralysis
DNA topoisomerase I inhibitors ameliorate seizure-like behaviors and paralysis in a Drosophila model of epilepsy.
Parasitic Diseases
Characterizing the bi-subunit type IB DNA topoisomerase of Leishmania parasites; a novel scenario for drug intervention in trypanosomatids.
Parkinson Disease
Down regulation of DNA topoisomerase II? exerts neurodegeneration like effect through Rho GTPases in cellular model of Parkinson's disease by Down regulating tyrosine hydroxylase.
Peptic Ulcer
Xer recombinase and genome integrity in Helicobacter pylori, a pathogen without topoisomerase IV.
Peripheral Nerve Injuries
Topoisomerase I inhibition and peripheral nerve injury induce DNA breaks and ATF3-associated axon regeneration in sensory neurons.
Peritoneal Neoplasms
Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis.
Pharyngitis
Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Pheochromocytoma
Inhibitory effect of the non-camptothecin topoisomerase I inhibitor LMP-400 on female mice models and human pheochromocytoma cells.
Pheochromocytoma
Low Doses of Camptothecin Induced Hormetic and Neuroprotective Effects in PC12 Cells.
Pheochromocytoma
Plasma membrane phospholipid asymmetry precedes DNA fragmentation in different apoptotic cell models.
Pheochromocytoma
Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
Pituitary Neoplasms
The relation of pituitary adenomas invasiveness and the proliferative index measured by immunoexpression of topoisomerase II?.
Pituitary Neoplasms
Topoisomerase II? as a prognostic factor in pituitary tumors.
Plasmacytoma
Eukaryotic DNA topoisomerase I reaction is topology dependent.
Pneumococcal Infections
Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.
Pneumococcal Infections
Nonoptimal DNA topoisomerases allow maintenance of supercoiling levels and improve fitness of Streptococcus pneumoniae.
Pneumococcal Infections
Seconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains.
Pneumonia
The frequency of DNA gyrase and topoisomerase IV mutations, and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
Polycystic Kidney Diseases
Altered gene expression pattern in cultured human breast cancer cells treated with hepatocyte growth factor/scatter factor in the setting of DNA damage.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activity of CoII-Quinalizarin: A Novel Analogue of Anthracycline-Based Anticancer Agents Targets Human DNA Topoisomerase, Whereas Quinalizarin Itself Acts via Formation of Semiquinone on Acute Lymphoblastic Leukemia MOLT-4 and HCT 116 Cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of functional markers in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Impact of Topoisomerase II alpha and spermine on the clinical outcome of children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Isolation of a mitochondrial DNA topoisomerase from human leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Prostatic Hyperplasia
Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma.
Prostatic Neoplasms
9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer.
Prostatic Neoplasms
A comparative study of protein profiling by proteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostate cancer cells.
Prostatic Neoplasms
A novel 1-((3-(2-toluyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-(trifluoromethyl)pyrimidin-2(1H)-one activates intrinsic mitochondria-dependent pathway and decreases angiogenesis in PC-3 cells.
Prostatic Neoplasms
A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
Prostatic Neoplasms
A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Prostatic Neoplasms
Adrenomedullin prevents apoptosis in prostate cancer cells.
Prostatic Neoplasms
beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells.
Prostatic Neoplasms
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response.
Prostatic Neoplasms
Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death.
Prostatic Neoplasms
Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells.
Prostatic Neoplasms
Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
Prostatic Neoplasms
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Prostatic Neoplasms
Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins.
Prostatic Neoplasms
Differences between latent and clinical prostate carcinomas: lower cell proliferation activity in latent cases.
Prostatic Neoplasms
DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selective prostate cancer cell targeting.
Prostatic Neoplasms
Dynamic Regulation of Rad51 by E2F1 and p53 in Prostate Cancer Cells upon DrugInduced DNA Damage under Hypoxia.
Prostatic Neoplasms
Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Prostatic Neoplasms
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.
Prostatic Neoplasms
Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells.
Prostatic Neoplasms
Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer.
Prostatic Neoplasms
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
Prostatic Neoplasms
Induction of DNA damage and ATF3 by retigeric acid B, a novel topoisomerase II inhibitor, promotes apoptosis in prostate cancer cells.
Prostatic Neoplasms
Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine.
Prostatic Neoplasms
Ligand-dependent enhancer activation regulated by topoisomerase-I activity.
Prostatic Neoplasms
NKX3.1 contributes to S phase entry and regulates DNA damage response (DDR) in prostate cancer cell lines.
Prostatic Neoplasms
NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity.
Prostatic Neoplasms
Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2? expression to TMPRSS2-ERG fusion status in prostate cancer.
Prostatic Neoplasms
Replication-deficient adenovirus induces host topoisomerase I activity: implications for adenovirus-mediated gene expression.
Prostatic Neoplasms
Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.
Prostatic Neoplasms
Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKC?-independent pathway.
Prostatic Neoplasms
SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
Prostatic Neoplasms
Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I.
Prostatic Neoplasms
Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro.
Prostatic Neoplasms
Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma.
Prostatic Neoplasms
Topoisomerase II-binding protein 1 promotes the progression of prostate cancer via ATR-CHK1 signaling pathway.
Prostatic Neoplasms
Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress.
Protein Deficiency
[Mechanisms of pandrug-resistance of Pseudomonas aeruginosa]
Proteinuria
Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.
Proteinuria
The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis.
Pseudorabies
Stimulation of type I DNA topoisomerase gene expression by pseudorabies virus.
Psoriasis
Experimental studies on topoisomerase inhibitor camptothecin as an antipsoriatic agent.
Psoriasis
Synthesis and identification of quinoline derivatives as topoisomerase I inhibitors with potent antipsoriasis activity in an animal model.
Psoriasis
Topical treatment of psoriasis with the topoisomerase inhibitors novobiocin and nalidixic acid: a pilot study.
Pulmonary Disease, Chronic Obstructive
Dissociation between airway and systemic autoantibody responses in chronic obstructive pulmonary disease.
Pulmonary Fibrosis
Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis.
Pulmonary Fibrosis
B-Cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis.
Pulmonary Fibrosis
Immunization with DNA topoisomerase I and complete Freund's adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling.
Pulmonary Fibrosis
Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype.
Pulmonary Fibrosis
Leflunomide prevents ROS-induced systemic fibrosis in mice.
Pulmonary Fibrosis
Massive pericardial effusion in scleroderma: a review of five cases.
Pulmonary Fibrosis
Niclosamide Prevents Systemic Sclerosis in a Reactive Oxygen Species-Induced Mouse Model.
Pulmonary Fibrosis
Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model.
Rectal Neoplasms
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
Rectal Neoplasms
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.
Rectal Neoplasms
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
Renal Insufficiency, Chronic
Transcriptomic signatures of exacerbated progression in leptospirosis subclinical chronic kidney disease with secondary nephrotoxic injury.
Reoviridae Infections
Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
Respiratory Insufficiency
[Interstitial lung disease in patients with connective tissue diseases]
Retinitis Pigmentosa
Mutations in the TOPORS gene cause 1% of autosomal dominant retinitis pigmentosa.
Retinitis Pigmentosa
Mutations in TOPORS Cause Autosomal Dominant Retinitis Pigmentosa with Perivascular Retinal Pigment Epithelium Atrophy.
Retinoblastoma
Caspase-dependent activation of calpain during drug-induced apoptosis.
Retinoblastoma
Functional interaction between human topoisomerase IIalpha and retinoblastoma protein.
Retinoblastoma
Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors.
Retinoblastoma
Nodular lesions of monocytic component in myelodysplastic syndrome.
Retinoblastoma
Nuclear export of proteins and drug resistance in cancer.
Retinoblastoma
pRb suppresses camptothecin-induced apoptosis in human osteosarcoma Saos-2 cells by inhibiting c-Jun N-terminal kinase.
Retinoblastoma
Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
Retinoblastoma
Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: the effect of combined treatment with the topoisomerase I-inhibitor topotecan.
Retinoblastoma
Synergistic cytotoxic interactions between sodium butyrate, MG132 and camptothecin in human retinoblastoma Y79 cells.
Retinoblastoma
The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes.
Retinoblastoma
Topoisomerase alpha II, retinoblastoma gene product, and p53: potential relationships with aggressive behavior and malignant transformation in recurrent respiratory papillomatosis.
Retinoblastoma
Topotecan hydrochloride effects on retinal vessels in newborn rats.
Rhabdomyosarcoma
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
Rhabdomyosarcoma
Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
Rhabdomyosarcoma
Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies.
Rhabdomyosarcoma
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Rhabdomyosarcoma
Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.
Rhabdomyosarcoma
Functional interaction between human topoisomerase IIalpha and retinoblastoma protein.
Rhabdomyosarcoma
In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
Rhabdomyosarcoma
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Rhabdomyosarcoma
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Rhabdomyosarcoma
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Rhabdomyosarcoma
UCHL3 Regulates Topoisomerase-Induced Chromosomal Break Repair by Controlling TDP1 Proteostasis.
Rhabdomyosarcoma, Alveolar
Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas.
Rheumatic Diseases
Different distribution of HLA class II alleles in anti-topoisomerase I autoantibody responders between silicosis and systemic sclerosis patients, with a common distinct amino acid sequence in the HLA-DQB1 domain.
Rheumatic Diseases
Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.
Rheumatic Diseases
Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases.
Sarcoidosis
Lymphocyte proliferation induced by high-affinity peptides for HLA-B*51:01 in Behçet's uveitis.
Sarcoma
CPT-11 Chemotherapy Rescued A Patient with Atypical Sclerosing Epithelioid Fibrosarcoma from Emergent Condition.
Sarcoma
Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies.
Sarcoma
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Sarcoma
Human DNA topoisomerase I: An anticancer drug target present in human sarcomas.
Sarcoma
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.
Sarcoma
SLFN11 is widely expressed in pediatric sarcoma and induces variable sensitization to replicative stress caused by DNA damaging agents.
Sarcoma
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Sarcoma
Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas.
Sarcoma, Avian
DNA topoisomerase activity associated with Rous sarcoma virus.
Sarcoma, Avian
Virus- and cell-encoded tyrosine protein kinases inactivate DNA topoisomerases in vitro.
Sarcoma, Ewing
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
Sarcoma, Ewing
E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
Sarcoma, Ewing
Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
Sarcoma, Synovial
Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
Scleroderma, Diffuse
A casein kinase type II (CKII)-like nuclear protein kinase associates with, phosphorylates, and activates topoisomerase I.
Scleroderma, Diffuse
Antibody specificities of Thai and Australian scleroderma sera with topoisomerase I recombinant fusion proteins.
Scleroderma, Diffuse
Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis.
Scleroderma, Diffuse
IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts.
Scleroderma, Diffuse
IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients.
Scleroderma, Diffuse
Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype.
Scleroderma, Diffuse
Involvement of lysosomal cathepsins in the cleavage of DNA topoisomerase I during necrotic cell death.
Scleroderma, Diffuse
Specificity of anti-Scl-70 antibodies in scleroderma: increased sensitivity of detection using purified DNA topoisomerase I from calf thymus.
Scleroderma, Diffuse
The expression and localization of Scl-70/DNA topoisomerase I vary throughout the cell cycle.
Scleroderma, Diffuse
Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis.
Scleroderma, Localized
Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.
Scleroderma, Systemic
A recombinant topoisomerase I used for autoantibody detection in sera from patients with systemic sclerosis.
Scleroderma, Systemic
An immunodominant epitope on DNA topoisomerase I is conformational in nature: heterogeneity in its recognition by systemic sclerosis sera.
Scleroderma, Systemic
Analysis of an immunodominant epitope of topoisomerase I in patients with systemic sclerosis.
Scleroderma, Systemic
Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells.
Scleroderma, Systemic
Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality?
Scleroderma, Systemic
Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma).
Scleroderma, Systemic
Are ACA and Scl 70 antibodies mutually exclusive?
Scleroderma, Systemic
Association between centromere and topoisomerase specific immune responses and the degree of microangiopathy in Systemic Sclerosis.
Scleroderma, Systemic
Autoantibodies against topoisomerase I detected with the natural enzyme and overlapping recombinant peptides.
Scleroderma, Systemic
Autoantibodies in the diagnosis of systemic rheumatic diseases.
Scleroderma, Systemic
Autoantigenic epitopes on DNA topoisomerase I. Clinical and immunogenetic associations in systemic sclerosis.
Scleroderma, Systemic
Autoreactive T cells to topoisomerase I in monozygotic twins discordant for systemic sclerosis.
Scleroderma, Systemic
B-Cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis.
Scleroderma, Systemic
Chromosome studies in systemic sclerosis with consideration of antibodies to topoisomerase I.
Scleroderma, Systemic
Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis.
Scleroderma, Systemic
Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.
Scleroderma, Systemic
Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis.
Scleroderma, Systemic
Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis.
Scleroderma, Systemic
Detection of anti-topoisomerase I antibodies using a full length human topoisomerase I recombinant protein purified from a baculovirus expression system.
Scleroderma, Systemic
Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis.
Scleroderma, Systemic
Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody.
Scleroderma, Systemic
Different distribution of HLA class II alleles in anti-topoisomerase I autoantibody responders between silicosis and systemic sclerosis patients, with a common distinct amino acid sequence in the HLA-DQB1 domain.
Scleroderma, Systemic
Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
Scleroderma, Systemic
Distinct autoreactive T cell responses to native and fragmented DNA topoisomerase I: influence of APC type and IL-2.
Scleroderma, Systemic
DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients.
Scleroderma, Systemic
Does Sc1-70 modulate collagen production in systemic sclerosis?
Scleroderma, Systemic
Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases.
Scleroderma, Systemic
Heparin inhibits the interaction of DNA topoisomerase I (topo-I)/anti-topo-I immune complexes with heparan sulfate on dermal fibroblasts.
Scleroderma, Systemic
Highly restricted TCR-alpha beta usage by autoreactive human T cell clones specific for DNA topoisomerase I: recognition of an immunodominant epitope.
Scleroderma, Systemic
IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.
Scleroderma, Systemic
Immunization with DNA topoisomerase I and complete Freund's adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling.
Scleroderma, Systemic
Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice.
Scleroderma, Systemic
Implications for the use of topoisomerase I inhibitors in treatment of patients with systemic sclerosis.
Scleroderma, Systemic
Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody.
Scleroderma, Systemic
Interactions of HLA-DR and Topoisomerase I Epitope Modulated Genetic Risk for Systemic Sclerosis.
Scleroderma, Systemic
Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis.
Scleroderma, Systemic
Mapping of the immunodominant T cell epitopes of the protein topoisomerase I.
Scleroderma, Systemic
MHC class II associations with autoantibody and T cell immune responses to the scleroderma autoantigen topoisomerase I.
Scleroderma, Systemic
Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation.
Scleroderma, Systemic
Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis.
Scleroderma, Systemic
Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.
Scleroderma, Systemic
Progressive appearance of overlap syndrome together with autoantibodies in a patient with fatal thrombotic microangiopathy.
Scleroderma, Systemic
Relationship between natural and infection -induced antibodies in systemic autoimmune diseases (SAD); SLE, SSc and RA.
Scleroderma, Systemic
Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse.
Scleroderma, Systemic
Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association.
Scleroderma, Systemic
T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis.
Scleroderma, Systemic
T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I.
Scleroderma, Systemic
T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors.
Scleroderma, Systemic
The autoantigen DNA topoisomerase I interacts with chemokine receptor 7 and exerts cytokine-like effects on dermal fibroblasts.
Scleroderma, Systemic
The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma).
Scleroderma, Systemic
The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis.
Scleroderma, Systemic
The level of anti-topoisomerase I antibodies highly correlates with metacarpophalangeal and proximal interphalangeal joints flexion contractures in patients with systemic sclerosis.
Scleroderma, Systemic
Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis.
Scleroderma, Systemic
[The clinical significance of detecting the inhibition of topoisomerase I by the sera of patients with systemic scleroderma]
Seizures
From bench to drug: human seizure modeling using Drosophila.
Seizures
Seizure suppression by top1 mutations in Drosophila.
Seminoma
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Seminoma
Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas.
Sepsis
The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients.
Sepsis
Topotecan Alleviates Lipopolysaccharide-Mediated Acute Lung Injury Via the NF-?B Signaling Pathway.
Sjogren's Syndrome
Antitopoisomerase I antibody in patients with systemic lupus erythematosus/sicca syndrome without a concomitant scleroderma: two case reports.
Skin Neoplasms
Coralyne, a protoberberine alkaloid, causes robust photosenstization of cancer cells through ATR-p38 MAPK-BAX and JAK2-STAT1-BAX pathways.
Skin Neoplasms
Cryptolepine, a Plant Alkaloid, Inhibits the Growth of Non-Melanoma Skin Cancer Cells through Inhibition of Topoisomerase and Induction of DNA Damage.
Small Cell Lung Carcinoma
A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Small Cell Lung Carcinoma
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Small Cell Lung Carcinoma
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Small Cell Lung Carcinoma
Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.
Small Cell Lung Carcinoma
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Small Cell Lung Carcinoma
Clinical pharmacokinetics of topotecan.
Small Cell Lung Carcinoma
Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells.
Small Cell Lung Carcinoma
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.
Small Cell Lung Carcinoma
Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer.
Small Cell Lung Carcinoma
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.
Small Cell Lung Carcinoma
ERCC1 and topoisomerase I expression in small cell lung cancer: Prognostic and predictive implications.
Small Cell Lung Carcinoma
Expressions of Topoisomerase II? and BCRP in Metastatic Cells are Associated with Overall Survival in Small Cell Lung Cancer Patients.
Small Cell Lung Carcinoma
Intracellular uptake study of radiolabeled anticancer drug and impedimetric detection of its interaction with DNA.
Small Cell Lung Carcinoma
Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Small Cell Lung Carcinoma
Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Small Cell Lung Carcinoma
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
Small Cell Lung Carcinoma
Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.
Small Cell Lung Carcinoma
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Small Cell Lung Carcinoma
Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Small Cell Lung Carcinoma
Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer.
Small Cell Lung Carcinoma
Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOP?-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide.
Small Cell Lung Carcinoma
Real-Time Positron Emission Tomography Evaluation of Topotecan Brain Kinetics after Ultrasound-Mediated Blood-Brain Barrier Permeability.
Small Cell Lung Carcinoma
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Small Cell Lung Carcinoma
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Small Cell Lung Carcinoma
Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Small Cell Lung Carcinoma
The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells.
Small Cell Lung Carcinoma
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Small Cell Lung Carcinoma
Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
Small Cell Lung Carcinoma
Topotecan: An evolving option in the treatment of relapsed small cell lung cancer.
Small Cell Lung Carcinoma
Update on the role of topotecan in the treatment of non-small cell lung cancer.
Small Cell Lung Carcinoma
[Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines]
Small Cell Lung Carcinoma
[Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer]
Smallpox
Kinetic Study of DNA Topoisomerases by Supercoiling-Dependent Fluorescence Quenching.
Smallpox
Microheterogeneity of Topoisomerase IA/IB and Their DNA-Bound States.
Smallpox
Regulation of catalysis by the smallpox virus topoisomerase.
Smallpox
Structural basis for specificity in the poxvirus topoisomerase.
Smallpox
Unraveling the structure of the variola topoisomerase IB-DNA complex: a possible new twist on smallpox therapy.
Smallpox
Variola type IB DNA topoisomerase: DNA binding and supercoil unwinding using engineered DNA minicircles.
Smallpox
Variola virus topoisomerase: DNA cleavage specificity and distribution of sites in Poxvirus genomes.
Smith-Magenis Syndrome
Gene for topoisomerase III maps within the Smith-Magenis syndrome critical region: analysis of cell-cycle distribution and radiation sensitivity.
Spinocerebellar Ataxias
Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy.
Spinocerebellar Ataxias
TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage.
Spinocerebellar Degenerations
Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes.
Spinocerebellar Degenerations
TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy.
Squamous Cell Carcinoma of Head and Neck
Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines.
Squamous Cell Carcinoma of Head and Neck
Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
Squamous Cell Carcinoma of Head and Neck
Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Squamous Cell Carcinoma of Head and Neck
Expression of human DNA Topoisomerase II-alpha in squamous cell carcinoma of the larynx and its correlation with clinicopathologic variables.
Squamous Cell Carcinoma of Head and Neck
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Topoisomerase expression in oral squamous cell carcinoma: relationship with cancer stem cells profiles and lymph node metastasis.
Staphylococcal Infections
New aminocoumarin antibiotics as gyrase inhibitors.
Staphylococcal Infections
Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Starvation
Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs.
Starvation
Topoisomerase mutants and physiological conditions control supercoiling and Z-DNA formation in vivo.
Stomach Neoplasms
(S)-Erypoegin K, an isoflavone isolated from Erythrina poeppigiana, is a novel inhibitor of topoisomerase II?: Induction of G2 phase arrest in human gastric cancer cells.
Stomach Neoplasms
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
Stomach Neoplasms
A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2.
Stomach Neoplasms
Cisplatin and irinotecan in upper gastrointestinal malignancies.
Stomach Neoplasms
Combating liver cancer through GO-targeted biomaterials.
Stomach Neoplasms
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Stomach Neoplasms
Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Stomach Neoplasms
Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
Stomach Neoplasms
Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.
Stomach Neoplasms
Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways.
Stomach Neoplasms
High glucose promotes gastric cancer chemoresistance in vivo and in vitro.
Stomach Neoplasms
Inhibition of gastric cancer by camptothecin involves apoptosis and multiple cellular pathways.
Stomach Neoplasms
Inhibition of Topoisomerase II? and Induction of Apoptosis in Gastric Cancer Cells by 19-Triisopropyl Andrographolide
Stomach Neoplasms
MHY440, a Novel Topoisomerase ? Inhibitor, Induces Cell Cycle Arrest and Apoptosis via a ROS-Dependent DNA Damage Signaling Pathway in AGS Human Gastric Cancer Cells.
Stomach Neoplasms
Mining topoisomerase isoforms in gastric cancer.
Stomach Neoplasms
Mitochondrial topoisomerase I absence enhances aerobic glycolysis in cancer.
Stomach Neoplasms
Precursor-Directed Generation of Indolocarbazoles with Topoisomerase II? Inhibitory Activity.
Stomach Neoplasms
Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes.
Stomach Neoplasms
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-?-benzyl ester derivatives as potent topoisomerase II? inhibitors.
Stomach Neoplasms
Tissue microarray analysis of topoisomerase IIalpha protein in gastric adenocarcinomas: histogenetic and prognostic implications.
Stomach Neoplasms
Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity.
Stomach Neoplasms
Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
Stomach Neoplasms
Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
Stomach Neoplasms
Trastuzumab Deruxtecan: First Approval.
Stomach Neoplasms
Xer recombinase and genome integrity in Helicobacter pylori, a pathogen without topoisomerase IV.
Stomach Neoplasms
[Effects of hydroxycamptothecin and teniposide on proliferation and apoptosis of gastric cancer cell line BGC-823]
Telangiectasis
Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I.
Teratocarcinoma
[Effect of inhibitors of topoisomerases and poly(ADP-ribosylation) on homologous and non-homologous integration of exogenous DNA in genes of mammalian somatic cells]
Teratoma
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Teratoma
Method for selective ablation of undifferentiated human pluripotent stem cell populations for cell-based therapies.
Testicular Neoplasms
A study of topoisomerase activity in human testicular cancers.
Testicular Neoplasms
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Thrombocytopenia
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
Thymus Neoplasms
Endogenous topoisomerase II-mediated DNA breaks drive thymic cancer predisposition linked to ATM deficiency.
Thyroid Cancer, Papillary
RET rearrangements in radiation-induced papillary thyroid carcinomas: high prevalence of topoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes.
Thyroid Neoplasms
Prognostic Value and Significant Pathway Exploration Associated with TOP2A Involved in Papillary Thyroid Cancer.
Triple Negative Breast Neoplasms
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
Triple Negative Breast Neoplasms
Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
Triple Negative Breast Neoplasms
Expression of Topoisomerase II-? in Triple Negative Breast Cancer.
Triple Negative Breast Neoplasms
Impact of Topoisomerase II?, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
Triple Negative Breast Neoplasms
Loss of O?-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Triple Negative Breast Neoplasms
New Dibenzoquinoxalines Inhibit Triple-Negative Breast Cancer Growth by Dual Targeting of Topoisomerase 1 and the c-MYC G-Quadruplex.
Triple Negative Breast Neoplasms
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
Triple Negative Breast Neoplasms
Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase II? in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Triple Negative Breast Neoplasms
The selective effect of glycyrrhizin and glycyrrhetinic acid on topoisomerase II? and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells.
Triple Negative Breast Neoplasms
Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase II?.
Triple Negative Breast Neoplasms
[Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Trypanosomiasis, African
Newly identified antibacterial compounds are topoisomerase poisons in African trypanosomes.
Tuberculosis
Amsacrine Derivatives Selectively Inhibit Mycobacterial Topoisomerase I (TopA), Impair M. smegmatis Growth and Disturb Chromosome Replication.
Tuberculosis
Analysis of DNA relaxation and cleavage activities of recombinant Mycobacterium tuberculosis DNA topoisomerase I from a new expression and purification protocol.
Tuberculosis
Antimicrobial Susceptibility and SOS-Dependent Increase in Mutation Frequency Are Impacted by Escherichia coli Topoisomerase I C-Terminal Point Mutation.
Tuberculosis
Autoregulation of topoisomerase I expression by supercoiling sensitive transcription.
Tuberculosis
Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
Tuberculosis
Boldine-Derived Alkaloids Inhibit the Activity of DNA Topoisomerase I and Growth of Mycobacterium tuberculosis.
Tuberculosis
Characterization of an interplay between a Mycobacterium tuberculosis MazF homolog, Rv1495 and its sole DNA topoisomerase I.
Tuberculosis
Characterization of DNA topoisomerase I from Mycobacterium tuberculosis: DNA cleavage and religation properties and inhibition of its activity.
Tuberculosis
Characterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters.
Tuberculosis
Cloning, expression, purification and characterization of DNA topoisomerase I of Mycobacterium tuberculosis.
Tuberculosis
Conditional silencing of topoisomerase I gene of Mycobacterium tuberculosis validates its essentiality for cell survival.
Tuberculosis
Determination of the recognition sequence of Mycobacterium smegmatis topoisomerase I on mycobacterial genomic sequences.
Tuberculosis
Direct regulation of topoisomerase activity by a nucleoid-associated protein.
Tuberculosis
Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays.
Tuberculosis
Distinct Mechanism Evolved for Mycobacterial RNA Polymerase and Topoisomerase I Protein-Protein Interaction.
Tuberculosis
DNA topoisomerase I and DNA gyrase as targets for TB therapy.
Tuberculosis
DNA topoisomerase I from Mycobacterium smegmatis. An enzyme with distinct features.
Tuberculosis
First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis.
Tuberculosis
Galeon: A Biologically Active Molecule with In Silico Metabolite Prediction, In Vitro Metabolic Profiling in Rat Liver Microsomes, and In Silico Binding Mechanisms with CYP450 Isoforms.
Tuberculosis
Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target.
Tuberculosis
Identification of potential Mycobacterium tuberculosis topoisomerase I inhibitors: A study against active, dormant and resistant tuberculosis.
Tuberculosis
Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison.
Tuberculosis
Inhibition of Zn(II) binding type IA topoisomerases by organomercury compounds and Hg(II).
Tuberculosis
Insights from the Structure of Mycobacterium tuberculosis Topoisomerase I with a Novel Protein Fold.
Tuberculosis
Investigating mycobacterial topoisomerase I mechanism from the analysis of metal and DNA substrate interactions at the active site.
Tuberculosis
Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I.
Tuberculosis
Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound.
Tuberculosis
Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.
Tuberculosis
Mycobacterium tuberculosis Gyrase Inhibitors as a New Class of Antitubercular Drugs.
Tuberculosis
Physical and functional interaction between d-ribokinase and topoisomerase I has opposite effects on their respective activity in Mycobacterium smegmatis and Mycobacterium tuberculosis.
Tuberculosis
Physical and functional interactions between 3-methyladenine DNA glycosylase and topoisomerase I in mycobacteria.
Tuberculosis
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
Tuberculosis
Small-Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents.
Tuberculosis
Targeting Mycobacterium tuberculosis Topoisomerase I by Small-Molecule Inhibitors.
Tuberculosis
The DNA relaxation activity and covalent complex accumulation of Mycobacterium tuberculosis topoisomerase I can be assayed in Escherichia coli: application for identification of potential FRET-dye labeling sites.
Tuberculosis
Transcription facilitated genome-wide recruitment of topoisomerase I and DNA gyrase.
Tuberculosis
Type IA topoisomerase inhibition by clamp closure.
Tuberculosis
Xer recombinase and genome integrity in Helicobacter pylori, a pathogen without topoisomerase IV.
Tuberculosis, Multidrug-Resistant
Insights from the Structure of Mycobacterium tuberculosis Topoisomerase I with a Novel Protein Fold.
Tumor Lysis Syndrome
Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.
Tumor Virus Infections
Characterization of a DNA topoisomerase encoded by Amsacta moore entomopoxvirus.
Tumor Virus Infections
Identification and DNA sequence of the Shope fibroma virus DNA topoisomerase gene.
Tumor Virus Infections
SFV topoisomerase: sequence specificity in a genetically mapped interval.
Tumor Virus Infections
Shope fibroma virus DNA topoisomerase catalyses holliday junction resolution and hairpin formation in vitro.
Urinary Bladder Neoplasms
DNA topoisomerase II? and RAD21 cohesin complex component are predicted as potential therapeutic targets in bladder cancer.
Urinary Bladder Neoplasms
Genistein sensitizes bladder cancer cells to HCPT treatment in vitro and in vivo via ATM/NF-?B/IKK pathway-induced apoptosis.
Urinary Bladder Neoplasms
Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
Urinary Bladder Neoplasms
[Detecting multi-drug resistance of bladder cancer for the intravesical chemotherapy]
Urinary Tract Infections
The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs.
Urinary Tract Infections
The frequency of DNA gyrase and topoisomerase IV mutations, and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
Uterine Cervical Neoplasms
Biological activity and molecular docking studies of some new quinolines as potent anticancer agents.
Uterine Cervical Neoplasms
Chemotherapeutic Drugs Inhibiting Topoisomerase 1 Activity Impede Cytokine-Induced and NF-?B p65-Regulated Gene Expression.
Uterine Cervical Neoplasms
CKD-602, a topoisomerase I inhibitor, induces apoptosis and cell-cycle arrest and inhibits invasion in cervical cancer.
Uterine Cervical Neoplasms
Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Uterine Cervical Neoplasms
Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose)polymerase.
Uterine Cervical Neoplasms
Irinotecan for the treatment of cervical cancer.
Uterine Cervical Neoplasms
Irinotecan in cervical cancer.
Uterine Cervical Neoplasms
Latex of Euphorbia antiquorum-induced S-phase arrest via active ATM kinase and MAPK pathways in human cervical cancer HeLa cells.
Uterine Cervical Neoplasms
Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells.
Uterine Cervical Neoplasms
Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling.
Uterine Cervical Neoplasms
Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells.
Uterine Cervical Neoplasms
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-?-benzyl ester derivatives as potent topoisomerase II? inhibitors.
Uterine Cervical Neoplasms
The First Berberine-Based Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), an Important DNA Repair Enzyme.
Uterine Cervical Neoplasms
Topoisomerase I deficiency results in chromosomal alterations in cervical cancer cells.
Uterine Cervical Neoplasms
[Promising new drugs for gynecological cancer]
Uveitis
Lymphocyte proliferation induced by high-affinity peptides for HLA-B*51:01 in Behçet's uveitis.
Vaccinia
19F NMR studies of vaccinia type IB topoisomerase. Conformational dynamics of the bound DNA substrate.
Vaccinia
3'-modified oligonucleotides by reverse DNA synthesis.
Vaccinia
5'OH DNA breaks in apoptosis and their labeling by topoisomerase-based approach.
Vaccinia
A catalytic domain of eukaryotic DNA topoisomerase I.
Vaccinia
A DNA nicking-closing enzyme encapsidated in vaccinia virus: partial purification and properties.
Vaccinia
A functional type I topoisomerase from Pseudomonas aeruginosa.
Vaccinia
A poxvirus-like type IB topoisomerase family in bacteria.
Vaccinia
A universal cloning vector using vaccinia topoisomerase I.
Vaccinia
An Alternative Method to Facilitate cDNA Cloning for Expression Studies in Mammalian Cells by Introducing Positive Blue White Selection in Vaccinia Topoisomerase I-Mediated Recombination.
Vaccinia
An engineered mutant of vaccinia virus DNA topoisomerase I is sensitive to the anti-cancer drug camptothecin.
Vaccinia
Analogues of vaccinia virus DNA topoisomerase I modified at the active site tyrosine.
Vaccinia
Application of DNA topoisomerase-activated adapters to riboprobe synthesis.
Vaccinia
Atomic force microscopy shows that vaccinia topoisomerase IB generates filaments on DNA in a cooperative fashion.
Vaccinia
ATP independent type IB topoisomerase of Leishmania donovani is stimulated by ATP: an insight into the functional mechanism.
Vaccinia
Benzo[a]pyrene-dG adduct interference illuminates the interface of vaccinia topoisomerase with the DNA minor groove.
Vaccinia
Benzo[c]phenanthrene adducts and nogalamycin inhibit DNA transesterification by vaccinia topoisomerase.
Vaccinia
Biochemical analysis of mutant alleles of the vaccinia virus topoisomerase I carrying targeted substitutions in a highly conserved domain.
Vaccinia
Catalytic phosphoryl interactions of topoisomerase IB.
Vaccinia
Characterization of a DNA topoisomerase encoded by Amsacta moore entomopoxvirus.
Vaccinia
Characterization of DNA Binding by the Isolated N-Terminal Domain of Vaccinia Virus DNA Topoisomerase IB.
Vaccinia
Characterization of vaccinia virus DNA topoisomerase I expressed in Escherichia coli.
Vaccinia
Chemical and traditional mutagenesis of vaccinia DNA topoisomerase provides insights to cleavage site recognition and transesterification chemistry.
Vaccinia
Chemical mutagenesis of vaccinia DNA topoisomerase lysine 167 provides insights to the catalysis of DNA transesterification.
Vaccinia
Conditional growth of Escherichia coli caused by expression of vaccinia virus DNA topoisomerase I.
Vaccinia
Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases.
Vaccinia
Covalent and noncovalent DNA binding by mutants of vaccinia DNA topoisomerase I.
Vaccinia
Covalent DNA binding by vaccinia topoisomerase results in unpairing of the thymine base 5' of the scissile bond.
Vaccinia
Crystal Structure of a Bacterial Type IB DNA Topoisomerase Reveals a Preassembled Active Site in the Absence of DNA.
Vaccinia
Crystal structure of the amino-terminal fragment of vaccinia virus DNA topoisomerase I at 1.6 A resolution.
Vaccinia
Deletions at the carboxyl terminus of vaccinia DNA topoisomerase affect DNA binding and enhance distributivity in DNA relaxation.
Vaccinia
Diverse Energetic Effects of Charge Reversal Mutations of Poxvirus Topoisomerase IB.
Vaccinia
DNA strand transfer catalyzed by vaccinia topoisomerase: ligation of DNAs containing a 3' mononucleotide overhang.
Vaccinia
DNA strand transfer catalyzed by vaccinia topoisomerase: peroxidolysis and hydroxylaminolysis of the covalent protein-DNA intermediate.
Vaccinia
DNA strand transfer reactions catalyzed by vaccinia topoisomerase I.
Vaccinia
DNA strand transfer reactions catalyzed by vaccinia topoisomerase: hydrolysis and glycerololysis of the covalent protein-DNA intermediate.
Vaccinia
Effect of 2'-5' phosphodiesters on DNA transesterification by vaccinia topoisomerase.
Vaccinia
Effects of ATP and inhibitory factors on the activity of vaccinia virus type I topoisomerase.
Vaccinia
Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
Vaccinia
Expression and Purification of Vaccinia Virus DNA Topoisomerase IB Produced in the Silkworm-Baculovirus Expression System.
Vaccinia
Fluorescence spectroscopy studies of vaccinia type IB DNA topoisomerase. Closing of the enzyme clamp is faster than DNA cleavage.
Vaccinia
Fluoroquinolone-dependent DNA supercoiling by Vaccinia topoisomerase I.
Vaccinia
Generation of linear expression constructs by one-step PCR with vaccinia DNA topoisomerase I.
Vaccinia
Genome-scale cloning and expression of individual open reading frames using topoisomerase I-mediated ligation.
Vaccinia
High-throughput backbone resonance assignment of small 13C,15N-labeled proteins by a triple-resonance experiment with four sequential connectivity pathways using chemical shift-dependent, apparent 1J(1H,13C): HNCACBcodedHAHB.
Vaccinia
Histidine 265 is important for covalent catalysis by vaccinia topoisomerase and is conserved in all eukaryotic type I enzymes.
Vaccinia
Identification and DNA sequence of the Shope fibroma virus DNA topoisomerase gene.
Vaccinia
Identification of a vaccinia virus gene encoding a type I DNA topoisomerase.
Vaccinia
Identification of contacts between topoisomerase I and its target DNA by site-specific photocrosslinking.
Vaccinia
In vitro assembly of semi-artificial molecular machine and its use for detection of DNA damage.
Vaccinia
Individual nucleotide bases, not base pairs, are critical for triggering site-specific DNA cleavage by vaccinia topoisomerase.
Vaccinia
Insertional mutagenesis of the vaccinia virus gene encoding a type I DNA topoisomerase: evidence that the gene is essential for virus growth.
Vaccinia
Intercalating polycyclic aromatic hydrocarbon-DNA adducts poison DNA religation by Vaccinia topoisomerase and act as roadblocks to digestion by exonuclease III.
Vaccinia
Intramolecular synapsis of duplex DNA by vaccinia topoisomerase.
Vaccinia
Kinetic analysis of DNA and RNA strand transfer reactions catalyzed by vaccinia topoisomerase.
Vaccinia
Major groove interactions of vaccinia Topo I provide specificity by optimally positioning the covalent phosphotyrosine linkage.
Vaccinia
Mapping the active-site tyrosine of vaccinia virus DNA topoisomerase I.
Vaccinia
Mechanism and specificity of DNA strand exchange catalyzed by vaccinia DNA topoisomerase type I.
Vaccinia
Mechanism of DNA transesterification by vaccinia topoisomerase: catalytic contributions of essential residues Arg-130, Gly-132, Tyr-136 and Lys-167.
Vaccinia
Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin.
Vaccinia
Mechanisms for the processing of a frozen topoisomerase-DNA conjugate by human cell-free extracts.
Vaccinia
Melanoplus sanguinipes entomopoxvirus DNA topoisomerase: site-specific DNA transesterification and effects of 5'-bridging phosphorothiolates.
Vaccinia
Molluscum contagiosum virus topoisomerase: purification, activities, and response to inhibitors.
Vaccinia
Mutational analysis of 26 residues of vaccinia DNA topoisomerase identifies Ser-204 as important for DNA binding and cleavage.
Vaccinia
Mutational analysis of 39 residues of vaccinia DNA topoisomerase identifies Lys-220, Arg-223, and Asn-228 as important for covalent catalysis.
Vaccinia
Mutational analysis of vaccinia DNA topoisomerase defines amino acid residues essential for covalent catalysis.
Vaccinia
Mutational analysis of vaccinia virus topoisomerase identifies residues involved in DNA binding.
Vaccinia
Mutations of vaccinia virus DNA topoisomerase I that stabilize the cleavage complex.
Vaccinia
Mutations within a conserved region of vaccinia topoisomerase affect the DNA cleavage-religation equilibrium.
Vaccinia
Nanoblinker: Brownian motion powered bio-nanomachine for FRET detection of phagocytic phase of apoptosis.
Vaccinia
New peptide inhibitors of type IB topoisomerases: similarities and differences vis-a-vis inhibitors of tyrosine recombinases.
Vaccinia
Nonpolar nucleobase analogs illuminate requirements for site-specific DNA cleavage by vaccinia topoisomerase.
Vaccinia
Novel and specific inhibitors of a poxvirus type I topoisomerase.
Vaccinia
Novel approach to molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase.
Vaccinia
On the simultaneous binding of eukaryotic DNA topoisomerase II to a pair of double-stranded DNA helices.
Vaccinia
Oscillating probe for dual detection of 5'PO4 and 5'OH DNA breaks in tissue sections.
Vaccinia
p-Thiophenylalanine-induced DNA cleavage and religation activity of a modified vaccinia topoisomerase IB.
Vaccinia
Peptide inhibitors of DNA cleavage by tyrosine recombinases and topoisomerases.
Vaccinia
Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I.
Vaccinia
Phenotypic selection and characterization of mutant alleles of a eukaryotic DNA topoisomerase I.
Vaccinia
Polynucleotide ligase activity of eukaryotic topoisomerase I.
Vaccinia
Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription.
Vaccinia
Protein footprinting by the combined use of reversible and irreversible lysine modifications.
Vaccinia
Proteolytic footprinting of vaccinia topoisomerase bound to DNA.
Vaccinia
Proton relay mechanism of general acid catalysis by DNA topoisomerase IB.
Vaccinia
Reactions of Cre with methylphosphonate DNA: similarities and contrasts with Flp and vaccinia topoisomerase.
Vaccinia
Recombination mediated by vaccinia virus DNA topoisomerase I in Escherichia coli is sequence specific.
Vaccinia
Recombinogenic flap ligation mediated by human topoisomerase I.
Vaccinia
Recombinogenic flap ligation pathway for intrinsic repair of topoisomerase IB-induced double-strand breaks.
Vaccinia
Remote phosphate contacts trigger assembly of the active site of DNA topoisomerase IB.
Vaccinia
Replacement of the active site tyrosine of vaccinia DNA topoisomerase by glutamate, cysteine or histidine converts the enzyme into a site-specific endonuclease.
Vaccinia
Requirements for noncovalent binding of vaccinia topoisomerase I to duplex DNA.
Vaccinia
Resolution of a Holliday junction by vaccinia topoisomerase requires a spacer DNA segment 3' of the CCCTT/ cleavage sites.
Vaccinia
Resolution of Holliday junctions by eukaryotic DNA topoisomerase I.
Vaccinia
Resolution of undistorted symmetric immobile DNA junctions by vaccinia topoisomerase I.
Vaccinia
Ribonuclease activity of vaccinia DNA topoisomerase IB: kinetic and high-throughput inhibition studies using a robust continuous fluorescence assay.
Vaccinia
Selective transport of cationized fluorescent topoisomerase into nuclei of live cells for DNA damage studies.
Vaccinia
Self-cleaving purification tags re-engineered for rapid Topo® cloning.
Vaccinia
SFV topoisomerase: sequence specificity in a genetically mapped interval.
Vaccinia
Site-specific DNA cleavage by vaccinia virus DNA topoisomerase I. Role of nucleotide sequence and DNA secondary structure.
Vaccinia
Site-specific DNA transesterification by vaccinia topoisomerase: effects of benzo[alpha]pyrene-dA, 8-oxoguanine, 8-oxoadenine and 2-aminopurine modifications.
Vaccinia
Site-specific DNA transesterification by vaccinia topoisomerase: role of specific phosphates and nucleosides.
Vaccinia
Site-specific interaction of vaccinia virus topoisomerase I with base and sugar moieties in duplex DNA.
Vaccinia
Site-specific interaction of vaccinia virus topoisomerase I with duplex DNA. Minimal DNA substrate for strand cleavage in vitro.
Vaccinia
Site-specific ribonuclease activity of eukaryotic DNA topoisomerase I.
Vaccinia
Specific DNA cleavage and binding by vaccinia virus DNA topoisomerase I.
Vaccinia
Stereochemical outcome and kinetic effects of Rp- and Sp-phosphorothioate substitutions at the cleavage site of vaccinia type I DNA topoisomerase.
Vaccinia
Stimulation of vaccinia topoisomerase I by nucleoside triphosphates.
Vaccinia
Structural insights into the function of type IB topoisomerases.
Vaccinia
The domain organization of human topoisomerase I.
Vaccinia
The role of lysine 532 in the catalytic mechanism of human topoisomerase I.
Vaccinia
Two classes of DNA end-joining reactions catalyzed by vaccinia topoisomerase I.
Vaccinia
Type I topoisomerase activity after infection of enucleated, synchronized mouse L cells by vaccinia virus.
Vaccinia
Unmasking Anticooperative DNA-binding interactions of vaccinia DNA topoisomerase I.
Vaccinia
Vaccinia DNA topoisomerase I promotes illegitimate recombination in Escherichia coli.
Vaccinia
Vaccinia DNA topoisomerase I: evidence supporting a free rotation mechanism for DNA supercoil relaxation.
Vaccinia
Vaccinia DNA topoisomerase I: kinetic evidence for general acid-base catalysis and a conformational step.
Vaccinia
Vaccinia DNA topoisomerase I: single-turnover and steady-state kinetic analysis of the DNA strand cleavage and ligation reactions.
Vaccinia
Vaccinia topoisomerase and Cre recombinase catalyze direct ligation of activated DNA substrates containing a 3'-para-nitrophenyl phosphate ester.
Vaccinia
Vaccinia topoisomerase binds circumferentially to DNA.
Vaccinia
Vaccinia topoisomerase mutants illuminate conformational changes during closure of the protein clamp and assembly of a functional active site.
Vaccinia
Vaccinia topoisomerase mutants illuminate roles for Phe59, Gly73, Gln69 and Phe215.
Vaccinia
Vaccinia virus DNA topoisomerase I preferentially removes positive supercoils from DNA.
Vaccinia
Vaccinia virus DNA topoisomerase: a model eukaryotic type IB enzyme.
Vaccinia
Vaccinia virus encapsidates a novel topoisomerase with the properties of a eucaryotic type I enzyme.
Varicocele
Decrease of topoisomerase I activity in the testes of infertile men with varicocele.
Virus Diseases
Biochemical analysis of mutant alleles of the vaccinia virus topoisomerase I carrying targeted substitutions in a highly conserved domain.
Virus Diseases
Prognostic markers of low-grade squamous intraepithelial lesions: the role of topoisomerase IIalpha and active caspase-3.
Virus Diseases
Stimulation of type I DNA topoisomerase gene expression by pseudorabies virus.
Virus Diseases
Topological DNA damage, telomere attrition and T cell senescence during chronic viral infections.
Virus Diseases
Type I topoisomerase activity after infection of enucleated, synchronized mouse L cells by vaccinia virus.
Vitreoretinopathy, Proliferative
The topoisomerase I inhibitors, camptothecin and beta-lapachone, induce apoptosis of human retinal pigment epithelial cells.
Waldenstrom Macroglobulinemia
XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways.
Werner Syndrome
A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity.
Werner Syndrome
DNA damage modulates nucleolar interaction of the Werner protein with the AAA ATPase p97/VCP.
Werner Syndrome
Mammalian DNA topoisomerase IIIalpha is essential in early embryogenesis.
Werner Syndrome
Overexpression of a truncated human topoisomerase III partially corrects multiple aspects of the ataxia-telangiectasia phenotype.
Werner Syndrome
The Werner syndrome gene product co-purifies with the DNA replication complex and interacts with PCNA and topoisomerase I.
Werner Syndrome
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.
Werner Syndrome
Topoisomerase III is essential for accurate nuclear division in Schizosaccharomyces pombe.
Werner Syndrome
WRN helicase defective in the premature aging disorder Werner syndrome genetically interacts with topoisomerase 3 and restores the top3 slow growth phenotype of sgs1 top3.
Whooping Cough
Inhibition of endothelin-mediated topoisomerase I activation by pertussis toxin.
Whooping Cough
Stimulation of intracellular topoisomerase I activity by vasopressin and thrombin. Differential regulation by pertussis toxin.
Wilms Tumor
Expression of resistance-related proteins in nephroblastoma after chemotherapy.
Xeroderma Pigmentosum
Enhanced sensitivity to camptothecin in ataxia-telangiectasia cells and its relationship with the expression of DNA topoisomerase I.
Xeroderma Pigmentosum
Subnuclear distribution of DNA topoisomerase I and Bax protein in normal and xeroderma pigmentosum fibroblasts after irradiation with UV light and gamma rays or treatment with topotecan.
Xeroderma Pigmentosum
Ultraviolet-induced DNA damage stimulates topoisomerase I-DNA complex formation in vivo: possible relationship with DNA repair.
Yellow Fever
Topoisomerase III-? is required for efficient replication of positive-sense RNA viruses.
Yellow Fever
Topoisomerase III-ß is required for efficient replication of positive-sense RNA viruses.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
5.6.2.1 DNA topoisomerase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
